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Summary 
Hypoglycaemia is the major complication associated with insulin therapy in type 1 
diabetes.  Repeated exposure to hypoglycaemia leads to suppression of normal counter 
regulatory responses (CRR) to subsequent hypoglycaemia, which increases the risk of 
severe episodes of hypoglycaemia.  Studies have demonstrated the important role the 
brain plays in the regulation of whole body glucose homeostasis, including a vital role 
in mounting the CRR.  Detection of hypoglycaemia by specialised glucose-sensing 
neurons of the hypothalamus is critical for initiating the associated CRR.  It is believed 
that defective CRRs are mediated by brain adaptations leading to impaired central 
glucose sensing, although the mechanisms by which these occur remain unknown.  
Hypoglycaemia evokes a significant systemic and central stress response with an 
increase in inflammatory mediators including interleukin-6 (IL-6).  The aim of the 
current study was to investigate whether IL-6 played a role in the regulation of central 
glucose sensing.  This was addressed by examining the effects of IL-6 exposure on 
electrophysiological and biochemical responses in hypothalamic glucose-excited GT1-7 
neurons.  Antecedent exposure to IL-6 induced defective glucose sensing of subsequent 
hypoglycaemia, with a role for the exchange protein activated by cAMP (EPAC) 
implicated in this observation.  The results obtained suggest that EPAC may mediate 
this effect by enhancing the sensitivity of ATP-sensitive potassium (KATP) channels to 
ATP-mediated inhibition following IL-6 exposure.  The current results identify IL-6 and 
EPAC2 as novel mediators of defective hypothalamic glucose sensing, suggesting they 
may contribute to the development of blunted CRR observed with recurrent 
hypoglycaemia exposure.   
 
 
 
1 
1 Introduction 
1.1 Diabetes 
Diabetes Mellitus (DM) describes a metabolic disorder of multiple causes characterised 
by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion and or action (WHO, About 
Diabetes, retrieved July 24th 2015).  Diabetes leads to damage, dysfunction and failure 
of multiple organs. 
The two main types of diabetes are Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D).  
T1D is an autoimmune disease that usually, but not exclusively, develops in childhood 
and is characterised by destruction of the pancreatic beta-cells leading to an absence of 
endogenous insulin.  This type of diabetes represents 10% of all DM worldwide.  The 
other 90% of DM is T2D, which usually develops in adulthood and is related to obesity, 
sedentary lifestyle and the consumption of unhealthy, high-fat and high-sugar diets 
(WHO, About Diabetes, retrieved July 24th 2015).  Weight loss and physical activity are 
effective therapies for T2D. 
Chronic hyperglycaemia leads to microvascular and macrovascular disease including 
retinopathy, nephropathy and neuropathy and increases the risk of cardiovascular 
disease (Yan 2014; Laakso & Kuusisto 2014).  Regaining glycaemic control to limit 
hyperglycaemia has been shown to prevent or delay hyperglycaemia associated 
complications.  However, the use of sulphonylurea drugs to increase insulin secretion or 
administration of exogenous insulin to achieve this can lead to unregulated 
hyperinsulinaemia, which poses the significant risk of hypoglycaemia. 
1.2 Hypoglycaemia in Diabetes 
It is estimated that 285 million people worldwide had diabetes in 2010, and the number 
of sufferers is predicted to increase by ~50% to 438 million people by the year 2030 
(Cryer 2013).  Improving glycaemic control by lowering blood glucose concentrations 
closer to the non-diabetic range in patients delays the microvascular (retinopathy, 
nephropathy, and neuropathy) and macrovascular (coronary, cerebral, and peripheral 
atherosclerosis) complications of type 1 and 2 diabetes.  However, the use of 
sulphonylureas or insulin administration to achieve this introduces the considerable risk 
of hypoglycaemia, which is widely regarded as the major complication of improving 
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glycaemic control in patients with T1D and many with advanced stage T2D.  The 
maintenance of circulating plasma glucose levels in the normal physiological range of 
4-6 mM is critical as the brain relies almost exclusively on blood glucose as its primary 
source of energy and accounts for 60-80% of total body glucose uptake (Wasserman 
2009; Zierler 1999).  When blood glucose falls below 3 mM symptoms such as 
nervousness and irritability will ensue, and hypoglycaemia allowed to continue 
unchallenged will lead to impaired cognitive and motor function, coma and death 
(Donovan & Watts 2014).  Unlike complications associated with chronic 
hyperglycaemia, acute hypoglycaemia can mediate negative effects within minutes 
(Donovan & Watts 2014).  Hypoglycaemia impairs defences against subsequent 
hypoglycaemia and thus causes a vicious cycle of recurrent hypoglycaemia (Cryer 
2013).  In healthy individuals a very effective combination of behavioural and 
physiological responses to hypoglycaemia act rapidly to restore euglycaemia upon 
detection of falling plasma glucose levels, however these counter regulatory responses 
(CRR) are compromised in diabetes.  Attenuated epinephrine and sympathetic neural 
responses to falling glucose levels play a key role in the pathophysiology of T1D and 
advanced stage T2D in the absence of normal insulin and glucagon responses. 
Hypoglycaemia is a huge detriment to the lives of patients with T1D.  They suffer 
immeasurable episodes of asymptomatic hypoglycaemia, an average of two 
symptomatic episodes per week and an average of one episode of severe hypoglycaemia 
requiring the assistance of another person each year.  A 2007 study found that duration 
of T1D did not influence the prevalence or incidence of mild hypoglycaemia (UK 
Hypoglycaemia Study Group 2007).  However, in the same study, the long-duration 
T1D group experienced the highest frequency of severe episodes of hypoglycaemia (UK 
Hypoglycaemia Study Group 2007).  In T2D, the administration of sulphonylureas to 
increase insulin secretion or exogenous insulin can cause therapeutic hyperinsulinaemia 
independent of the plasma glucose level, and therefore hypoglycaemia.  However, 
studies have shown that hypoglycaemia frequency in T2D is much lower than that seen 
in T1D, with Donnelly et al. reporting that participants with T1D in their trial had a rate 
of 42.89 episodes of hypoglycaemia per patient year compared to a rate of 16.37 
episodes of hypoglycaemia per patient year in the T2D cohort (Donnelly et al. 2005).  
As insulin secretion and action is impaired increasingly with duration of T2D, 
hypoglycaemia becomes more limiting to glycaemic control (Cryer 2013).  The UK 
Hypoglycaemia Study Group reported that the frequency of severe hypoglycaemia 
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increases with the duration of insulin therapy in T2D, such that the incidence of mild 
and severe hypoglycaemia for T2D patients on insulin for more than 5 years was similar 
to that for T1D patients with short disease duration (UK Hypoglycaemia Study Group 
2007). 
1.3 Physiology and Pathophysiology of Defence 
Against Hypoglycaemia    
As previously mentioned, physiological and behavioural responses combine to prevent 
or correct the incidence of clinical hypoglycaemia in healthy individuals.  Physiological 
responses are primarily decreased endogenous insulin secretion as plasma glucose 
levels fall within the physiological range and increased glucagon secretion, and if 
glucose continues to fall, increased epinephrine responses as glucose levels fall below 
the physiological range.  These responses act to increase hepatic glucose production and 
decrease glucose clearance by insulin-sensitive tissues such as skeletal muscle; 
therefore leading to an increase in plasma glucose levels.  All CRR hormones are 
initiated at blood glucose levels just below the normal range, i.e., 3.6-3.8 mM (Cryer 
1997).  The behavioural component of the CRR leads to the ingestion of carbohydrates 
that is prompted by symptoms of hypoglycaemia; critical for patient awareness of 
hypoglycaemia.   
In T1D three major defects in this homeostatic response contribute to the high 
frequency of hypoglycaemia observed.  Firstly, T1D is characterised by an absence of 
insulin due to auto-immune destruction of the pancreatic beta-cells and the 
administration of exogenous insulin can lead to the development of unregulated and 
sustained hyperinsulinaemia (McCrimmon & Sherwin 2010).  Secondly, reduced or 
absent glucagon, the principal rapid-acting CRR hormone, results in considerable 
impairment of glucose recovery from hypoglycaemia (Gerich et al. 1973).  The cause of 
suppressed glucagon responses to hypoglycaemia in individuals with T1D is still 
disputed and a number of both intra- and extra-pancreatic factors have been implicated 
in this defect, including beta to alpha-cell signalling (Fukuda et al. 1988) and 
ventromedial hypothalamus (VMH)-mediated effects of insulin (Paranjape et al. 2010).  
Thirdly, a reduced autonomic response to hypoglycaemia affects the majority of 
patients with T1D by 10 years of disease duration (Mokan et al. 1994).  Hypoglycaemia 
normally activates the autonomic nervous system leading to increased hepatic glucose 
production and reduced glucose uptake from the circulation in peripheral tissues.  
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Activation of the sympathetic nervous system stimulates glycogenolysis and 
gluconeogenesis in the liver, processes that are important in the correction of falling 
plasma glucose levels.  The autonomic response is closely associated with the 
generation of symptomatic responses to hypoglycaemia and therefore impairment of 
this response can lead to reduced awareness of hypoglycaemia due to lack of symptoms 
(McCrimmon & Sherwin 2010).  The major driver of reduced autonomic responses to 
hypoglycaemia is antecedent hypoglycaemia itself, thus leading to a vicious cycle of 
hypoglycaemia in patients with T1D (Heller & Cryer 1991). 
The barrier of hypoglycaemia can range from being a nuisance to being life-threatening 
(Cryer 2013).  Fortunately, the incidence of prolonged, profound hypoglycaemia that 
can result in serious brain injury is rare, however, hypoglycaemia can be fatal, with 
percentage estimates of hypoglycaemia mortality rates ranging from 2-10% (Feltbower 
2008; Skrivarhaug et al. 2006).  
1.4 Hypoglycaemia Detection 
To initiate the vital CRR to correct hypoglycaemia, it first must be rapidly detected.  
Specialised glucose sensors are distributed at multiple sites throughout the body that are 
capable of detecting decreases in glucose levels, and activation of these sensors results 
in stimulation of CRR (Verberne et al. 2014).  Although there are peripheral glucose 
sensors situated in the pancreas (beta-cell), the hepatic portal vein, the gut and the 
carotid body, overwhelming evidence implicates central nervous system (CNS) glucose 
sensing as being critical in inducing CRR to hypoglycaemia.   
The brain has been recognised as an important regulator of glucose homeostasis since 
Claude Bernard’s initial observation that a puncture of the floor of the fourth ventricle 
of dogs induced diabetes (Thorens 2012).  Later, Jean Mayer proposed the glucostatic 
hypothesis, stating that feeding behaviour is regulated by central glucose sensing 
(Mayer 1953).  Subsequent lesioning experiments demonstrated the importance of 
distinct hypothalamic nuclei and their involvement in the regulation of feeding and 
fasting.  Lesioning of the lateral hypothalamus reduced feeding and body weight, 
whereas lesion of the VMH induced hyperphagia and hyperinsulinaemia (Hoebel 1965; 
King 2006).  The use of gold thioglucose, which causes the destruction of VMH 
neurons, induces obesity; an effect providing evidence for central glucose responsive 
structures as the toxic effect of gold thioglucose is not replicated when gold is 
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conjugated with other metabolites or nutrients, suggesting a specific effect on glucose-
sensitive neurons (Thorens 2012).   
Studies in dogs demonstrated that maintaining brain glucose levels during systemic 
hypoglycaemia resulted in a reduced neurohumoral reaction to the hypoglycaemic 
challenge, suggesting that it was the fall in glucose within the brain that triggered the 
process leading to counter regulation (Frizzell et al. 1993; Biggers et al. 1989).  The 
importance of the VMH in the mounting of the CRR to hypoglycaemia was 
demonstrated by studies using 2-deoxyglucose (2-DG) to induce neuroglucopenia in 
rats, stimulating the CRR (Borg et al. 1995).  Furthermore, studies involving lesioning 
of the VMH by stereotaxic injection of ibotenic acid reduced counter regulation (Borg 
et al. 1994).  Similarly, maintenance of VMH glucose levels during hypoglycaemia 
reduced counter regulation (Borg et al. 1997).  Furthermore, mice with VMH specific 
deletion of the vesicular glutamate transporter, VGLUT2, in steroidogenic factor-1 (SF-
1) expressing neurons had a marked defect in glucagon secretion in response to fasting 
or hypoglycaemia, suggesting that glutametergic neurons of the VMH are required for 
the CRR (Tong et al. 2007).  
Brain nutrient sensors need to be able to rapidly and accurately detect changes in blood 
glucose.  Specialised glucose-sensing neurons with this inherent property were first 
described in the 1960s by Anand BK et al. and Oomura et al. (Oomura & Yoshimatsu 
1984; Anand et al. 1964).  These neurons were reported to not only use glucose as a fuel 
source but also as a signalling molecule to regulate their activity.  These neurons are 
classified as being either glucose-excited (GE) or glucose-inhibited (GI), increasing or 
decreasing their activity in response to glucose respectively.  GE and GI neurons are 
present in the arcute (ARC), ventromedial (VMH), paraventricular (PVN) and lateral 
hypothalamic (LH) nuclei (Silver & Erecińska 1998; Wang et al. 2004). 
The ARC is an important site for the integration of hormonal, nutritional and neuronal 
signals comprising neurons expressing anorexigenic and orexigenic peptides (Kohno & 
Yada 2012). Neurons in the ARC as well as the PVN and the LH are involved in the 
regulation of peripheral metabolism through regulation of the activity of the 
sympathetic and parasympathetic branches of the autonomic nervous system (Thorens 
2012).  Neurons in this circuitry are regulated by hormones including ghrelin, insulin 
and leptin as well as nutrients such as lipids, amino acids and glucose (Gale et al. 2004; 
Schwartz 2000).  Importantly, glucose has been found to inhibit 40% of orexigenic 
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neuropeptide Y (NPY)-expressing neurons, while anorexigenic pro-opiomelanocortin 
(POMC) neurons are GE neurons and orexin neurons in the LH are GI (Thorens 2012). 
1.4.1 Non-Hypothalamic Glucose Sensing      
In studies similar to those performed in the VMH, the importance of the hindbrain 
structures involved in glucose-dependent regulation of feeding and glucose 
homeostasis, including the dorsal vagal complex (DVC), area postrema (AP), nucleus of 
the tractus solitarius (NTS), dorsal motor nucleus of the vagus (DMNX) and basolateral 
region (BLM), have been demonstrated by intracerebroventricular (ICV) injection of 2-
DG, which only stimulates feeding if the cerebral aqueduct is open to allow access of 
the injected substance to the brainstem (Ritter et al. 1981) and the finding that 5-
thioglucose (5-TG) can increase food intake when injected into the NTS, DMNX or 
BLM (Ritter et al. 2000).  NTS neurons have been shown to be glucose sensitive in 
studies measuring their firing activity (Yettefti et al. 1995).  NTS neurons project to the 
LH and PVN and neurons from the BLM project to the ARC, and destruction of the 
circuitry from the BLM to the ARC suppresses the effect of brainstem 2-DG injection to 
increase food intake and regulate expression of orexigenic agouti-related peptide 
(AgRP) and NPY, suggesting a highly functional interrelationship between GS neurons 
from the brainstem and hypothalamus in the control of feeding (Fraley & Ritter 2003; 
Ritter et al. 2001). 
The medial amygdala nucleus (MAN) was also identified as a novel, limbic glucose-
sensing region, containing glucokinase (GK)-expressing glucose-sensing neurons that 
responded directly to alterations in glucose availability in both in vitro and in vivo 
experiments (Zhou et al. 2010).      
1.4.2 Non-Neuronal Glucose Sensing 
Non-neuronal glial cells such as astrocytes and tanycytes may also be involved in 
hypoglycaemia detection.  Importantly, astrocytes have been shown to be important for 
neuronal support, and metabolic coupling between astrocytes and neurons has been 
described whereby glucose utilisation by neurons occurs subsequent to its initial uptake 
and metabolism by astrocytes that produces lactate.  The lactate produced can then be 
transferred to neurons via specific monocarboxylate transporters (MCTs) and used by 
neurons for ATP generation (Magistretti et al. 1999; Pellerin et al. 2007).  The coupling 
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of metabolism in this way between the two cell types may be important in the function 
of glucose sensing. 
The increase in c-fos labelling of neurons and astrocytes in the ARC, PVN and NTS 
induced by intracarotid or brainstem injection of glucose or 2-DG can be blocked by 
administration of the astrocyte-specific glycolytic inhibitor methyl sulfoximide 
(Guillod-Maximin et al. 2004; Young et al. 2000) demonstrating the importance of 
astrocytic glucose metabolism in neuronal activation in response to glucose deprivation.  
C-fos labelling studies have demonstrated the involvement of astrocyte-derived lactate 
in the control of glucose-sensing neurons in the AP and NTS of the brainstem using an 
MCT inhibitor to prevent astrocyte to neuron shuttling of lactate, with the intervention 
leading to elevations in blood glucose concentrations (Briski & Patil 2005; Patil & 
Briski 2005; Patil & Briski 2005)  
Tanycytes are another subpopulation of glial cells that line the lateral lower part and the 
floor of the third ventricle.  They have extended basal processes that reach regions of 
the median eminence devoid of blood-brain barrier (BBB) and sometimes are in direct 
contact with microvessels present in the median eminence (Thorens 2012).  These 
processes form contact with neurons of the ARC, particularly those expressing NPY 
(Thorens 2012).  These cells are therefore optimally positioned to contact both the 
cerebrospinal fluid (CSF) and the general circulation and they express glucose 
transporter 2 (GLUT2) and GK (García et al. 2003; Millán et al. 2010), suggesting that 
they may be involved in glucose sensing.  Coppola et al. demonstrated a functional link 
between tanycytes and NPY neurons of the ARC with the observation that a reaction 
catalysed by deiodinase II (DIO2) in tanycytes can effect glucose sensing by inducing 
uncoupling protein 2 (UCP2) expression in NPY neurons (Coppola et al. 2007). 
1.5 Mechanisms of Glucose Sensing – Glucose Excited 
Neurons 
GE neurons for the most part use metabolic sensing mechanisms, requiring the uptake 
and subsequent metabolism of glucose to regulate their activity.  The mechanisms of 
glucose sensing by GE neurons are thought to be analogous to those of the pancreatic 
beta-cell, which depend on glucose metabolism and production of coupling factors 
predominantly from mitochondrial metabolism which induce depolarisation of the 
plasma membrane prior to Ca2+ entry and stimulated secretion (Thorens 2012).  Briefly, 
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this pathway involves uptake of glucose through GLUT2, phosphorylation of glucose 
by GK and a subsequent rise in the intracellular ATP/ADP ratio, which induces closure 
of ATP-sensitive potassium channels (KATP) resulting in depolarisation of the cell 
membrane and opening of voltage-gated calcium channels (VDCCs), resulting in Ca2+ 
influx which triggers insulin secretion. 
1.5.1 The Role of Glucose Transport in Glucose Sensing 
The Thorens group have focused on the role of Glut2 in glucose sensing and have 
observed its expression in the mouse brain in neurons, astrocytes, tanycytes and 
endothelial cells (Arluison et al. 2004; Marty et al. 2007).  However, co-localisation of 
Glut2 has not been observed in NPY, POMC, orexin or melanin-concentrating hormone 
(MCH) neurons of the hypothalamus (Mounien et al. 2010).  Similarly, only low Glut2 
expression has been confirmed by qRT-PCR in the rat ARC, VMH, PVN and LH (Li et 
al. 2003).  In 2004, Kang et al. conducted a study using single-cell RT-PCR and were 
able to show expression of Glut2 in about 33% of GE, GI and non-glucose-sensing 
neurons studied (Kang et al. 2004).  In support of a role for GLUT2 in the central 
glucose-sensing machinery, Roncero et al. did observe its expression co-localised with 
GK in the hypothalamus and brainstem (Roncero et al. 2004).  To further identify Glut2 
expressing cells in the brain, the Thorens lab developed a transgenic mouse with yellow 
fluorescent protein (YFP) labelled Glut2, and were able to determine that Glut2 was 
only expressed in neuronal cells (Mounien et al. 2010).  These cells were located most 
abundantly in the LH, with only a few cells present in the VMH and no positive cells in 
the ARC.  Further YFP expressing cells were located in NTS, DMNX and BLM of the 
brainstem.  Encouragingly, the YFP positive cells were demonstrated to be glucose 
responsive as intraperitoneal (IP) glucose or 2-DG increased c-fos immunoreactivity in 
these cells (Thorens 2012). 
The Thorens lab developed another elegant mouse model to investigate the role of Glut2 
in glucose sensing, in which they genetically inactivated Glut2 and transgenically re-
expressed Glut1 in the beta-cells to normalise glucose-stimulated insulin secretion 
(GSIS).  These mice had a reduced glucagon response to hypoglycaemia which was 
able to be restored upon re-expression of Glut2 in astrocytes but not in neurons, which 
also restored c-fos activation in the DVC in response to IP 2-DG injection (Thorens et 
al. 2000; Marty et al. 2005).  These findings lend support to the view that astrocyte-
neuron metabolic coupling is required for appropriate hypoglycaemia detection and 
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associated CRR, although make the subsequent observations by Mounien et al. of Glut2 
expression only in neurons puzzling (Mounien et al. 2010).  Importantly in these 
studies, c-fos labelling in the VMN in response to 2-DG was observed to be similar in 
GLUT2 positive and GLUT2-/- animals, suggesting that GLUT2 is not involved in 
hypoglycaemia detection in the VMN. 
There is evidence that Na+-dependent glucose transporters SGLT1 and 3 are required 
for glucose to excite neuronal activity.  ICV injection of phlorizin, a specific of inhibitor 
of SGLT1 enhances food intake in rats (Tsujii & Bray 1990) and inhibits activation of 
GE neurons in the VMH (Yang et al. 1999).  Furthermore, a majority of isolated GE 
hypothalamic neurons can be activated by the SGLT1 substrate α-MDG and the activity 
of these neurons cannot be increased by tolbutamide, suggesting that the increased 
activity induced by α-MDG may not be KATP-dependent (O’Malley et al. 2006).  
Glucose has been shown to induce a large inward current in Xenopus oocytes expressing 
SGLT3 and the mRNA for this transporter is expressed in cultured hypothalamic 
neurons and adult hypothalamus suggesting it may also be involved in glucose sensing 
(O’Malley et al. 2006). 
1.5.2 Role of Glucokinase in Glucose Sensing 
Phosphorylation of glucose by the low affinity enzyme GK is the regulated step in 
glycolysis (Lenzen 2014).  GK has a Km in the physiological range of blood glucose and 
is expressed in pancreatic beta and alpha-cells, hepatocytes and neurons.  
The expression of GK has been confirmed in the brain of mice (Jetton et al. 1994).  
Barry Levin’s group attempted to further characterise GK expression in the brain and 
were able to demonstrate its co-localisation with certain neuropeptides (Lynch et al. 
2000; Dunn-Meynell et al. 2002).  Jeffrey Friedman’s group generated an enhanced 
green fluorescent protein (EGFP)-tagged GK mouse line and confirmed GK expression 
in the hypothalamus and limbic regions of the brain (Stanley et al. 2013).  Similarly to 
the studies previously described for Glut2, the EGFP-GK cells demonstrated increased 
c-fos immunoreactivity in response to 2-DG or glucose, confirming them to be 
responsive to alterations in glucose levels.  By exploiting dual immunohistochemistry, 
GK was shown to be expressed in 36% of GI orexin positive LH neurons, in 20% of 
POMC and 28% of NPY/AgRP ARC neurons which are GE and GI respectively.  GK 
expression was also observed in glial cells in this work (Stanley et al. 2013).  Growth 
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hormone releasing hormone (GHRH) neurons were confirmed to express GK and were 
further studied with electrophysiology confirming that they were GI neurons, with their 
activity increasing with glucose deprivation (Stanley et al. 2013).  Importantly, growth 
hormone (GH) is one of the CRR hormones released in response to hypoglycaemia, and 
the findings in this study suggest it may be secreted as a direct consequence of glucose 
sensing by GK positive GI neurons that express GHRH. 
Hypothalamic brain slices and cultures have been studied ex vivo in order to investigate 
the effects of GK manipulation on glucose sensing (Kang et al. 2004; L. Kang et al. 
2006; Yang et al. 1999; Yang et al. 2004).  Interfering RNA mediated knockdown of 
GK in VMH preparations largely abolished GE and GI glucose sensing, while 
conversely GK activation of dissociated VMN glucose-sensing neurons amplified GE 
and GI response (L. Kang et al. 2006).  Furthermore, infusion of GK activators into the 
VMN reduced glucagon responses to hypoglycaemia while the GK inhibitor alloxan or 
siRNA knockdown of GK increased epinephrine responses to hypoglycaemia (Levin et 
al. 2008).   
The MAN was identified as a glucose-sensing brain region, with the presence of GK 
positive glucose-sensing neurons confirmed to have a role in increasing or decreasing 
the CRR to hypoglycaemia (Zhou et al. 2010).  Also, with infusion of GK inhibitors, 
feeding responses to glucoprivation were stimulated, with ICV administration inducing 
a more robust response than IV, consolidating the importance of central glucose-sensing 
mechanisms in this phenomenon (Osundiji et al. 2010).   
The Evans laboratory has investigated the role of GK in hyperglycaemia.  They found 
that while infusion of glucose into the third ventricle during systemic glucose overload 
enhanced glucose handling with facilitated insulin release, infusion of the GK inhibitors 
glucosamine or mannoheptulose reduced glucose tolerance associated with a decrease in 
insulin release (Osundiji et al. 2012).  Furthermore, brain delivery of the two GK 
inhibitors rapidly triggered robust feeding responses, a physiological response to 
glucose deprivation, which was more potent than when delivered intravenously 
(Osundiji et al. 2010).  
Whether GK may mediate defective central glucose sensing observed in patients with 
compromised CRR to hypoglycaemia, particularly those with T1D, is unconfirmed.  An 
increase in GK expression was observed in the rat VMN after hypoglycaemia, 
associated with a shift in the glucose responsiveness of GE neurons (L. Kang et al. 
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2008).  An increase in GK or hexokinase (HK) expression, if involved in regulating 
glucose-sensing neurons, would be predicted to impair CRR to low glucose, or at least 
shift the threshold for activation of CRR to a lower glucose value. 
1.5.3 Role of AMPK in Glucose Sensing 
AMP-activated protein kinase (AMPK) is an ubiquitously expressed enzyme composed 
of a catalytic α subunit and regulatory β and γ subunits, often referred to as the “fuel 
gauge” of a cell.  The α1 subunit of AMPK is ubiquitously expressed whereas the α2 
subunit is mainly expressed in skeletal muscle, heart and liver.  The α2 subunit however 
has also been shown in brain to be critical for angiogenesis of astrocytomas and for 
glucose sensing ability by specialised hypothalamic neurons (Neurath et al. 2006; Beall, 
Hamilton, et al. 2012).  AMPK is activated by an increase in the cellular AMP/ATP 
ratio.  This has led to the “fuel gauge” analogy whereby AMPK is activated when 
cellular ATP levels are depleted (Hardie & Carling 1997).  AMPK can also be activated 
by increased calcium concentrations (even in energy-replete cells), an effect which 
involves calcium/calmodulin-dependent kinase kinase-β (CAMKKβ)-dependent 
phosphorylation of threonine 172 (T172) in the activation loop of the α subunit of 
AMPK.  AMPK can also be activated by liver kinase B1 (LKB1) or serine/threonine 
kinase 11 (STK11), the TGFβ-associated kinase and by glucosamine (Lang & Föller 
2014).  AMPK can inhibit cell proliferation, counteract hypertrophy and stimulate 
autophagy. 
Cotero and Routh observed no effect of manipulating AMPK activity on the glucose 
sensing capacity of GE neurons from the ventrolateral-ventromedial nucleus (VL-
VMN) of rats.  In their study, inducing hypoglycaemia in the presence of the AMPK 
inhibitor Compound C had no effect on membrane hyperpolarisation in response to 0.1 
mM glucose which was comparable to the hyperpolarisation seen in the absence of 
Compound C.  In support of this finding, there was no significant difference in action 
potential frequency in VL-VMH neurons in the presence or absence of the AMPK 
activator AICAR, suggesting that AMPK does not regulate glucose sensing in this cell 
type (Cotero & Routh 2009).  In contrast, the Routh group also showed that in GI 
neurons of the VMN, application of AICAR mimicked the excitatory effect of low 
glucose on action potential frequency, suggesting that AMPK might play in a role in 
stimulated neuronal activity in GI neurons (Canabal et al. 2007).   
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In another study from the Routh lab focusing on NPY expressing GI neurons, 
phosphorylation of AMPK α2 was increased in rat VMH tissue preparations in response 
to a reduction in glucose from 2.5 mM to 0.7 mM for 30 minutes, suggesting activation 
of AMPK in response to glucose deprivation in the VMH (Murphy et al. 2009).  
AICAR incubation was found to increase the percentage of depolarised VMH neurons, 
and also further increase the number of depolarised VMH neurons in response to 
glucose reduction from 2.5 mM to 0.7 mM than glucose reduction alone in the absence 
of AICAR.  The AMPK inhibitor Compound C was found to prevent VMH neuron 
depolarisation in response to glucose reduction suggesting the importance of AMPK in 
the ability of GI neurons to depolarise in response to decreases in glucose levels 
(Murphy et al. 2009; Murphy et al. 2009).  
Thorens’ group have also identified that GI neurons expressing GLUT2 in the NTS are 
activated by hypoglycaemia, a depolarising effect which can be blocked by Compound 
C (Lamy et al. 2014).  When stimulated these neurons were found to increase glucagon 
secretion, suggesting they are part of the circuitry involved in linking hypoglycaemia 
detection to a CRR, which is dependent on AMPK.   
In 2004, Robert Sherwin’s group observed that VMH microinjection of the AMPK 
activator AICAR in rats markedly reduced the glucose infusion rate (GIR) required to 
maintain an insulin-induced hypoglycaemic plateau (McCrimmon et al. 2004).  The 
group confirmed that this observation was due to increased endogenous glucose 
production in AICAR treated rats.  However, levels of the main CRR hormones 
glucagon and epinephrine did not differ between the two treatment groups, somewhat 
unexpectedly, leading to the assumption that AMPK activation stimulates glucose 
production via a non-hormonally mediated signal (McCrimmon et al. 2004). 
Barbara Khan’s group used ICV injection of 2-DG to induce neuroglucopenia which 
induced a robust CRR and a rapid and potent activation of both α1 and α2 AMPK in the 
ARC, VMH and DMH (Alquier et al. 2007).  In this study, the authors also used a 
recurrent 2-DG protocol to induce defective CRR and showed that this was associated 
with reduced α1 and α2 AMPK activation in the ARC and MH.  Furthermore, injection 
of AICAR was able to partially restore the impaired CRR in recurrent 2-DG treated rats, 
reinforcing the importance for appropriate AMPK activation in mounting CRR to 
hypoglycaemia (Alquier et al. 2007). 
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The Sherwin lab extended their findings about the role of AMPK in hypothalamic 
glucose sensing in 2008 by demonstrating that knockdown of VMH AMPK α2 resulted 
in an increased requirement for exogenous glucose to maintain the hypoglycaemic 
plateau during a subsequent hyperinsulinaemic clamp study, reinforcing their finding 
that AMPK activation had the opposite effect to reduce the GIR during the same clamp 
(McCrimmon et al. 2008; McCrimmon et al. 2004).  AMPK α2 knockdown reduced 
endogenous glucose production and increased peripheral glucose utilisation in this 
study.  Furthermore, knockdown of AMPK α2 suppressed CRR hormone response 
during hypoglycaemic clamps with significant reductions in the secretion of glucagon 
and epinephrine observed.  The group went on to show that in a rat recurrent 
hypoglycaemia model of T1D, VMH activation of AMPK with AICAR restored 
defective CRR hormonal responses to hypoglycaemia induced by the recurrent 
hypoglycaemia protocol, supporting a crucial role of AMPK in mounting the CRR to 
hypoglycaemia (Fan et al. 2009).  The finding that modulation of hypothalamic AMPK 
can regulate glucose production has been confirmed by others (Yang et al. 2010).         
Another study has demonstrated that injection of glucose into the third ventricle of the 
hypothalamus results in suppressed activation of AMPK as indexed by its 
phosphorylation status.  The study also confirmed the phosphorylation of AMPK as an 
indicator of low energy status, as activation of AMPK with AICAR led to increased 
food intake after a 6 hour fast in wild-type (WT) mice (Zhang et al. 2011).      
In GT1-7 cells, a GE population of mouse hypothalamic neurons, overexpression of 
GLUT2 has been found to increase cellular ATP levels associated with reduced AMPK 
phosphorylation (Li et al. 2006).  Functionally, this study also demonstrated that 
GLUT2 overexpression attenuated the increase in AgRP mRNA expression and AMPK 
phosphorylation observed in response to 2-DG treatment, implicating a role for AMPK 
in the response to low glucose (Li et al. 2006).  Another in vitro study using 
hypothalamic N-43/5 neurons showed that these were GE neurons that had increased 
intracellular calcium mobilisation in response to depolarising stimuli including high 
glucose, high potassium and the KATP antagonist tolbutamide (Cai et al. 2007).  The 
depolarising stimuli suppressed AMPK phosphorylation in these cells which was 
associated with increased POMC expression, demonstrating an involvement of AMPK 
in the glucose-regulated expression of POMC. 
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Claret et al. showed the importance of functional α2 AMPK for glucose sensing in GE 
POMC neurons using electrophysiological recordings from mouse hypothalamic slices.  
In control POMC neurons a decrease in glucose from 2 mM to 0.1 mM resulted in 
reversible membrane hyperpolarisation, however this response was absent in POMC 
neurons lacking α2 AMPK (Claret et al. 2007).  Similarly, AgRP neurons also failed to 
hyperpolarise appropriately to 0.1 mM glucose stimulus when α2 AMPK was knocked 
out.  These data suggest that POMC and AgRP are GE neurons that require α2 AMPK 
for glucose responsiveness.       
The importance of AMPK for pancreatic beta-cell glucose sensing capacity has been 
investigated in vitro using isolated pancreatic islets and the CRI-G1 beta-cell line (Beall 
et al. 2010).  In line with previous studies detailed, loss of AMPK α2 from mouse islets 
resulted in defective hypoglycaemia sensing, an effect also seen with expression of a 
dominant negative form of AMPK (Beall et al. 2010).  This finding was also confirmed 
in GT1-7 neurons, a population of GE mouse hypothalamic neurons, where AMPK α2 
but not α1 knockdown resulted in reduced hypoglycaemia detection (Beall, Hamilton, et 
al. 2012). 
1.5.4 Role of KATP in Glucose Sensing 
1.5.4.1 Structure and Function of KATP Channels 
KATP channels are expressed in multiple tissues including heart, skeletal muscle, 
vascular smooth muscle, pancreatic islet cells and brain where they function to couple 
the metabolic state of the cell to its membrane excitability (Ashcroft 1988).  KATP 
channels are hetero-octameric structures of two different subunits that assemble in a 4:4 
stoichiometry (Tarasov et al. 2004).  The pore of the channel is formed by a tetramer of 
inwardly rectifying K+ channel (Kir6.x) subunits, either Kir6.1 or 6.2.  Each Kir6.x 
subunit is associated with a regulatory sulphonylurea receptor (SUR) subunit, either 
SUR1 or SUR2.  Different combinations of these subunits are expressed to form 
functional channels in different tissues, with Kir6.2 and SUR1 constituting the channels 
expressed in pancreatic beta-cells and brain (Sakura et al. 1995; Kang et al. 2004).  
Although all four Kir6.2 subunits have an ATP binding site, ATP binding to a single 
Kir6.2 subunit is sufficient to close the channel (Markworth et al. 2000).  The associated 
SUR1 subunit confers the channel sensitivity to the sulfonylurea class of drugs and K+ 
channel openers, as well as to the stimulatory action of magnesium-ADP (MgADP) 
(Tarasov et al. 2004).  SUR1 belongs to the ATP-binding cassette (ABC) transporter 
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family of proteins and, like its family members, has two cytosolic nucleotide-binding 
domains (NBDs).  The channel is opened by binding of magnesium nucleotides (eg 
MgATP, MgADP) to the NBDs of SUR1 (Tarasov et al. 2004).  Nucleotide regulation 
of the KATP channel is therefore complex, with activity inhibited by nucleotide binding 
to Kir6.2 and activated by Mg-nucleotide binding to SUR1 (Tarasov et al. 2004).  
Electrophysiological and biochemical experiments have been performed to characterise 
these channels and have revealed the nucleotide, pharmacological and intracellular 
signalling-mediated regulation of the channel gating (Aguilar-Bryan & Bryan 1999; 
Seino 1999; Dzeja & Terzic 1998).   
1.5.4.2 Beta-Cell KATP Channels 
In the pancreatic beta-cell, KATP channels function as metabolic sensors where they play 
a crucial role in GSIS by coupling pancreatic beta-cell metabolism to calcium entry 
(Tarasov et al. 2004).  Insulin is secreted in response to an elevation of cytosolic 
calcium levels, which results from influx through VDCCs in the plasma membrane.  
The opening of these channels is controlled by membrane potential, which is in turn 
determined largely by the activity of KATP channels (Tarasov et al. 2004). 
At substimulatory glucose levels, KATP channels are open and potassium (K+) efflux 
through the channels maintains the resting membrane potential at a hyperpolarised level 
of around -70 mV.  As glucose levels rise, uptake and metabolism is increased leading 
to an elevation in the ATP/ADP ratio, which closes KATP channels.  The inhibition of K+ 
efflux through KATP channels depolarises the cell membrane.  A sufficient 
depolarisation will lead to activation of VDCCs, calcium influx and the trigger of 
insulin secretion (Tarasov et al. 2004).  Therefore, opening of pancreatic beta-cell KATP 
channels inhibits insulin secretion where as closure initiates insulin release (Tarasov et 
al. 2004).  In this manner, KATP channels link metabolic changes to electrical activity 
and membrane excitability of beta-cells (Miki & Seino 2005).  Furthermore, the SUR1 
subunit of beta-cell KATP channels is the molecular target of the anti-diabetic 
sulphonylurea drugs including glibenclamide and tolbutamide which are widely used to 
reduce hyperglycaemia in T2D, as these agents are capable of enhancing insulin 
secretion by closing KATP channels (Ashcroft & Rorsman 1990).  Conversely, KATP 
channel openers like diazoxide can inhibit insulin secretion. 
Genetic manipulation of KATP channels including knockout and transgenic animal 
models have further clarified the physiological and pathophysiological roles that they 
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play (Miki & Seino 2005).  Kir6.2-/- mice have an absolute lack of beta-cell KATP 
channel activity, indicating that this subunit is essential for functional beta-cell KATP 
channels (Miki et al. 1998).  Kir6.2 containing channels are important for GSIS as 
Kir6.2-/- mice have neonatal hypoglycaemia and inappropriately high insulin levels 
(Miki et al. 1998; Seino et al. 2000).  Furthermore, membrane potential of beta-cells 
from Kir6.2-/- did not depolarise in response to high glucose, confirming that Kir6.2 
containing KATP channels are essential for glucose mediated regulation of electrical 
excitability of beta-cells (Miki et al. 1998; Seino et al. 2000).  Kir6.2-/- beta-cells also 
had abnormal intracellular calcium levels and failed to demonstrate a change in 
intracellular calcium levels upon treatment with tolbutamide, indicating a lack of 
functional KATP channels (Miki et al. 1998; Seino et al. 2000).  Impaired insulin 
secretion was observed in these animals in response to oral glucose tolerance test as 
well as from isolated islets in response to both high glucose and tolbutamide (Miki et al. 
1998; Seino et al. 2000).  The lack of KATP channel activity and insulin secretory defects 
of these mice were also observed in SUR1-/-, reinforcing the presence of Kir6.2/SUR1 
KATP channels in pancreatic beta-cells (Seghers et al. 2000; Shiota 2002).  SUR1-/- islets 
similarly had impaired glucose and tolbutamide stimulated insulin secretion. 
Consolidating the glucose sensing and insulin secretory defects observed in Kir6.2-/- and 
SUR1-/- mice, inactivating mutations of beta-cell KATP channel genes cause a severe 
form of persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI) (Glaser et al. 
1994).  KATP channel mutations in Kir6.2 and SUR1 are also responsible for a particular 
pathogenesis of T2D (Huopio et al. 2000; Gloyn et al. 2006) and a neonatal form of 
diabetes in humans (Gloyn et al. 2004). 
1.5.4.3 Regulation of KATP Channels 
Much of what is understood about the regulation of KATP channel activity has come 
from studies performed in pancreatic beta-cells. 
KATP channels are regulated by the intracellular concentrations of nucleotides, 
particularly ATP and ADP, as well as by lipids such as phosphatidylinositides and long-
chain acyl-CoA esters (Tarasov et al. 2004).   
In the pancreatic beta-cell a substantial fraction of ATP (68%) and ADP (45%) is non-
diffusible and contained in intracellular organelles, especially the insulin secretory 
granules (Detimary et al. 1995).  Intracellular ATP has been measured in purified rat 
beta-cells indicating that it exists at a concentration of 2 mmol/l at rest and increases to 
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4 mmol/l upon stimulation with 10 mmol/l glucose (Detimary et al. 1998).  In the same 
study intracellular ADP was measured at a concentration of 750 µmol/l in the absence 
of glucose and fell to 250 µmol/l in response to 10 mmol/l glucose (Detimary et al. 
1998).  Furthermore, glucose also causes a marked increase in phosphocreatine (PCr) 
and a fall in phosphate levels (Krippeit-Drews et al. 2003).   
ATP-mediated KATP channel inhibition has been demonstrated in response to nutrients 
that elevate ATP such as glucose, as well as by supply of reducing equivalents directly 
to cytochrome C, the final step in the electron transport chain (ETC) (Duchen et al. 
1993).  In contrast, metabolic inhibition of mitochondria with rotenone, DNP and azide 
reduce ATP generation and activate KATP channels in pancreatic beta-cells (Tarasov et 
al. 2004).  Furthermore, inhibition of ATP translocase by bongkrekic acid, which 
prevents ATP export from the mitochondria, also activates KATP channels (Kiranadi et 
al. 1991).      
It is clear however that ATP is not the sole regulator of KATP channel activity, 
evidenced by the fact that the sensitivity of the KATP channel for ATP-mediated 
inhibition differs in inside-out patches and the intact cell (IC50 = 10-30 µmol/l and 0.8 
mmol/l respectively) (Tarasov et al. 2004; Tucker et al. 1998; Schmid-Antomarchi et al. 
1987).  This data suggests that there are factors other than ATP in the intact cell that 
contribute to KATP channel regulation.  Importantly, it may be possible that the 
submembrane ATP level may not be the same as the bulk concentration, potentially 
owing to the activity of membrane ATPases, for example the Na+/K+ ATPase (Tarasov 
et al. 2004).  Similarly, ATP may provide a tonic level of inhibition against which 
metabolically generated changes in other substances regulate channel activity (Tarasov 
et al. 2004).      
The sensitivity of the channel to ATP is regulated at least by phosphatidylinositol-4,5-
bisphosphate (PIP2) and related phosphoinositides (PPIs), long-chain acyl-CoA esters 
(LC-CoAs) and MgADP (Tarasov et al. 2004).  All of these decrease the ability of ATP 
to close the KATP channel.   
Direct application of the PPIs PIP2 and PIP3 to excised patches has demonstrated that 
they interact with KATP channels to increase their open probability and reduce their ATP 
sensitivity (Fan & Makielski 1997; Baukrowitz et al. 1998).  Furthermore, 
overexpression of phosphatidylinositol 5-kinase (PI5-K), which increases PIP2 levels, 
reduces the ATP sensitivity of the KATP channel (Shyng et al. 2000) whereas breakdown 
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of PIP2 by phospholipase C (PLC) increases channel ATP sensitivity (Xie et al. 1999).  
These effects are mediated by the Kir6.2 subunit (Baukrowitz et al. 1998).  PPIs and 
ATP have been reported to occupy distinct binding sites on Kir6.2 (Schulze et al. 2003) 
but interact allosterically with ATP reducing the binding of PPIs and vice versa (Wang 
et al. 2002).   
LC-CoAs also enhance the open probability of the KATP channel and reduce its ATP 
sensitivity by interaction with the Kir6.2 subunit (Larsson et al. 1996; Gribble et al. 
1998) and appear to bind to the same site as PIP2 (Schulze et al. 2003).  In the 
pancreatic beta-cell, elevations in LC-CoA can result from glucose metabolism and 
from free fatty acids (FFAs) delivered from the blood or released from endogenous 
stores (Deeney et al. 2000).  Interestingly, LC-CoAs have been suggested to contribute 
to the reduced glucose sensitivity of the beta-cell observed in obese diabetic individuals 
due to chronic exposure to FFA leading to increased levels of LC-CoA which 
subsequently reduce the ATP sensitivity of the KATP channel inhibiting insulin secretion 
(Larsson et al. 1996; Tarasov et al. 2004).  Alternatively, LC-CoAs may exert a tonic 
stimulatory effect on the KATP channel as they have been reported to inhibit ATP/ADP 
translocase and upregulate UCP2, which would decrease ATP production (Chan et al. 
2004).  As a result, glucose metabolism would not fully close KATP channels leading to 
defective insulin secretion (Tarasov et al. 2004).      
MgADP shifts the ATP dose-response curve to higher ATP concentrations favouring an 
open state of the channel even at increased ATP levels (Kakei et al. 1986).  However, 
metabolic changes affecting the level of MgADP have also been proposed to couple cell 
metabolism to channel activity.  A mutation within NBD2 of SUR1 strongly reduces 
channel activation by MgADP, with channels expressing this mutation permanently 
closed even under conditions of low glucose (Nichols et al. 1996), indicating that 
MgADP interaction with SUR1 is important for appropriate channel opening.  Other 
mutations in both Kir6.2 and SUR1 have been found to reduce MgADP activation and 
prevent channel activation by metabolic inhibition (Dunne et al. 2004; Shyng et al. 
1997).  Some have suggested that an ATP hydrolysis cycle at NBD2 generates bound 
MgADP and that changes in cell metabolism influence KATP channel activity by 
modulating the length of time that NBD2 remains in the MgADP-bound (active) state 
(Zingman et al. 2001; Tarasov et al. 2004).  Under conditions of high metabolic activity, 
ADP levels will be low, so MgADP should dissociate rapidly from NBD2 causing 
channel activity to decrease (Tarasov et al. 2004).  In contrast, as metabolic activity 
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reduces, the rise in intracellular ADP will slow the dissociation of MgADP from NBD2 
and promote channel opening (Tarasov et al. 2004).  This model suggests that SUR1 
would be a sensor of the intracellular MgADP concentration.  The alternative view 
however is that MgADP simply shifts the ATP dose-response curve for channel 
inhibition and that the changes in ATP levels in response to fluctuations in metabolic 
rate constitute the means by which metabolism regulates KATP channel activity (Tarasov 
et al. 2004).   
Studies to delineate the contributions of MgADP and ATP to KATP channel regulation 
have been performed by expressing WT and mutant channel subunits in Xenopus 
oocytes.  In these studies, addition of 3 mmol/l azide, which blocks mitochondrial 
metabolism and lowers cytosolic ATP, produces a large increase in WT KATP channel 
current (Tarasov et al. 2004; Gribble, Ashfield et al. 1997).  Mutations in highly 
conserved residues in the NBDs of SUR1 abrogate nucleotide binding and abolish the 
ability of MgADP or MgATP to stimulate channel activity (Gribble, Tucker et al. 
1997).  Importantly, when Kir6.2 is co-expressed with SUR1 in which two key 
nucleotide-binding residues are mutated (SUR1-KAKM), azide is no longer able to 
stimulate channel activity (Tarasov et al. 2004).  This finding suggests that a reduction 
in metabolically derived ATP is only able to activate KATP channels upon its hydrolysis 
to MgADP and interaction with the SUR1 subunit of the channel.  However, MgADP 
can also shift the ATP concentration-course for ATP-mediated inhibition of the KATP 
channel, thus it is possible that the lack of metabolic activation of Kir6.2/SUR1-KAKM 
channels simply reflects a greater ATP sensitivity (due to the absence of MgADP 
mediated stimulation of the channel), keeping the channel closed even when ATP levels 
fall upon metabolic inhibition (Tarasov et al. 2004).   
Mutation of K185 to aspartate in Kir6.2 causes a profound decrease in the ability of 
ATP to block KATP channels, with the IC50 for ATP-mediated inhibition increasing from 
10 µmol/l to 1.9 mmol/l in Kir6.2-K185D channels (John et al. 2003).  Oocytes 
expressing Kir6.2-K185D/SUR1 channels had large KATP currents under control 
conditions, which were increased further by metabolic poisoning with azide (Tarasov et 
al. 2004).  Co-expression of Kir6.2-K185D with SUR1-KAKM in oocytes resulted in 
smaller whole-cell currents under control conditions than Kir6.2-K185D/SUR1 
channels, indicating that the difference in resting currents must be due to the 
contribution of MgADP/MgATP to the regulation of KATP channel activity at SUR1.  
The observation that both Kir6.2-K185D/SUR1 and Kir6.2-K185D/SUR1-KAKM had 
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comparable IC50 for ATP-mediated inhibition of the channel (1.9 mmol/l and 2.0 
mmol/l respectively) is consistent with the idea that cytosolic Mg-nucleotides induce a 
significant decrease in the apparent ATP sensitivity of the channel in the cell through 
regulation of SUR1 (Tarasov et al. 2004).   
If KATP channel activation upon metabolic inhibition were to be mediated only by Mg-
nucleotide interaction with SUR1, Kir6.2/SUR1-KAKM channels should not be 
activated by azide, as these channels are insensitive to MgADP stimulation.  However, 
Tarasov et al. were able to demonstrate activation of Kir6.2-K185D/SUR1-KAKM 
channels by azide, suggesting that this increase in current must be due to a reduction in 
ATP levels sensed by Kir6.2 (Tarasov et al. 2004).  These experiments suggest that 
changes in intracellular ATP couple beta-cell metabolism to KATP channel closure and 
that Kir6.2 serves as a metabolic sensor (Tarasov et al. 2004).  They are also consistent 
with the notion that MgADP can shift the ATP dose-response curve for inhibition of 
KATP channels at Kir6.2 (Tarasov et al. 2004).  The results do not rule out that 
alterations in the rate of MgATP hydrolysis to MgADP may also play a role in coupling 
cellular metabolism to KATP channel inhibition (Zingman et al. 2001; Tarasov et al. 
2004).    
In the pancreatic beta-cell, KATP activity may also be regulated by creatine and 
adenylate kinase shuttles, with creatine kinase (CK) linking ATP generation to KATP 
channel closure and adenylate kinase (AK) regulating KATP channel opening (Tarasov et 
al. 2004).  The proposition is that in the microenvironment of the channel, AK could 
convert AMP and ATP to ADP and promote channel opening, whereas CK could 
catalyse the transfer of phosphate from PCr to ADP, producing creatine and ATP, and 
consequently induce channel closure (Tarasov et al. 2004).  In support of these notions, 
PCr concentration increases in islets in response to glucose (Krippeit-Drews et al. 2003) 
and has been shown to reduce the ability of ADP to stimulate KATP channel activity in 
beta-cells (Tarasov et al. 2004).  Importantly, in the heart CK has been shown to 
physically associate with the KATP channel (Crawford et al. 2001).    
Regulation of the KATP channel is complex, with PPIs and LC-CoAs exerting tonic 
effects on the channel and adenine nucleotides modulating channel activity.  
Furthermore, additional factors that regulate levels of nucleotides in the immediate 
environment of the channel may further modulate channel activity. 
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1.5.4.4 Brain KATP Channels 
KATP channels exist throughout the brain, including in the hippocampus, cortex, 
substantia nigra and high expression observed in the hypothalamus, including regions 
thought to be involved in glucose sensing such as the VMH (Ashford et al. 1990; Kang 
et al. 2004).   
KATP channels are most abundantly expressed in the hypothalamus (Ashford et al. 
1990), which is well established as a homeostatic centre involved in the regulation of 
energy metabolism, body weight and glucose levels (Levin 1999).  Glucose-sensing 
neurons of the hypothalamus are depolarised by tolbutamide (Ashford et al. 1990) and 
the presence of KATP channels has been demonstrated in hypothalamic glucose 
responsive neurons of Zucker rats (Rowe et al. 1996).   
Interestingly, the expression of KATP channel subunits Kir6.2 and SUR1 has been shown 
to be regulated by glucose in the mediobasal hypothalamus, with a downregulation of 
expression observed in response to hyperglycaemia (Acosta-Martínez & Levine 2007).  
Kong et al. demonstrated KATP-dependent, GE electrical activity in MCH expressing 
hypothalamic neurons (Kong et al. 2010).  Amoroso et al., characterised KATP channels 
in the substantia nigra of rats, observing increased γ-aminobutyric acid (GABA) release 
from slices in response to high potassium, glucose or the potent sulphonylurea 
gliquidone (Amoroso et al. 1990).  In this study, KATP channels were also demonstrated 
to open in response to ATP depletion by oligomycin, a complex V mitochondrial ETC 
inhibitor, which was completely inhibited by gliquidone (Amoroso et al. 1990).  
Together, these data demonstrate that KATP channels are inhibited by high glucose levels 
and opened in response to energy deprivation. 
Glucose-sensing neurons of the VMH have been shown to express Kir6.2 and SUR1 by 
RT-PCR and VMH neurons from Kir6.2-/- mice failed to alter their electrical activity in 
response to glucose during electrophysiological experiments demonstrating the 
importance of KATP channels for glucose sensing (Miki et al. 2001).  Furthermore, 
Kir6.2-/- mice were found to have a compromised recovery from insulin-induced 
hypoglycaemia, suggesting that they have an impaired CRR.  These mice were found to 
have markedly reduced glucagon secretion in response to hypoglycaemia compared to 
WT mice (Miki et al. 2001).  Intriguingly, the glucagon response to low glucose was 
intact in isolated islets from Kir6.2-/-, suggesting that the primary defect in the glucagon 
response was centrally mediated.  In support of this notion, neuroglycopenia stimulates 
 
 
 
22 
glucagon secretion by activating autonomic neurons (Taborsky Jr et al. 1998).  
Importantly, 2-DG-induced neuroglycopenia failed to stimulate glucagon secretion in 
Kir6.2-/- demonstrating the critical importance of KATP channels in hypoglycaemia 
detection (Miki et al. 2001).   
In a pilot study of ten patients, Stephanie Amiel’s group found no effect of 
administering either diazoxide or glibenclamide compared to placebo on CRR hormone 
responses during a subsequent hypoglycaemic clamp procedure, suggesting that 
modulation of KATP channels did not affect hormonal CRRs to hypoglycaemia 
(Bingham et al. 2002).  Importantly however, studies in conscious mice demonstrated 
that CRRs to hypoglycaemia were attenuated by brain delivery of sulphonylureas to 
close brain KATP channels (Evans et al. 2004).  In this work, glibenclamide was infused 
directly into the VMH, as well as via the usual ICV method, confirming that 
epinephrine and glucagon responses to brain glucopenia or systemic hypoglycaemia 
were suppressed by VMH sulphonylureas (Evans et al. 2004).  The data demonstrate 
that closing hypothalamic KATP channels during hypoglycaemia prevents the triggering 
of the protective hormonal CRR, thereby confirming that the open state of hypothalamic 
KATP channels is critical for glucose-sensing neurons to detect falling blood glucose 
levels and stimulate downstream CRRs against glucose deprivation (Evans et al. 2004).  
The following year, McCrimmon et al. were able to demonstrate that in vivo delivery of 
pharmacological agents that open or close the KATP channel within the VMH have 
opposite effects to enhance or suppress respectively the CRR to acute hypoglycaemia 
(McCrimmon et al. 2005).  By using a Kir6.2/SUR1 selective KATP channel opener, 
NN414, the observed amplification of the CRR was proven to be mediated specifically 
by this isoform of KATP channel, confirming their involvement in the mechanism of 
VMH neuronal glucose sensing (McCrimmon et al. 2005).  Importantly, this study also 
demonstrated that VMH injection of diazoxide to open KATP channels produced an 
amplification of hormonal CRRs and a reduction in the amount of exogenous glucose 
required to maintain a hyperinsulinaemic-hypoglycaemic clamp in rats with defective 
CRR caused by recurrent hypoglycaemia (McCrimmon et al. 2005).  This data suggests 
that defective KATP opening to acute hypoglycaemia, induced by recurrent 
hypoglycaemia exposure, may be a mediator of defective CRR observed in T1D.  A 
recent study in humans has demonstrated for the first time the potential utility of KATP 
channel activators, such as diazoxide, to improve CRRs to hypoglycaemia in 
individuals with T1D (George et al. 2015). 
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1.6 Defective Glucose Sensing in T1D 
Defective central glucose-sensing mechanisms may be the root cause of defective CRR 
observed in T1D.  Exposing hypothalamic but not hindbrain glucose-sensing regions to 
antecedent hypoglycaemia induces reduced CRR hormone responses to acute 
hypoglycaemia, with antecedent hypothalamic glucoprivation causing a defect similar 
to that in magnitude observed after recurrent hypoglycaemia (Sanders et al. 2007).  
Furthermore a single exposure to insulin-induced hypoglycaemia in vivo induces a left 
shift in the glucose responsiveness of VMH GE neurons to subsequent hypoglycaemia 
when studied ex vivo, resulting in hyperpolarisation of the cells only at lower glucose 
concentrations than controls (L. Kang et al. 2008).  
1.6.1 Enhanced Glucose Metabolism 
Evidence from rat studies shows that prolonged hypoglycaemia for one or two weeks 
increases GLUT1 or GLUT3 expression, raises glucose levels and enhances glucose 
uptake in the brain (Simpson et al. 1999; Duelli et al. 1999).  Furthermore, as previously 
mentioned recurrent hypoglycaemia upregulates GK mRNA (L. Kang et al. 2008) and 
enhances HK activity as measured by increased glucose phosphorylation (Osundiji et al. 
2010), while direct activation of GK suppresses the CRR to hypoglycaemia (Levin et al. 
2008).  These observations would be predicted to lead to enhanced glucose metabolism, 
preserving the intracellular energy status, increasing ATP levels and therefore leading to 
inhibition of KATP channels and a lack of activation of CRR to hypoglycaemia (Beall, 
Ashford, et al. 2012).  Importantly, human studies suggest that after 56 hours of 
intermittent hypoglycaemia, brain glucose uptake is preserved in response to stepped 
hypoglycaemia, in contrast to the normal decrease in brain glucose uptake usually 
observed in response to hypoglycaemia (Boyle et al. 1994).  This enhancement of brain 
glucose uptake would preserve energy status and impede activation of CRR to 
hypoglycaemia.   
1.6.2 Alternate Fuel Usage 
Alternatively, the metabolism of alternate fuel sources other than glucose, particular 
entailing a switch from glucose to lipid to metabolism, may underpin defective CRR to 
hypoglycaemia.  Evidence supporting this hypothesis includes the finding of increased 
brain acetate concentration and utilisation during hypoglycaemia in patients with T1D 
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compared to control volunteers (Mason et al. 2006).  Glycogen is stored in astrocytes 
and is mobilised during energy stress, being released as lactate, which can be 
transported to neurons to preserve their activity (Brown et al. 2004).  Also, rats treated 
with a glycogen phosphorylase inhibitor under euglycaemic conditions, which permits 
accumulation of astrocyte glycogen stores, maintained brain activity significantly longer 
during hypoglycaemia than untreated rats with normal brain glycogen levels, 
demonstrating that glycogen can provide a central fuel source during hypoglycaemia 
(Suh et al. 2007).  Brain glycogen content is reduced in mice, rats and humans during 
hypoglycaemia (Canada et al. 2011; Herzog et al. 2008; Lei & Gruetter 2006), 
demonstrating that glycogen is utilised and may serve as a temporary energy source 
(Beall, Ashford, et al. 2012).  Lending further support to this finding is the measurement 
of increased glycogen content in rat hypothalamus after recurrent ICV 2-DG injections 
on three consecutive days (Alquier et al. 2007).  These findings would be expected to 
delay the responses of glucose-sensing neurons to hypoglycaemia and impede initiation 
of the CRR (Beall, Ashford, et al. 2012).  The increase of glycogen content in rat 
hypothalamus after recurrent 2-DG correlated with a delayed activation of AMPK in 
response to hypoglycaemia, suggesting that suppressed AMPK activity may be linked to 
delayed detection of glucose deprivation (Beall, Ashford, et al. 2012; Alquier et al. 
2007).  Local delivery of lactate into the VMH suppresses CRRs to systemically 
induced hypoglycaemia (Borg et al. 2003), and the uptake and utilisation of 
monocarboxylic acids is enhanced by antecedent hypoglycaemia (Herzog et al. 2013) 
and diabetes (Mason et al. 2006).  It has been proposed that lactate suppresses CRRs to 
hypoglycaemia by increasing extracellular GABA levels in the VMH (Chan et al. 2013) 
presumably by increased activity of GE neurons.  Data suggest that lactate affords 
neurons the capacity to maintain the same rate of glucose oxidation and TCA cycle 
activity during hypoglycaemia as under euglycaemic conditions (Herzog et al. 2013).  
This would lead to lactate mediated stimulation of GE neurons and silencing of GI 
neurons, presumably by inactivation of AMPK.  Lactate recapitulated the effect of 
recurrent hypoglycaemia to decrease the glucose threshold at which GI neurons become 
active (Song & Routh 2006), therefore implicating a role for lactate in the impairment 
of glucose sensing in individuals with antecedent exposure to hypoglycaemia (Chan & 
Sherwin 2013).                
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1.6.3 Altered Hypothalamic Neurotransmission 
There is also data implicating a role for GABA in the control of glucose sensing and 
CRR.  GABA is an inhibitory neurotransmitter that may act downstream of KATP to 
modulate glucagon responses to hypoglycaemia (Ogunnowo-Bada et al. 2014).  Studies 
showed that pharmacological closing of KATP increased VMN GABA levels while 
opening conversely decreased GABA levels, effects which were associated with 
suppressed or enhanced glucagon and other CRRs to hypoglycaemia (Chan et al. 2007; 
Chan et al. 2006).  Furthermore, acute hypoglycaemia decreases VMH GABA levels 
while recurrent hypoglycaemia prevents the fall in GABA (Chan et al. 2008).  Together 
these data permit speculation that KATP channel-expressing GE VMH neurons are 
GABAergic, and fail to hyperpolarise in response to low glucose following antecedent 
hypoglycaemia.  Further promoting a role for GABA in the regulation of VMH glucose 
sensing, infusion of glucose into the VMH of rats suppressed glucagon and epinephrine 
responses to hypoglycaemia and altered VMH GABA levels, with the effects of glucose 
being antagonised by GABAA receptor inhibition (Zhu et al. 2010).   
Glutamate is the predominant excitatory neurotransmitter in the CNS.  One particular 
study has demonstrated that specific knockout VGLUT2, in SF-1 neurons of the VMH 
leads to loss of the glucagon response to hypoglycaemia, suggesting an integral role of 
glutamate neurotransmission in the stimulation of glucagon release (Tong et al. 2007).  
Another study has shown that EphA5 receptor signalling in the VMH can augment 
CRRs to hypoglycaemia by enhancing glutamatergic neurotransmission in the VMH 
(Murai & Pasquale 2011).    
Serotonin has also been implicated in modulating CRRs to hypoglycaemia, with the 
serotonin selective reuptake inhibitor (SSRI) sertraline augmenting glucagon, 
epinephrine and norepinephrine responses to hypoglycaemia in rats (Sanders et al. 
2008).  Human studies have confirmed SSRI-mediated increases in catecholamine 
responses to hypoglycaemia (Briscoe et al. 2008; Briscoe et al. 2008).   
1.6.4 Altered VMH Neuropeptide Input 
Corticotrophin-releasing hormone (CRH) and urocortins 1-3 (UCN1-3) are 
neuropeptides that are capable of regulating the CRR to hypoglycaemia, with CRH via 
the CRH receptor 1 (CRHR1) amplifying, and UCN via the CRH receptor 2 (CRHR2) 
suppressing these responses (McCrimmon et al. 2006).  UCN3 was shown to reduce 
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VMH glucose-sensing neuronal responses to hypoglycaemia, such that their electrical 
activity was only altered at a lower glucose threshold (McCrimmon et al. 2006).  UCN3 
positive nerve terminals innervate the VMH (Chen et al. 2011; Zhou et al. 2010) and 
therefore may be a mediator of defective CRRs to hypoglycaemia via their action to 
suppress VMH glucose sensing.      
1.7 Mechanisms of Glucose Sensing – Glucose 
Inhibited Neurons 
In VMH GI neurons, hypoglycaemia is thought to induce firing by a glucose 
metabolism-dependent signalling pathway.  Kang et al. used single-cell RT-PCR 
analysis to demonstrate that different populations of GI neurons express Glut1, 2 and 3 
so any of these transporters may be involved in glucose uptake in GI neurons (Kang et 
al. 2004).  The same group has also identified the importance of GK for GI neuron 
glucose sensing (L. Kang et al. 2006).  The mechanism of glucose sensing by VMH GI 
neurons proposed by Vanessa Routh’s group is initially similar to that observed in GE 
neurons; namely an increase in the cellular AMP/ATP ratio in response to reduced 
glucose metabolism.  This activates AMPK, which in turn triggers production of nitric 
oxide (NO) by endothelial nitric oxide synthase (eNOS), and the subsequent activation 
of guanylate cyclase by NO further activates AMPK.  Contrastingly to GE neurons 
however, the subsequent regulation of the chloride conductance of cystic fibrosis 
transmembrane conductance regulator (CFTR) by AMPK is responsible for the 
induction of neuronal firing (Canabal et al. 2007; Murphy et al. 2009; Fioramonti et al. 
2010). 
Denis Burdakov’s laboratory has also described orexin neurons from the LH as being 
GI but with glucose-sensing mechanisms distinct from those neurons described by 
Routh.  Studies from the Burdakov group have reported that the activation of these 
neurons can be triggered by the non-metabolisable analogue 2-DG, that lactate cannot 
reproduce the glucose response and that GK inhibitors do not affect glucose sensing by 
these neurons (Dunn-Meynell et al. 2002; González et al. 2008).  This led to the 
hypothesis that glucose activates a cell surface receptor that leads to regulation of 
channel activity, which was proposed to be controlled by tandem pore K+ channels 
(TRPs) (Burdakov et al. 2006), but TRP knockout mice failed to directly support this 
hypothesis (Gonzàlez et al. 2009).   
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In GI neurons from the brainstem, electrophysiological studies have shown that they are 
activated in response to glucose removal by a signalling pathway that requires the 
presence of GK and the regulation of a K+ current (Balfour et al. 2006; Balfour & Trapp 
2007).   
1.8 Interleukin-6 – Discovery and Function 
Cytokines are secreted proteins which are involved in communication between cells of 
the immune system that also perform regulatory functions outside of this system 
(Schaper & Rose-John 2015).  What is now called Interleukin-6 (IL-6) was originally 
identified as a novel mRNA in the 1980s, when two independent laboratories observed 
its expression after fibroblasts were stimulated with interferon-β (IFN-β) (Weissenbach 
et al. 1980; Sehgal & Sagar 1980).  These groups called the discovery IFN-β2, and over 
the subsequent years, further groups worldwide also identified the same protein as a T-
cell secreted factor involved in the stimulation of B-cells with varying nomenclature 
(Content et al. 1982; Haegeman et al. 1986; Hirano et al. 1986; Van Damme et al. 
1987), before it was finally termed IL-6 (Yasukawa et al. 1987).  The IL-6 mRNA 
encodes a secreted protein which consists of 184 amino acids which would translate into 
a protein of molecular weight around 21 kDa, however subsequent N-linked 
glycosylation means IL-6 exists as several isoforms of 21-28 kDa (Wolf et al. 2014).  
Glycosylation may be important for the stability or half-life of IL-6, but is not essential 
for its function, as non-glycosylated recombinant IL-6 produced in Escherichia coli (E. 
coli) is functional and is routinely used for in vivo and in vitro experiments (Wolf et al. 
2014). 
IL-6 is the strongest activator of the hepatic acute phase response which involves the 
expression of C-reactive protein (CRP), serum amyloid A (SAA), haptoglobin and α1-
acid glycoprotein, which are secreted by hepatocytes during bacterial infections 
(Schaper & Rose-John 2015).  IL-6 also plays a role in liver regeneration (Cressman et 
al. 1996), controls body weight (K. Wallenius et al. 2002), the development of local 
antibody responses (Ramsay et al. 1994) and has key roles in the CNS (Erta et al. 2012). 
Over the last twenty years interest in the role of inflammation in a wide range of 
diseases not commonly thought of as immune-mediated disorders has led to studies that 
demonstrate that inflammatory mediators, such as IL-6, may not only be biomarkers of 
metabolic disease but may directly contribute to beta-cell dysfunction and insulin 
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resistance, among other pathologies (Kristiansen & Mandrup-Poulsen 2005).  These 
will be addressed subsequently.   
1.9 Interleukin-6 Signalling 
IL-6 activates cells via a heterodimeric signalling complex consisting of the IL-6 α-
receptor (IL-6Rα) and the signal transducing β-subunit glycoprotein 130 (gp130), which 
is shared with several other members of the IL-6 cytokine family (Wolf et al. 2014).  
The IL-6R exists in two forms, a membrane bound and a soluble version, which 
transduce classical and trans-signalling by IL-6 respectively.  Gp130 of the IL-6R 
complex is ubiquitously expressed in all cell types, whereas the IL-6Rα subunit is 
predominantly expressed in hepatocytes, megakaryocytes and several leukocyte 
populations (Wolf et al. 2014).  Studies have suggested that IL-6 trans-signalling via the 
soluble IL-6R accounts for the pro-inflammatory actions of IL-6, meaning that specific 
inhibition of this pathway, which does not mediate anti-inflammatory properties of 
classical membrane bound IL-6 signalling, could be a valuable therapeutic target to treat 
human inflammatory diseases (Rose-John 2012; Jones et al. 2011).   
IL-6 signalling involves first the binding of IL-6 to its non-signalling α-receptor, which 
then permits recruitment of the signalling transducing gp130 subunit (Heinrich et al. 
2003).  As mentioned, there are multiple components of the IL-6 signalling system 
including membrane bound gp130 and IL-6Rα, as well as soluble forms of both 
proteins, sIL-6R and sgp130, making the biology of IL-6R signalling highly complex.  
For example, given the ubiquitous expression of gp130 on all cell types, a complex of 
IL-6 and sIL-6R can act agonistically rather than antagonistically, while sIL-6Rα 
potentiates the antagonistic activity of sgp130 (Heinrich et al. 2003).   
1.10 sIL-6R and Trans-Signalling 
As mentioned, classical signalling by IL-6 involves signal transduction via the 
formation of a signalling complex consisting of gp130 and IL-6Rα, where as in cell 
types lacking the IL-6Rα, trans-signalling is transferred via the combination of gp130 
with the sIL-6R, which exists in human plasma at a concentration of 25-35 ng/ml 
(Chalaris et al. 2011).  sIL-6R arises either via shedding of the membrane bound form 
due to proteolytic cleavage (Müllberg et al. 1993) or via alternative splicing of the IL-
6R gene resulting in omission of the transmembrane domain coding exon (Muller-
Newen et al. 1996; Wolf et al. 2014).  In humans, an alternatively spliced mRNA has 
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been observed leading to translation of a sIL-6R protein (Lust et al. 1992).  The pro-
inflammatory consequences of IL-6 trans-signalling have already been targeted 
therapeutically, based on the efficacy of a naturally occurring soluble form of gp130 to 
inhibit trans-signalling (Jostock et al. 2001).  Based on this data, the artificial fusion 
protein sgp130-Fc, a dimerisation of two sgp130 monomers and the Fc-part of a human 
IgG antibody, has been developed (Tenhumberg et al. 2008) and an optimised version 
of this inhibitor is at the time of writing being tested in phase I clinical trials (Jones et 
al. 2011; Wolf et al. 2014).  This construct was shown to completely block IL-6 trans-
signalling without affecting classical IL-6 signalling (Jostock et al. 2001).  Sgp130-Fc is 
able to bind IL-6/sIL-6R complexes preventing trans-signalling via sequestering the IL-
6/sIL-6R complexes. 
Efforts to discover the cellular origin of the sIL-6R in mice have identified hepatocytes 
and myeloid cells, such as monocytes and macrophages, as the major contributors to 
sIL-6R levels, as a 30% or 63% reduction in circulating sIL-6R levels were observed 
with knockout of the IL-6R in hepatocytes and myeloid cells respectively (McFarland-
Mancini et al. 2010).  Interestingly, IL-6-/- mice were found to have a 50% reduction in 
sIL-6R levels, implicating a role for IL-6 itself in the regulation of cellular expression of 
IL-6R and subsequent sIL-6R generation (Coles et al. 2007).  Sgp130 also exists as a 
component of IL-6 signalling, similarly formed via either alternative splicing or 
proteolytic cleavage resulting in shedding from the cell membrane.  As of 2014, three 
different splice variants of sgp130 have been discovered, all of which are potent 
inhibitors of IL-6 trans-signalling (Jostock et al. 2001; Richards et al. 2006).  
Functionally, the ability of sgp130 to suppress trans-signalling is responsible for the 
anti-inflammatory effect of epigallocatechin-3-gallate, a compound studied in models of 
arthritis (Ahmed et al. 2006). 
1.11 Signalling Cascades Activated by IL-6 
Signalling by IL-6 is transduced by the Janus kinase/signal transducer and activator of 
transcription (JAK/STAT), mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol-3-kinase (PI3K) pathways (Heinrich et al. 2003). 
IL-6 via its receptor complex rapidly induces activation of tyrosine kinases of the Janus 
kinase (JAK) family, which are constitutively associated with the cytoplasmic tail 
region of gp130, by autophosphorylation (Heinrich et al. 2003; Schaper & Rose-John 
2015).  Gp130 binds to JAK1, JAK2 and tyrosine kinase 2 (TYK2), with JAK1 having 
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been demonstrated to play an essential role as cells lacking JAK1 have impaired IL-6 
signal transduction (Guschin et al. 1995; Rodig et al. 1998).  A second kinase family, 
the Src-family, has also been shown to be involved in IL-6 signalling, with a strong 
interaction of tyrosine protein kinase HCK and gp130 observed in response to IL-6 
stimulation (Ernst et al. 1994).  Studies have demonstrated HCK to be important for IL-
6-dependent growth of myeloma cells (Hausherr et al. 2007) with MAPK involvement 
(Schaeffer et al. 2001).   
The signal transducer and activator of transcription (STAT) family of proteins have a 
central role in IL-6-type cytokine signalling and their activation requires the transient 
association of the STATs with the cytokine receptors, homo- or heterodimerisation of 
tyrosine phosphorylated STATs and subsequent translocation of these dimers to the 
nucleus where they bind to the promoter regions of IL-6-inducible genes (Heinrich et al. 
2003; Schaper & Rose-John 2015; Pranada et al. 2004).  Once activated by 
autophosphorylation, JAK kinases phosphorylate tyrosine residues in the cytoplasmic 
region of gp130, leading to recruitment of STAT proteins.  All IL-6-type family 
cytokines potently activate STAT3, which is phosphorylated on tyrosine 705 (Y705) via 
gp130 (Heinrich et al. 1998; Kaptein et al. 1996).  STATs can then dimerise via their 
SH2 domains and translocate to the nucleus where they regulate transcription of target 
genes.   
As well as tyrosine phosphorylation of STATs which leads to their nuclear 
translocation, STAT3 can also be phosphorylated at its serine 727 (S727) residue, with 
evidence suggesting a mitochondrial targeting and action of S727 phosphorylated 
STAT3 (Tian & An 2004; Wegrzyn et al. 2009; Gough et al. 2013). 
The MAPK signalling cascade is also activated by IL-6, dependent on the SH2-domain-
containing tyrosine phosphatase (SHP2)-binding site, Y759 of gp130 (Schiemann et al. 
1997; Friederichs et al. 2001).  Activation of the MAPK cascade by IL-6 involves the 
SHP2 linkage of the growth factor receptor bound protein/Son of Sevenless (Grb2-SOS) 
complex and/or Grb2-associated binder-1 (Gab1) to gp130 (Heinrich et al. 2003).  
SHP2 is rapidly recruited to tyrosine-phosphorylated gp130 and becomes 
phosphorylated in a JAK1-dependent manner (Schaper et al. 1998).  Phosphorylated 
SHP2 can then interact with Grb2 (Fukada et al. 1996).   
Gab1 is able to activate the Ras-Raf-MAPK cascade in response to IL-6.  IL-6 
stimulation leads to the tyrosine phosphorylation of Gab1 and its subsequent interaction 
 
 
 
31 
with SHP2 and PI3K, leading to activation of extracellular signal-regulated kinase 2 
(ERK2) (Takahashi-Tezuka et al. 1998).  The role of Gab1 in activating the MAPK 
cascade was confirmed in fibroblasts deficient in Gab1, which show a markedly reduced 
MAPK activity in response to IL-6 (Itoh et al. 2000).  The balance between STAT3 and 
MAPK activation is crucial for the homeostasis of the organism and for controlled cell 
proliferation (Fukada et al. 1998; Fukada et al. 1996).  Y759 of gp130 controls this 
balance, where its phosphorylation facilitates MAPK activation and dephosphorylation 
increases STAT3 activation (Schaper et al. 1998; Eulenfeld et al. 2012). 
IL-6 also activates the PI3K signalling pathway. Studies have documented that IL-6 has 
both pro- and anti-apoptotic function that is dependent on activation of PI3K signalling 
in cancer cell lines (Hideshima et al. 2001; Jee et al. 2004).  The adaptor protein Gab1 
interacts with PI3K and therefore may couple gp130 to PI3K activation (Takahashi-
Tezuka et al. 1998).   
1.12 Negative Regulation of IL-6 Signalling 
The recruitment of SHP2 to gp130 is also functionally important due to its phosphatase 
activity (Fischer et al. 2004).  Binding of SHP2 to gp130 induces a conformational 
change in the former, leading to its enzymatic activity (Pluskey et al. 1995).  As 
described above, SHP2 is important as an adaptor for IL-6-induced MAPK signalling, 
however, it also negatively regulates the JAK/STAT pathway (Lehmann et al. 2002).  
Lehmann et al. showed that overexpression of dominant-negative SHP2 mutants in 
COS-7 cells led to enhanced gp130, JAK, STAT and SHP2 phosphorylation, 
demonstrating the importance of SHP2 to negatively regulate these pathways (Lehmann 
et al. 2002).  Co-immunoprecipitation (Co-IP) studies have demonstrated association of 
STAT3 and SHP2, suggesting STAT3 is a direct target for SHP2-mediated 
dephosphorylation (Gunaje & Bhat 2000).  A role for protein tyrosine phosphatase ε C 
(PTPεC) in inhibition of IL-6-induced JAK/STAT signalling has been described 
(Tanuma et al. 2000), as well as one for protein tyrosine phosphatase 1B (PTP1B) 
(Myers et al. 2001).   
The suppressor of cytokine signalling (SOCS) family of proteins are another 
mechanism of inhibition of IL-6-type family cytokine signalling (Yoshimura et al. 
1995; Starr et al. 1997; Endo et al. 1997; Naka et al. 1997), and their expression is 
rapidly upregulated in response to IL-6 (Starr et al. 1997; Naka et al. 1997).  SOCS 
proteins are induced via the JAK/STAT pathway and subsequently inhibit this pathway 
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at the level of JAKs in a classical negative feedback loop (Starr et al. 1997; Naka et al. 
1997).  SOCS3, potently induced by IL-6, has been found to bind to Y759 of gp130, 
which is also the residue that recruits SHP2 (Schmitz et al. 2000; Nicholson et al. 2000).  
Both SOCS3 mRNA and protein is induced rapidly in response to IL-6 stimulation and 
mediates negative regulation of IL-6 signalling via inhibition of the catalytic domain of 
JAKs (Endo et al. 1997; Starr et al. 1997; Naka et al. 1997; Sasaki et al. 1999; Kershaw 
et al. 2013).  Sustained activation of IL-6 signalling is observed in the absence of 
SOCS3 (Yasukawa et al. 2003; Lang et al. 2003).  
Furthermore, IL-6 signalling can be negatively regulated by receptor internalisation and 
subsequent protein degradation of the IL-6 receptor complex (Wang & Fuller 1994).  
Cells expressing gp130 mutants which do not internalise demonstrate more potent IL-6 
signalling (Kortylewski et al. 1999). 
1.13 Regulation of IL-6 Expression and Release 
Plasma IL-6 levels are low in healthy humans existing in the region of 1-5 pg/ml 
(Agorastos et al. 2014).  sIL-6R is found at concentrations in the range of 50-75 ng/ml 
and sgp130 is found around 400 ng/ml (Schaper & Rose-John 2015). Due to the 
presence of higher concentrations of sIL-6R and sgp130 in blood, secreted IL-6 will 
rapidly bind to sIL-6R that will immediately bind to sgp130 and be neutralised.  In this 
way, the high concentrations of sIL-6R and sgp130 act as a buffer for IL-6 (Schaper & 
Rose-John 2015).  In pathological conditions however, the concentration of sIL-6R and 
IL-6 increase rapidly (Nowell et al. 2003).  During sepsis, IL-6 in the low µg/ml range 
have been reported (Waage 1989).  
At the transcriptional level, the promoter region of the IL-6 gene has sequence motifs 
for the binding of activator protein 1 (AP-1), cyclic AMP (cAMP)-responsive element 
(CRE), CCAAT enhancer binding protein β (C/EBPβ, also termed NF-IL-6) and nuclear 
factor κ-light-chain-enhancer of activated B cells (NF-κB) (Wolf et al. 2014; Matsusaka 
& Fujikawa 1993; Ray et al. 1988; Ray et al. 1990; Asschert et al. 1999; Dendorfer et 
al. 1994).  NF-κB mediated transcription of IL-6 has been observed in response to 
lipopolysaccharide (LPS), the pro-inflammatory cytokines tumour necrosis factor α 
(TNFα), IL-1α and IL-1β and viral infections (Sehgal et al. 1988; Fong et al. 1989; 
Kohase et al. 1987; Chen et al. 2005).  Mutational analyses of the NF-κB binding site 
have demonstrated its importance for IL-6 gene expression induced by IL-1, TNFα and 
LPS (Shimizu et al. 1990; Libermann & Baltimore 1990).  In a rodent model of 
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myocardial ischaemia/reperfusion injury, induction of IL-6 gene expression by C/EBPβ 
has been shown (Chandrasekar et al. 1999).  Regulation of IL-6 mRNA has also been 
observed at the post transcriptional level both negatively (Iwasaki et al. 2011; 
Matsushita et al. 2009) and positively (Masuda et al. 2013) with microRNAs (miRNAs) 
also proposed to interfere with the expression of IL-6 (Rossato et al. 2012). 
The membrane bound IL-6R expression has been shown to be regulated by steroid 
hormones and their synthetic derivatives (Wolf et al. 2014).  Glucocorticoid treatment 
increases IL-6R mRNA and protein expression (Rose-John et al. 1990; Snyers et al. 
1990).  In hepatocytes, evidence suggests that IL-6 can enhance expression of its own 
membrane bound receptor in a positive feed-forward loop fashion, and also by IL-1 
(Bauer et al. 1989).  In contrast IL-6 was found to downregulate IL-6R expression in a 
natural killer cell line (Böttger et al. 2013) 
Gp130 expression is also regulated by IL-6.  Klouche et al. observed an increase in 
gp130 mRNA and surface protein expression in vascular smooth muscle cells following 
stimulation with an IL-6/sIL-6R complex, which also stimulated IL-6 secretion causing 
an autocrine stimulatory loop (Klouche et al. 1999).  In a rat model of ischaemia and 
reperfusion, a significant upregulation of gp130 was found in the myocardium, 
accompanied by an increase in IL-6 and IL-6R expression, suggesting a role of IL-6 
signalling in myocardial infarction (Chandrasekar et al. 1999).  Fittingly, gp130 
expression can be downregulated by the anti-inflammatory antibiotic minocycline, 
which led to blockade of the STAT3 and ERK1/2 pathways in human ovarian cancer 
cell lines (Ataie-Kachoie et al. 2013).  ERK2 has been shown to bind to the gp130 
promoter and regulate its expression, and inhibition of ERK2 prevents gp130 expression 
(Bonito et al. 2014).  Since IL-6 can activate ERK1/2 signalling (Neurath & Finotto 
2011), this suggests the presence of a feed-forward loop enhancing IL-6 signalling via 
an ERK2-mediated increase in gp130 expression.  Conversely, gp130 expression has 
been shown to be downregulated by p38 MAPK mediated pro-inflammatory stimuli 
(Honke et al. 2014). 
1.14 IL-6 in Diabetes 
For T1D, the auto-immune nature of the destruction of pancreatic beta-cells is thought 
to result from an interaction of activated T cells and pro-inflammatory cytokines of the 
infiltrate, depicting a negative role of cytokines in the pathogenesis of the disease 
(Eizirik & Mandrup-Poulsen 2001).  Having said this, the role of IL-6 in both human 
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and rodent diabetes is debated, with a lack of direct evidence for a deleterious role of 
IL-6 in the pathogenesis of T1D from human studies (Kristiansen & Mandrup-Poulsen 
2005).  It remains unclear as to whether IL-6 plays a role in beta-cell destruction, as 
direct evidence of a cytotoxic effect of IL-6 on beta-cells only exists in vitro, and 
contrastingly, cytoprotective effects have also been demonstrated in mouse islets and a 
beta-cell line (Choi et al. 2004; Oh et al. 2011).  The likelihood is that the combination 
of factors from the beta-cells themselves and the immune infiltrate will converge to 
mediate beta-cell destruction. 
In the context of T2D, work during the 1990s has suggested a potential role of 
immunological related mechanisms and associated factors in the development of 
peripheral insulin resistance as well as the progressive beta-cell failure observed in this 
disease (Pickup 2004; Kolb & Mandrup-Poulsen 2005).  Low-grade inflammation has 
been shown to precede and be a risk factor for the development of T2D and intervening 
to reduce the inflammatory state has been shown to reduce the risk of developing T2D, 
implicating inflammation in the pathogenesis of this disease (Kolb & Mandrup-Poulsen 
2005; Pickup 2004). Regarding the regulation of insulin secretion, which is impaired in 
T2D, IL-6 has been reported to inhibit GSIS from rodent islets (Wadt et al. 1998; 
Southern et al. 1990).  Contrastingly, IL-6-/- mice have comparable fasting insulin levels 
as littermate control animals (Di Gregorio et al. 2004) but have been shown to develop 
mature onset obesity and disturbed glucose metabolism, but insulin was not investigated 
in this latter study (V. Wallenius et al. 2002).  Interestingly, ICV but not IP replacement 
of IL-6 in the knockout animals increased energy expenditure (V. Wallenius et al. 2002) 
suggesting a role for central IL-6 in this regulation.            
IL-6 appears to negatively regulate insulin signalling in peripheral tissues.  In adipocyte 
cell lines IL-6 decreases insulin receptor substrate (IRS) phosphorylation and 
expression, decreases insulin receptor β subunit, inhibits insulin-induced 
phosphorylation of protein kinase B (PKB), increases expression of SOCS3 and reduces 
insulin-stimulated glucose transport by reducing GLUT4 expression (Rotter et al. 2003; 
Lagathu et al. 2003; Shi et al. 2004).  Another study has however demonstrated an 
enhancement of glucose transport by IL-6 in 3T3-L1 adipocytes (Stouthard et al. 1996).  
In skeletal muscle, the human body’s largest insulin-responsive organ, IL-6 has been 
shown to either enhance or have no effect on basal and insulin stimulated glucose 
uptake (Benrick et al. 2012; Carey et al., 2006; Geiger et al. 2007; Kim et al., 2004; 
Neill et al., 2013; Nieto-Vazquez & Ferna, 2008; Rotter Sopasakis et al. 2004; Yuen et 
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al. 2009).  The data documenting the role of IL-6 on insulin sensitivity in liver is much 
more consistent.  IL-6 activates the JAK/STAT signalling pathway leading to SOCS3 
transcription and inhibition of insulin receptor autophosphorylation, tyrosine 
phosphorylation of IRS1 and 2 and decreased glycogen storage (Kristiansen & 
Mandrup-Poulsen 2005).  These data demonstrate that IL-6 can reduce insulin 
sensitivity by impairing the insulin signalling pathway.  
1.15 IL-6 in Metabolic Disease 
The currently accepted paradigm regarding the role of pro-inflammatory cytokines in 
metabolic disease is that nutrient overload promotes inflammation and links the 
metabolic and immune systems, where inflammation may be pathological (Febbraio 
2014). However, paradoxically, inflammation is an adaptive, protective and 
importantly, an energy consuming process, and therefore the roles of interleukins in 
metabolism and energy homeostasis is complex (Febbraio 2014).  Evidence suggests 
that for several cytokines, including IL-6, although excess production is negative, 
blockade or insufficiency is equally undesirable (Febbraio 2014).  
Given the observation that IL-6 is secreted from adipose tissue and macrophages and is 
elevated in obesity and metabolic disease (Hoene & Weigert 2007; Wellen & 
Hotamisligil 2005) it is generally assumed that elevations in IL-6 levels has negative 
effects on metabolism.  As described earlier, IL-6 can induce insulin resistance, 
however the fact that it is released from skeletal muscle in response to beneficial, non-
damaging muscle contraction (exercise) raises controversy regarding its negative 
implication in metabolic disease (Steensberg et al. 2000; Hiscock et al. 2004; Pedersen 
& Febbraio 2007). Furthermore, muscle derived IL-6 has cross tissue biological 
functions on liver, adipose, gut, pancreas and brain (Banzet et al. 2009; Wueest et al. 
2014; Ellingsgaard et al. 2011; Shirazi et al. 2013).  Importantly, IL-6-/- mice develop 
mature onset obesity, glucose intolerance and insulin resistance, implicating beneficial 
roles for IL-6 in protection against metabolic disease (V. Wallenius et al. 2002; Di 
Gregorio et al. 2004; Matthews et al. 2010).   
In line with this, the Brüning lab demonstrated that mice with specific reduction of IL-6 
signalling in hepatocytes had reduced insulin sensitivity and glucose tolerance, with 
liver-specific absence of IL-6 signalling affecting glucose uptake in adipose and muscle 
(Wunderlich et al. 2010).  Furthermore, these animals had exaggerated inflammation 
and inflammatory signalling revealing a role for hepatic IL-6 signalling to limit hepatic 
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inflammation (Wunderlich et al. 2010).  In another study from the same group, 
inactivation of IL-6 signalling specifically in myeloid cells induced exaggerated 
deterioration of glucose homeostasis during obesity due to enhanced insulin resistance 
(Mauer et al. 2014).  An increase in inflammation was also observed with a shift in 
macrophage polarisation, identifying IL-6 as an important determinant of the alternative 
activation of macrophages and assigning the cytokine a role in limiting inflammation 
(Mauer et al. 2014).   
IL-6 has been shown to be important for protection against bacterial infection mediated 
via classical signalling (Hoge et al. 2013; Sodenkamp et al. 2012) confirming the anti-
inflammatory effects of this mode of signalling, while IL-6 trans-signalling is involved 
in the pathogenic infiltration of adipose tissue by macrophages in obesity, an effect 
which was prevented by inhibition of trans-signalling with sgp130-Fc (Kraakman et al. 
2015), demonstrating the promiscuity of IL-6 and its signalling mechanisms in 
pathological states.  
1.16 Inflammation, IL-6 and Hypoglycaemia 
The link between hypoglycaemia and inflammation has been documented.  Insulin-
induced hypoglycaemic clamp studies in patients with T1D show that the pro-
inflammatory cytokine IL-6 is significantly increased from baseline levels after one and 
two hours of hypoglycaemia (Ceriello et al. 2013a).  Another insulin-induced 
hypoglycaemic study in healthy subjects resulted in significant increases in IL-6 at the 
nadir of the hypoglycaemia with elevated levels persisting four hours subsequently 
(Nematollahi et al. 2009).   
Although Wright et al. found similar elevations in IL-6 in response to hypoglycaemic 
but also in the euglycaemic control clamp in their 2010 study (Wright et al. 2010), they 
described this response as inexplicable, and it contrasts with another study 
demonstrating increases in IL-6 in response to hypoglycaemia (Dotson et al. 2008).  A 
comprehensive study using two hours of clamped hyperinsulinaemic euglycaemia and 
moderate hypoglycaemia measured increases in IL-6 during hypoglycaemia relative to 
euglycaemia and importantly, the magnitude of the increase observed in the control 
individuals in this study were comparable to those observed in the aforementioned 
studies by Dotson et al. and Nematollahi et al. (Gogitidze Joy et al. 2010).            
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To further support the increase in inflammation in response to hypoglycaemia, studies 
have also demonstrated increases in inflammatory mediators other than IL-6.  Wright et 
al. demonstrated increases in endothelin-1 in response to hypoglycaemia in T1D 
patients, and although not a classical inflammatory component of the immune system, 
analogously, endothelins have been implicated in the pathogenesis of several disorders, 
including atherosclerosis, diabetes and hypertension (Wright et al. 2007).  Furthermore, 
Galloway et al. demonstrated increases in CRP in response to insulin-induced 
hypoglycaemia in control individuals and those with T1D (Galloway et al. 2000) 
As mentioned, the debate surrounding whether IL-6 exerts positive or negative effects is 
intense and unresolved.  Nematollahi et al. proposed in their 2009 paper that “elevation 
of pro-inflammatory cytokines may be an adaptive response to acute stress for 
maintaining glucose homeostasis in glycemic excursions” (Nematollahi et al. 2009).     
While the aforementioned hypoglycaemic clamp studies have demonstrated 
conclusively that IL-6 and other inflammatory mediators are increased peripherally in 
plasma in response to low glucose, whether there is a central source of IL-6 that may 
directly regulate CNS glucose-sensing mechanisms is less established.  A 2001 study 
using populations of rat cortical mixed glial cells demonstrated accumulation of IL-6 
mRNA as early as 15 minutes after exposure to glucose deprivation and this increase in 
mRNA was proven to be functional with an increase in release of IL-6 protein by the 
cultures after two hours of hypoxia and hypoglycaemia (Wang et al. 2001).  This 
finding was consolidated by Choi SJ et al. who observed an increase in IL-6 mRNA and 
its secretion in mouse BV2 microglial cells as well as murine primary microglia in 
response to glucose deprivation (S. J. Choi et al. 2013). 
Many studies utilise a combined oxygen and glucose deprivation (OGD) to model 
ischaemic stroke of brain tissue or central cell types such as astrocytes and microglia.  
Several of these studies have reported increases in IL-6 in response to this stimulus in 
the BV-2 murine microglial cell line, mouse primary cortical astrocytes, mouse 
astroglial cultures, rat brain cortical slices, rat astrocyte cultures and using in vivo 
models of cerebral ischaemia (Xiang et al. 2014; Niu et al. 2009; Gesuete et al. 2011; 
Contartese et al. 2012; Pan et al. 2014; Gertz et al. 2012).  Unfortunately, none of these 
studies measured IL-6 increases in responses to glucose deprivation alone.  
Interestingly, although the majority of the aforementioned studies identify IL-6 as a 
marker of OGD, Redzic et al. demonstrated that microglia conditioned media, and 
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specifically TGFβ and IL-6, have cytoprotective effects on astrocyte, pericyte and brain 
endothelial cells exposed to OGD, suggesting that these two molecules mediate a 
protective mechanism against cell death following their secretion (Redzic et al. 2015).   
1.17 GT1-7 Cells 
The GT1 cell lines were developed by genetically targeting tumourigenesis to specific 
hypothalamic neurons in transgenic mice using the promoter region of the 
gonadotropin-releasing hormone (GnRH) gene to express the SV40 T-antigen (Tag) 
oncogene. This resulted in formation of neuronal tumours from which Mellon et al. 
developed clonal, differentiated, neurosecretory cell lines (Mellon et al. 1990). By 
targeting the expression of the potent oncogene to the GnRH promoter, anterior 
hypothalamic tumours were observed in two of the transgenic mice studied. Portions of 
one of these tumours from a mouse called GT-1 were taken for mRNA analysis and 
tissue culture, and it was confirmed by northern blot that the tumour tissue from this 
animal specifically expressed GnRH and Tag.  
The authors went on to culture cells from the GT-1 tumour and over a six month period 
were able to separate out neuronal and glial cell types. Characteristic cultures of a pure 
cell population were established and cloned by serial dilution resulting in the GT1-1, 
GT1-3 and GT1-7 cell lines. Northern blotting was again used to confirm that the three 
cell lines still expressed GnRH as the pure cell population did. When attached to plastic 
the GT1- cell lines exhibited a distinct neuronal phenotype, including extension of 
lengthy neurites. Interestingly, the authors noticed that the neuronal phenotype was 
more profound when cells were cultured in the absence of serum, preventing cell 
division. GT1-7 cells were specifically shown to express the neuron-specific enolase 
(NSE) mRNA, and also mRNA for the neurofilament proteins. In contrast, GT1-7 cells 
do not express the astrocyte marker glial fibrillary acidic protein (GFAP). Furthermore, 
the neuroendocrine phenotype of the GT1-7 cells was confirmed to be limited to GnRH 
expression, with a lack of somatostatin, POMC, CRH and GHRH mRNA expression in 
these cells. Further confirmation of the neuronal phenotype of GT1-7 cells came in the 
finding of the mRNA for the synaptic vesicle associated protein VAMP-2, which is 
known to be expressed in the hypothalamus (Trimble et al. 1990). mRNA for the 
presynaptic membrane protein SNAP-25 was also found in GT1-7 cells, along with that 
for chromogranin B, a neuroendocrine secretory vesicle protein found in the brain. 
Taken together the expression of neuronal, neurosecretory and synaptic membrane 
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proteins in the GT1-7 cells confirms their identity as neurons and documents their 
differentiated state.  
Functional confirmation of GnRH secretion was also confirmed in this paper. Firstly, 
GnRH protein was detected in the media of all three cultured cell lines (GT1-1, GT1-3 
and GT1-7) by radioimmunoassay. The authors also used the GT1-7 cells to 
demonstrate that depolarisation by treatment with 56 mM potassium resulted in a four-
fold increase in GnRH release compared to the basal measurable rate of GnRH secretion 
from these cells in 5.6 mM potassium. In a separate experiment, the sodium channel 
opener veratridine was used to depolarise GT1-7 cells causing a six-fold increase in 
GnRH release during a 15 minute time period. The veratridine response was blocked by 
a 30 minute pretreatment with tetrodotoxin demonstrating the presence of fast sodium 
channels that are necessary for the occurrence of propagated action potentials. In 
contrast, the GnRH release in response to depolarisation induced by high potassium was 
not blocked by tetrodotoxin, indicating that potassium stimulates GnRH release via a 
different mechanism to veratridine. Studies in hypothalamic brain slices demonstrating 
that high potassium releases GnRH via VDCCs support these findings. 
The GT1-7 cell line has proved to be a highly useful model for studying hypothalamic 
neurons at the molecular level; cells which are known to play fundamental roles in vivo 
in the whole body homeostatic regulation of diverse functions such as energy 
homeostasis, food intake, reproductive function and metabolic regulation (Y.-H. Choi et 
al. 2013; Flanagan-Cato et al. 2001).  Performing studies in GT1-7 cells permits the 
investigation of effects in an isolated population of hypothalamic neurons, independent 
from other neuronal innervation or glial cell influence.   
The advantages of using GT1-7 cells are that the cell line can be readily cultured, 
dividing about every 24 hours, allowing rapid generation of cultures to perform studies.  
The cells are relatively robust and stand up well to electrophysiological examination 
providing reliable recordings with a well established resting membrane potential of ∼ -
50 mV.  The cells are frequently used to investigate expression and secretion of the 
neurotransmitter GnRH, which cannot be easily done in vivo, and which from brain 
slice preparations is complicated by the heterogeneous nature of the cell types present.  
For the current studies, the validity of the GT1-7 cell model has been well characterised, 
as it is analogous to the pancreatic beta-cell and responsive to hypoglycaemia (Beall, 
Hamilton, et al. 2012).  The GT1-7 cell line has also been demonstrated to express the 
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IL-6Rα at low levels (McCrimmon Laboratory, unpublished data).  The model allows 
the detailed study of signalling pathways in isolated, metabolically-sensitive neurons 
which would otherwise be complex in intact hypothalami.  The model allows distinction 
of whether effects observed on whole hypothalami are mediated via a direct action on 
neurons.      
The disadvantages of the cell line are that culture conditions appear to have a 
considerable bearing on the responsiveness and phenotype of the cells.  For example, it 
has been reported that the cells are of a more neuronal morphology under low serum 
conditions to inhibit cell division (Mellon et al. 1990).  In my experience, the cells grow 
faster and appear healthier under high glucose conditions (25 mM), however this means 
that the cells have to be brought down to physiological glucose concentrations for 
experimentation.  Since the physiological glucose concentration in the brain is 2.5 mM 
(Watts & Donovan 2010), this involves a large reduction in cultured glucose levels to 
achieve levels within the physiological range.  This will likely induce a hypoglycaemic 
response in the cells meaning that cells either have to be reduced to lower glucose 
concentrations in a step wise manner or need to be allowed to recover and grow 
accustomed to 2.5 mM glucose conditions prior to experimentation.  Another drawback 
of the GT1-7 cell line is that cellular protein content is low, meaning that experiments 
need to be performed on relatively large cultures of cells to yield enough cellular 
protein for subsequent analysis.  Also, since the cell line is a tumour cell line, it is likely 
to be somewhat pathophysiological in phenotype.  Our laboratory has determined that 
the glucose sensing phenotype of the GT1-7 cells exists transiently over a period of time 
in culture, such that glucose sensing experiments must be performed within a narrow 
passage range of the cells (p47-p60).  
The GT1-7 cells were selected as the model for the current project as they are an easy to 
work with, homogenous, electrically active, hypothalamic GE neuronal cell line that 
permitted investigation of the direct effects of IL-6 on glucose-sensing neurons. 
1.18 Hypothesis and Aims 
The importance of CNS glucose sensing in the mounting of appropriate CRRs to 
hypoglycaemia, particularly by neurons of the VMH has been demonstrated.  Several 
potential mediators of defective CRRs, induced by antecedent and recurrent 
hypoglycaemia and observed in T1D, have been proposed, many of which involve 
impairment of glucose-sensing neuronal function.  There is a strong inflammatory 
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component associated with hypoglycaemia, but physiological roles for these 
inflammatory mediators in this setting remain undefined.  IL-6 represents one of the 
most well characterised cytokines, and the aim of the current project was to investigate 
the hypothesis that IL-6 may play a role in the regulation of hypothalamic GS and 
therefore hypoglycaemia detection.  The aims of the project were to determine if IL-6 
regulated the activity of hypothalamic GE neurons and if so, the mechanisms by which 
this regulation occurred.  Electrophysiological and biochemical analysis of an in vitro 
model of VMH GE neurons was employed to this end. 
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2 Materials and Methods 
 
2.1 Cell Culture  
GT1-7 cells were cultured in a category 1 biological safety rated cell culture facility and 
were maintained at 37°C in a 5% CO2 incubator. In order to maintain cells in culture, 
they were grown in T75 stock flasks which were passaged every two to five days to 
maintain the cells at an optimal confluency of no greater than 80%. Since GT1-7 cells 
are non-adherent, all plasticware was pre-coated with poly-L-lysine (PLL) prior to cell 
seeding to facilitate attachment. This was achieved by incubating the plasticware at 
room temperature with an appropriate volume of PLL to cover the base at a 
concentration of 0.2 mg/ml (in dH2O) for 30 minutes. PLL was removed and a 
phosphate buffered saline (PBS) rinse was performed prior to cell seeding.  
To passage the cells, the stock media was removed from the T75 flask and a 10 ml 37°C 
PBS rinse was performed. 2 ml of 0.05% trypsin-EDTA was then applied to the flask 
and incubated at 37°C in a 5% CO2 incubator for two-five minutes. Trypsinisation was 
inactivated by the addition of 3 ml of growth media to the flask. The resulting cell 
suspension was pipetted up and down thoroughly and used to rinse the base of the flask 
several times to ensure maximal retrieval of cells. The cell suspension was centrifuged 
at 800 rpm for 4 minutes in a 15 ml Falcon tube to pellet the cells. The media 
supernatant was removed to waste and the cell pellet was resuspended in 4-8 ml of 
growth media by thoroughly pipetting up and down. 1 ml of this cell suspension was 
added to a pre-PLL-coated T75 flask containing 10 ml of growth media to create a stock 
flask. If stock flasks required bulking up, or a higher density of cells was required in the 
stock flask, 2 ml of the cell suspension was added to a T75 flask containing 10 ml 
growth media. Stock flasks were given fresh growth media every 48 hours to replenish 
supply of glucose and other nutrients to the cells. To achieve this the media was 
removed from the flask and a fresh 10 ml of growth media was added.  
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Seeding protocols for experiments and assays differed depending on the specific assay 
being run, and will be discussed in detail according to the particular assay in the 
following methods.     
Table 2.1: GT1-7 Culture Medias 
Media Stock Supplements  
25 mM Glucose Growth 
DMEM (Stock Media) 
D5671 Dulbecco’s 
Modified Eagle’s Medium  
25 mM D-glucose, 10% 
v/v Fetal Bovine Serum 
(Hyclone), 4 mM L-
glutamine, 2% v/v 
penicillin-streptomycin 
(100,000 Units/ml) 
2.5 mM Glucose Plating 
Media (Plating Media) 
D11966 Dulbecco’s 
Modified Eagle’s Medium 
with 4 mM L-glutamine  
2.5 mM D-glucose, 2% v/v 
Fetal Bovine Serum 
(Hyclone), 2% v/v 
penicillin-streptomycin 
(100,000 Units/ml)  
2.5 mM Glucose Serum 
Free DMEM (Serum Free 
Media) 
D11966 Dulbecco’s 
Modified Eagle’s Medium 
with 4 mM L-glutamine  
2.5 mM D-glucose, 2% v/v 
penicillin-streptomycin 
(100,000 Units/ml) 
 
2.2 Cell Seeding  
2.2.1 Interleukin-6 (IL-6) Time Courses 
GT1-7 cells were plated in 60 mm culture dishes at a density of 400,000 cells in 3 ml of 
plating media the night before experiments. On the day of the experiment, media was 
removed from the dishes and a PBS rinse performed prior to incubation in 3 ml of 
serum free media for two hours at 37°C in a 5% CO2 incubator. This serum starve step 
was employed to ensure intracellular signalling cascades would be at a basal level of 
activation and comparable between experiments. After the two hour incubation the 
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serum free media was removed and a fresh 3 ml of serum free media was applied for the 
experiment. In the IL-6 timecourse experiments cells were treated with 20 ng/ml IL-6 
(12 µl 5 µg/ml IL-6 stock dissolved in distilled H2O) for five to 180 minutes. A control 
treatment was also performed in which cells were exposed to dH2O alone for the longest 
time point of that particular experiment (e.g. 180 minutes). Treatments were performed 
in duplicate and were performed in a reverse format, such that 180 minute treatments 
were treated first and shorter time points were treated subsequently so all cells could be 
lysed at the same time point at the end of the experiment.  
2.2.2 Antecedent IL-6 treatments 
An antecedent IL-6 protocol was employed to mimic a pre-exposure to elevated IL-6 
levels for subsequent observations of the effects this had on GT1-7 cells. GT1-7 cells 
were plated in 60 mm culture dishes at a density of 400,000 cells in 3 ml of plating 
media for biochemical experiments, or in 35 mm culture dishes at a density of 20,000 
cells in 2 ml of plating media for electrophysiological experiments, the night before 
experiments. On the day of the antecedent exposure, plating media was removed from 
the dishes and a PBS rinse was performed prior to application of serum free media. 
Cells were then treated with either dH2O vehicle control or 20 ng/ml IL-6 for three 
hours, incubated at 37°C in a 5% CO2 incubator during this time. At the end of the 
treatment the media was removed and a PBS rinse performed prior to application of 
plating media overnight. The following day, the pre-exposed cell cultures were either 
investigated electrophysiologically (whole-cell and perforated patch clamp 
configuration), or underwent an acute hypoglycaemia treatment before being lysed. This 
involved media removal and a PBS rinse prior to application of either 2.5 mM glucose 
serum free media (euglycaemic control) or 0.1 mM glucose serum free media 
(hypoglycaemia) for 15 minutes. A 15 minute exposure of GT1-7 cells to 0.1 mM 
glucose has previously been shown to induce an increase in the phosphorylation of 
AMPK in these cells (Beall, Hamilton, et al. 2012). At the end of the 15 minute 
euglycaemic and hypoglycaemic treatments cells were lysed. 
2.3 Cell Lysis for Western Blots 
Cell lysis to harvest protein for subsequent analysis was performed in a 1x lysis buffer 
solution diluted in dH2O from a 5x stock made up according to the recipe in Table 2.2.  
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Table 2.2: 5x Lysis Buffer 100 ml Stock 
Tris HCl at pH 7.4 125 mM 
NaF 250 M 
NaCl 0.5 M 
EDTA 5 mM 
EGTA 25 mM 
Triton X 100 5% v/v 
NaPPi 50 mM 
 
Prior to cell lysis, the 1x stock lysis buffer was supplemented with the protease 
inhibitors detailed in Table 2.3 and sucrose to increase osmolarity. 
Table 2.3: 1x Lysis Buffer Supplements 
Sucrose 92 mg/ml 
2-mercaptoethanol 0.1% v/v 
Benzamidine 1 mM 
Na3VO4 (Heated at 95°C for five minutes 
prior to addition) 
1 mM 
PMSF 0.1 mM 
 
Lysis buffer was always prepared on ice and vortexed prior to use. The amount of lysis 
buffer used varied depending on the number of cells being lysed and the surface area of 
the plasticware on which they were seeded. Table 2.3 demonstrates typical lysis buffer 
volumes used based on the plasticware being used with cells at a confluency of 70-80%. 
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Table 2.4: Lysis Buffer Volumes 
Plasticware Surface Area (cm2) Lysis Buffer Volume (µl) 
6 well plate 10  50  
60 mm plate 20  75  
100 mm plate 60  150  
   
To ensure sterility, cells were lysed in a tissue culture hood. The assay medium was 
removed from the plates and a 4°C PBS rinse was performed to remove as much of the 
assay medium as possible. The residual PBS was removed with a P1000 pipette. The 
appropriate volume of 1x lysis buffer was applied directly onto the base of the plastic 
and plates were scraped thoroughly with cell scrapers. The lysate was harvested and 
transferred to an eppendorf tube labelled appropriately and stored at -20°C.  
2.3.1 Bradford Assay 
A modified version of the well established Bradford protein assay (Bradford 1976) was 
used to determine the unknown protein concentrations of GT1-7 cell lysates. Cell 
lysates were thawed on ice and centrifuged at 13,000 rpm for 15 minutes at 4°C to pellet 
out the nuclear fraction. The resulting supernatant was transferred to a fresh eppendorf 
tube and the pellet was discarded. The Bradford assay utilised in this project was 
performed in a 96 well plate format. The unknown lysate protein concentrations were 
determined by extrapolating an absorbance value from a standard curve of known 
bovine serum albumin (BSA) absorbances of increasing concentration. Table 2.5 
demonstrates the points of the standard curve used and how they were achieved. 
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Table 2.5: BSA Standard Curve for Bradford Assay 
BSA Standard Curve 
(mg/ml) 
Volume of BSA stock (µl) Volume of MilliQ dH2O 
(µl) 
0 0 10 
0.25 1.25 of 0.2 mg/ml stock 8.75 
0.5 2.5 of 0.2 mg/ml stock 7.5 
1 5 of 0.2 mg/ml stock 5 
2 10 of 0.2 mg/ml stock 0 
5 2.5 of 2 mg/ml stock 7.5 
7 3.5 of 2 mg/ml stock 6.5 
     
1 µl of the protein lysates to be assayed was diluted in 9 µl of MilliQ dH2O and finally 
250 µl of Bradford Reagent, warmed to room temperature, was added to all of the 
standard curve and lysate wells. The plate was incubated at room temperature for ten 
minutes to allow the Bradford Reagent to interact with the protein present. The 
absorbance values of the wells were then measured using an EnVision plate reader 
(PerkinElmer) at 595 nm. The absorbance values from the standard curve were plotted 
in Microsoft Excel and the unknown protein concentrations of the lysates were 
extrapolated using the gradient of the standard curve.   
2.3.2 Sample Preparation for Western Blot 
100 µl protein samples for analysis by Western blot were prepared to a final 
concentration of 1 µg/µl by diluting an appropriate volume of protein lysate with a 4x 
sample buffer stock (used at a working concentration of 1x) and MilliQ dH2O. The 
recipe for the 4x sample buffer stock is shown in Table 2.6.  
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Table 2.6: 4x Sample Buffer Stock (12 ml) 
0.5 M Tris at pH 6.8 4 ml 
Glycerol 3.2 ml 
20% Sodium Dodecyl Sulphate 3.2 ml 
2-mercaptoethanol 1.6 ml 
Bromophenol Blue pinch 
 
Samples were heated at either 95°C for ten minutes for detection of cytosolic proteins or 
37°C for one hour for detection of membrane bound proteins. Samples were stored at -
20°C once prepared.   
2.3.3 Western Blot 
To investigate the expression of various cellular proteins, GT1-7 protein samples were 
subjected to Western blot. Proteins were separated using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli 1970) depending on their 
molecular weights. Several different percentages of acrylamide separating gels were 
used in this project to achieve different pore sizes in the gel matrices, as this can 
variably effect the migration of proteins through the gel due to the differing molecular 
weights of the proteins. Table 2.7 details the separating and stacking gels used in this 
project. 
Table 2.7: Commonly Used Gel Recipes 
Lower Gel 10% Acrylamide Volume required for 4 gels 
dH2O 8.3 ml 
Lower buffer 6.3 ml 
30% acrylamide 7.5 ml 
10% sodium dodecyl sulphate 220 µl 
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TEMED 22 µl 
20% ammonium persulphate 110.7 µl 
Lower Gel 7% Acrylamide Volume required for 4 gels 
dH2O 10.55 ml 
Lower buffer 6.3 ml 
30% acrylamide 5.25 ml 
10% sodium dodecyl sulphate 220 µl 
TEMED 22 µl 
20% ammonium persulphate 110.7 µl 
Upper Gel 4% Acrylamide Volume required for 4 gels 
dH2O 5.6 ml 
Lower buffer 2.5 ml 
30% acrylamide 1.7 ml 
10% sodium dodecyl sulphate 100 µl 
TEMED 10.7 µl 
20% ammonium persulphate 100 µl 
 
In this project, a 4% acrylamide stacking gel was used and cast with either 10- or 15-
well combs to create the desired number of wells for protein sample loading. Typically, 
10 µg protein was loaded from each sample. Every gel was also run with at least one 
lane containing 3 µl of molecular weight marker to allow determination of protein band 
sizes.  
Gels were cast using the BioRad blotting system and once loaded were run at 135 volts 
for one hour and 30 minutes in 1x Tris/Glycine running buffer.  
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After completion of SDS-PAGE, resolved proteins were transferred to nitrocellulose or 
polyvinylidene fluoride (PVDF) membrane (PVDF membrane was soaked in 100% 
methanol for two minutes prior to use). This was achieved by creating a transfer 
“sandwich” by stacking sponges and filter paper either side of the gel and membrane, 
which were in direct contact with one another, into a transfer cassette. By passing 
electrical current through the set up in the correct orientation it is possible to cause the 
negatively charged proteins to migrate out of the gel and onto the membrane. This was 
performed at a constant voltage of 100 volts for one hour in transfer buffer.  
Upon completion of the transfer the membranes were placed into square petri boxes and 
incubated in Ponceau S solution for two minutes at room temperature on a rocker to 
reversible stain protein bands to confirm successful transfer of the proteins to the 
membrane.  The Ponceau dye was rinsed off thoroughly by repeated washing in tris-
buffered saline with tween solution (TBST).  
Membranes were blocked in a 10% w/v non-fat dried milk solution made up in TBST 
for one hour at room temperature on a rocker to reduce non-specific binding sites prior 
to primary antibody incubation. After blocking, the membranes were rinsed several 
times in TBST to remove any residual milk solution. Primary antibodies were applied 
overnight in 5% BSA w/v solution in TBST at 4°C on a rocker. The following day 
primary antibodies were removed and membranes were washed five times for five 
minutes each time in TBST solution prior to incubation with secondary antibodies. 
Secondary antibodies were made up in 5% w/v non-fat dried milk solution in TBST and 
applied for one hour at room temperature on a rocker. Following this membranes were 
again washed five times for five minutes each time in TBST solution.  
Membranes were imaged using a Licor Odyssey scanner. Briefly, membranes were 
exposed to light of an appropriate wavelength to cause fluorescence emission from the 
secondary antibodies used and a digital image of the resulting fluorescence from the 
membrane was obtained. The images of the protein bands were then subjected to 
densitometry analysis in order to determine relative expression levels of the proteins to 
their appropriate controls and to a stably expressed housekeeping protein.     
  
 
 
 
51 
Table 2.8: Commonly Used Buffers 
Buffer Components 
Lower Buffer 1.5M Tris/HCl, pH 8.8 in dH2O 
Upper Buffer 0.5M Tris/HCl, pH 6.8 in dH2O 
1x Running Buffer  0.025M Tris, 0.192M Glycine, 0.1% v/v 
SDS in dH2O 
Transfer Buffer 48mM Tris, 39mM Glycine, 20% v/v 
methanol in dH2O 
TBST 20mM Tris/HCl pH 7.4, 148 mM NaCl, 
0.1% v/v Tween in dH2O  
2.3.4 Densitometry 
The intensity of the pixels in each protein band obtained was determined by drawing a 
rectangle around each band and quantifying the signal in these boxes using the Licor 
Odyssey Image Studio software. A background signal was also determined by 
quantifying the intensity of pixels in a box of the same size as those around the bands of 
interest but from a blank part of the membrane with no protein bands. The background 
value was subtracted away from the intensity values obtained for the protein bands to 
exclude the contribution of autofluoresence from the membrane to the observed signal. 
The expression of proteins of interest was normalised to the expression of the gel 
loading control protein actin to account for pipetting error in gel loading. The fold 
change in intensity, which directly indicates protein abundance, was then calculated 
from untreated or vehicle treated control samples to treated samples.      
2.4 Cell Lysis for Gene Expression (TRI Reagent) 
Lysis of cells that would subsequently undergo gene expression analysis was performed 
in the RNA isolation agent TRI Reagent. To ensure sterility cells were lysed in a tissue 
culture hood. The assay medium was removed and a 4°C PBS rinse was performed to 
remove as much media as possible. Residual PBS was removed with a P1000 pipette. 1 
ml of TRI reagent at 4°C was then applied directly onto the cells and this solution was 
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pipetted up and down thoroughly and used to rinse the base of the plastic to ensure 
recovery of as many cells as possible. The TRI reagent was transferred to appropriately 
labelled eppendorf tubes which were stored at -20°C.  
2.4.1 RNA Isolation 
RNA isolation was performed according to the manufacturer’s instructions included 
with the TRI Reagent. Samples were thawed on ice at 4°C and then were allowed to 
stand at room temperature for five minutes to allow phase separation to ensure complete 
dissociation of nucleoprotein complexes. 0.2 ml of chloroform was added to each 
sample, which were then shaken vigorously for 15 seconds. Samples were stood at room 
temperature for 15 minutes then the resulting mixture was centrifuged at 12,000 x g for 
15 minutes at 4°C. Centrifugation separates the mixture into three phases of which the 
clear, upper aqueous phase is RNA containing. The upper aqueous phase was 
transferred to a fresh eppendorf tube using a P200 pipette and 0.5 ml of isopropanol was 
added to this tube. The samples were stood at room temperature for ten minutes. Then 
they were centrifuged at 12,000 x g for ten minutes at 4°C. This caused the RNA to 
precipitate out of solution and form a pellet on the bottom on the tube. The supernatant 
was removed to waste and the RNA pellet was washed by adding 1 ml of 75% ethanol 
(in dH2O), vortexing briefly, then centrifuging at 12,000 x g for five minutes at 4°C. 
The ethanol was removed and the RNA pellets were allowed to air dry for ten minutes 
under a vacuum. The RNA pellets were resuspended in 30 µl of DNase free H2O and 
heated at 57°C for 15 minutes to facilitate dissolution. RNA purity and concentration 
was determined using a Nanodrop ND-8000 (Nanodrop).  
2.4.2 cDNA Synthesis Using SuperScript™ II Reverse 
Transcriptase (RT) 
cDNA was synthesised from isolated GT1-7 RNA according to the manufacturer’s 
protocol included with SuperScript™ II RT. The reaction was performed in 
microcentrifuge tubes at a final volume of 19 µl using 1 µg RNA. Following 
quantification of extracted RNA using the Nanodrop, the volume of the RNA sample 
required to achieve to 1 µg RNA was calculated and added to a microcentrifuge tube. 3 
µg random primers and 1 µl dNTP Mix (10 mM each) was added to the tube. The 
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volume was made up to 12 µl by adding an appropriate volume of DNase free H2O. The 
mixture was heated to 65°C for five minutes and then quick chilled on ice. Tubes were 
briefly centrifuged and 4 µl of 5x First-Strand Buffer and 2 µl of 0.1 M DTT were 
added to the tubes and the contents were mixed by gentle pipetting. Tubes were 
incubated at 25°C for two minutes before 1 µl (200 units) of SuperScript™ II RT was 
added and mixed by pipetting gently up and down. Tubes were incubated at 25°C for 
ten minutes, then at 42°C for 50 minutes. The reaction was then inactivated by heating 
at 70°C for 15 minutes. Finally, the cDNA was diluted 1:10 by adding 180 µl of DNase 
free H2O before being stored at -20°C.   
2.4.3 TaqMan® Gene Expression Assays (Real-time PCR) 
In this project, the TaqMan® real-time polymerase chain reaction (PCR; Life 
Technologies) assay was used for assessing gene expression in GT1-7 cells. After RNA 
isolation and cDNA synthesis described above, GT1-7 cDNA was subjected to PCR 
using primers and probes specific to several genes of interest, the expression of which 
was normalised to the housekeeping gene Cyclophillin A. The PCR was performed in a 
96 well plate at a final reaction volume of 20 µl. The plate was loaded on ice. Each well 
contained a reaction mixture comprising of 1 µl of primers and probes, 10 µl master 
mix, 6.5 µl of RNAse free H2O and 2.5 µl of cDNA. The plate was centrifuged for 15 
seconds prior to beginning the reaction. The plate was run using a real-time PCR 
machine (Applied Biosystems).  
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2.5 Electrophysiological Recordings  
Table 2.9: Electrophysiological Recording Solutions 
 NaCl 
(mM) 
KCl 
(mM) 
MgCl2 
6H2O 
(mM) 
CaCl2 
(mM) 
HEPES 
(mM) 
EGTA 
(mM) 
pH 
External 
Saline 
Solution 
135 5 1 1 10  7.4 
(NaOH) 
Internal 
Saline 
Solution 
 140 5 3.8 10 10 7.2 
(KOH) 
 
Two main configurations of electrophysiology were used in this project to record from 
GT1-7 cells. These were the whole-cell patch clamp configuration and the perforated 
patch clamp configuration. Both modes of recording required some set up in common. 
On the day of recording a syringe tip was prepared. This was achieved by melting a 
P200 pipette tip over a methanol burner and stretching it out to make a very fine tip 
capable of being inserted into and filling a glass micropipette with solution. The 
required internal saline was filter sterilised through a 0.22 µm filter and was collected in 
a 1 ml syringe onto which the prepared P200 tip was added. Borosilicate glass capillary 
tubing with an outer diameter of 1.2 mm and and inner diameter of 0.69 mm was used 
to prepare glass micropipettes. The glass capillaries were fire polished at either end 
using a Bunsen burner to smooth the edges and then pulled and stretched horizontally 
using a Flaming/Brown micropipette puller (Model P97, Sutter Instrument Co., USA). 
This resulted in two micropipettes of equal length that then had their tips fire polished 
using a micro forge (MF-830, Narishige, Japan). Tip resistance was typically between 5 
and 10 MΩ. Prior to use the micropipettes were half filled with the appropriate solution 
using the above described syringe preparation.  
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Before commencing recordings each day the bath and the perfusion tubing of the 
electrophysiology rig set up was thoroughly rinsed with 70% ethanol then MilliQ H2O 
to ensure sterility prior to experiments.     
22 mm2 glass coverslips with GT1-7 cells seeded at a density of around 50-300 cells 
were carefully transferred using forceps into the bath on the electrophysiology rig that 
contained 1-2 ml of 2.5 mM glucose physiological external saline solution. The 
reference electrode was introduced to the bath solution along with the inlet and outlet of 
the gravity perfusion system.       
2.5.1 Whole-Cell Patch Clamp Configuration 
The glass micropipettes described above were half filled with internal saline solution 
and attached to the pipette holder, such that the chloride-coated, silver wire electrode 
was submerged in the micropipette solution. Positive pressure was applied prior to entry 
of the micropipette into the recording bath external saline solution. The microelectrode 
was lowered to just above a single GT1-7 cell using an electronic micromanipulator 
(Luigs & Neumann) and the pipette offset was corrected by zeroing the current in 
voltage clamp mode. The microelectrode was then brought into contact with the cell 
membrane and gentle negative pressure was applied by mouth pipetting in order to form 
a giga ohm (GΩ) seal between the micropipette tip and the cell membrane. This is 
termed cell-attached configuration. The pipette capacitance transients, formed by 
charging and discharging of the cell membrane with test voltage pulses, were cancelled 
using the fast capacitance control on the amplifier (Axopatch 200B, Axon Instruments). 
From the cell-attached configuration, the negative pressure was increased in order to 
rupture the cell membrane and enter the whole-cell patch clamp configuration, gaining 
access to whole-cell macroscopic currents, with the micropipette holding potential set at 
-70 mV. Upon adoption of the whole-cell configuration, the sudden appearance of large 
capacitance transients were cancelled using the whole cell capacitance and series 
resistance controls on the amplifier, giving an estimation of the cell membrane 
capacitance (pF) and the resistance between the pipette and cell interiors, termed the 
series resistance (Rs in MΩ). Over time (typically 10-15 minutes) in the whole-cell 
configuration, the intracellular contents of the cell dialyse out and exchange with the 
contents of the glass micropipette.  
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In this project, the whole-cell patch clamp configuration was exploited to conduct a 
voltage clamp protocol to investigate current conductance at stepped voltage pulses 
ranging from -90 to +30 mV, from a holding potential of -70 mV (net membrane 
potential steps were therefore from -160 to -40 mV) in 20 mV steps which were a 
duration of 400 ms with a 20 ms interval between pulses. The steady-state currents 
elicited by each test pulse allow determination of the reversal potential, slope 
conductance, total whole-cell current and voltage-dependent kinetics. Conductance 
density of the cell was determined by plotting the current amplitude elicited by each 
voltage step against the magnitude of the test pulse, producing a linear current-voltage 
(I-V) relationship. Linear regression analysis of the line of best fit for the I-V 
relationship allows the slope conductance to be determined from the gradient of this 
line. The reversal potential (in mV) can be determined from the point where the I-V line 
intercepts the x-axis. The slope conductance can then be normalised to the cell size (pF) 
in order to determine the conductance density of the cell (pS/pF). In the experiments in 
the current work, the above described voltage clamp recordings were made at 
intermittent intervals during a current-clamp recording (detailed subsequently). These 
intervals were at the beginning of recording immediately after whole-cell formation, 
after complete dialysis of the intracellular and pipette solutions (termed run-up) and 
finally after closure of KATP channels using the sulphonylurea tolbutamide (reversing 
the run-up state of the cell). The recordings made in whole-cell voltage clamp 
configuration were sampled at 2 kHz and filtered at 10 kHz using a low pass Bessel 
filter incorporated in the amplifier.    
2.5.2 Perforated Patch Clamp Configuration  
Glass microelectrodes were half filled with internal saline solution supplemented with 
12.5 – 40 µg/ml Amphotericin B, an antibiotic capable of perforating the cell membrane 
by puncturing small holes in it that are permeable to ions but not to larger molecules. 
Since the perforated patch clamp configuration maintains the integrity of the cell 
membrane to a large extent, recordings made in this configuration are widely accepted 
as being more physiologically closer to intact cells than those made in whole-cell 
configuration.   
The attainment of the cell-attached configuration and cancellation of pipette capacitance 
was achieved in the same manner as that detailed in the above section for whole-cell 
 
 
 
57 
patch clamp configuration. The amplifier was then switched from voltage clamp to 
current clamp mode to start recording. The current clamp mode of recording allows 
observation of the membrane potential (Vm) and action potential frequency of the cell 
being recorded from in real time, allowing accurate measurement of the effects of 
exposure to varying solutions and agents on Vm. Upon commencement of current clamp 
recording in the perforated patch clamp configuration a period of stabilisation was 
permitted (up to 20 minutes) while the cell membrane perforated in response to 
Amphotericin B and a stable resting Vm was obtained. All recordings made in this 
configuration were sampled at 2 kHz and filtered at 10 kHz using a low pass Bessel 
filter incorporated in the amplifier.   
It should be mentioned that while every effort was made to only accept recordings from 
cells with no current injection (I=0), occasionally, negative current (up to -10 pA) was 
passed via the amplifier to the cells that didn’t perforate to a normal resting Vm for 
GT1-7 cells of -40 to -60 mV.   
For all electrophysiological experiments a gravity-flow perfusion system attached to a 
vacuum pump was used to exchange the bath solution. Bath glucose concentrations 
were altered by perfusing external saline supplemented with varying concentrations of 
glucose. This method was also employed for perfusing drugs into bath. Perfusion was 
manually operated using three way taps and a minimum of 10 ml of solution was 
perfused to ensure full exchange of the bath solution.    
2.6 Primary Mouse Cortical Astrocyte Preparation 
Mouse pups (postnatal day 2-4) were decapitated and heads placed on ice. An incision 
was made along the skull midline to allow the skin to be peeled back and the skull to be 
opened. The brain was removed and placed into 1 ml of ice cold Hank’s Balanced Salt 
Solution (HBSS). Meningeal membranes were peeled away using fine forceps under a 
dissection microscope and the cortex was dissected out and placed in a 60 mm dish 
containing a small volume of ice cold HBSS to prevent the tissue from drying. Brain 
tissue was minced using a scalpel and 3 ml of 0.5% trypsin was added and brain tissue 
was transferred to a 15 ml Falcon tube and incubated in a water bath at 37°C for 20 
minutes. Trypsin was neutralised by the addition of 3 ml of stock media followed by 
repeated pipetting to thoroughly triturate. The suspension was filtered through a 70 µm 
cell filter and then added to a T75 flask containing 10 ml of stock media. After 
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incubation at 37°C in a 5% CO2 incubator, media was removed and a fresh 10 ml of 
stock media was replaced. As astrocytes are selected for by their robust adherence to 
plasticware, at every media change thereafter the cell culture surface was rinsed with 
PBS three times before replenishment of stock media. Once astrocytes reached ~80% 
confluency they were split into 60 mm dishes for experiments. Media was removed and 
a PBS rinse performed before cells were detached from the flask by incubation in 2 ml 
of 0.5% trypsin for five minutes at 37°C in a 5% CO2 incubator. 3 ml of stock media 
was added and the suspension was centrifuged at 800 rpm for four minutes to pellet the 
cells. Cells were resuspended in an appropriate volume of stock media and seeded in 60 
mm dishes for experiments.       
2.7 Media Harvest from Astrocytes for IL-6 Secretion 
Measurement  
Primary mouse cortical astrocyte cultures in 60 mm dishes were incubated in 3 ml of 
2.5 mM glucose or 0.1 mM glucose serum-free DMEM for three hours. Media was 
harvested immediately at the end of the treatment time and a fresh 3 ml of 2.5 mM 
glucose serum-free DMEM was applied to all cultures. Cultures were incubated at 37°C 
in a 5% CO2 incubator for four hours after which time this media was harvested. The 
amount of IL-6 secreted in the harvested supernatants was measured by Mouse IL-6 
Quantikine ELISA (R&D Systems, Abingdon) according to the manufacturer’s 
protocol.      
2.8 shRNA Lentiviral Transduction 
Passage 51 (p51) GT1-7 cells were plated the day before infection in a pre-PLL-coated 
12 well plate at a density of 50,000 cells per well in 1 ml of stock media. Only eight 
wells of the plate were seeded as the infections would consist of one scrambled small 
hairpin RNA (shRNA) control, five different shRNAs targeting the IL-6 receptor and 
two cell death control wells. The optimum cell confluency for transduction is 50 – 70%. 
The plate was incubated at 37°C overnight in a 5% CO2 incubator.    
The media for the infection was made up on the day by supplementing 25 mM glucose, 
10 % FBS containing DMEM growth media with 20 µg/ml Polybrene to encourage 
virus particle uptake into GT1-7 cells.  
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The five shRNAs targeting the IL-6 receptor and the control were the commercially 
available MISSION® Transduction Particles and MISSION® Non-Mammalian shRNA 
Control Transduction Particles respectively. Since the constructs were of varying 
concentrations of transducing units (TU) per ml, it was necessary to calculate what 
volume of each construct was required to achieve a multiplicity of infection (MOI) of 
20. An example of this calculation is shown below: 
shRNA 1: 1.3 x 107 TU/ml = 13, 000 TU/µl 
50,000 cells/ 13,000 TU = 3.85 ul x 20 MOI = 77 µl   
The media was removed from each well and replaced with 500 µl of 20 µg/ml 
Polybrene containing DMEM and the appropriate volume of each lentivirus was added 
to the appropriate wells and the plate was gently swirled to mix. Cell death control wells 
just received a media change with no viral particles added. The plate was incubated at 
37°C overnight in a 5% CO2 incubator for 18-24 hours.  
The following day (day two) the cells were fed by adding 500 µl of 25 mM glucose, 
10% FBS containing growth media to each well. On day three a full media change was 
performed by removing the media and replacing it with a fresh 1 ml of 25 mM glucose, 
10% FBS containing growth media per well. On day four the GT1-7 cells were 
confluent enough to be scaled up into a 6 well plate. This was achieved by removing the 
media, performing a 500 µl 37°C rinse of each well and applying 500 µl trypsin per well 
and incubating at 37°C in a 5% CO2 incubator for two to five minutes. The plate was 
tapped gently to make sure cells were dissociated from the plastic. 500 µl of GT1-7 
growth media was added to each well and the suspension was pipetted up and down 
thoroughly before the full 1 ml of cell suspension was added to a pre-PLL-coated 6 well 
plate containing 2 ml of GT1-7 growth media. As there were eight wells in total, two 6 
well plates were required for this scale up. The cells were fed over the following days as 
described on day three above, until they had reached 70-80% confluency in the six well 
plate. The MISSION® constructs contain a puromycin-resistance cassette conferring 
resistance to this antibiotic in virally infected cells. Virally infected cells were therefore 
selected for by replacing the media on the six well plate with GT1-7 growth media 
supplemented with 5 µg/ml puromycin hydrochloride. With this media change only 
those cells successfully infected with virus were able to survive. Confirmation that this 
was indeed the case came via the lack of viable cells in the cell death control wells, 
 
 
 
60 
which were subsequently excluded from the rest of the protocol. The GT1-7 cells were 
then scaled up to T25 flasks and subsequently T75 flasks via trypsinising and replating 
as described above. The virally infected GT1-7 cells were maintained in GT1-7 growth 
media supplemented with 5 µg/ml puromycin hydrochloride.  
RNA was isolated from two different cultures of each of the shRNA infected GT1-7 cell 
lines as previously described above. cDNA was synthesised from this RNA and 
subjected to TaqMan RT-PCR using primers and probes specific for the IL-6Rα mRNA 
transcript. The expression of the mRNA for the IL-6Rα in the five shIL-6Rα infected 
GT1-7 cell lines was quantified and compared to the expression level in the shControl 
infected cell line. shIL-6Rα4-infected GT1-7 cells exhibited a ~74% reduction in 
expression of IL-6Rα mRNA compared to shControl infected cells. Stocks of the 
shRNA infected GT1-7 cells were obtained by freezing down cells from confluent T75 
flasks in 10% DMSO containing GT1-7 growth media in 1.8 ml cryotubes in a Mr. 
Frosty™ Freezing Container (Thermo Scientific™) at -80°C prior to storage in liquid 
nitrogen dewars.       
2.9 Seahorse Bioscience Extracellular Flux Analyser 
(XF24)  
The Seahorse Bioscience Extracellular Flux Analyser XF24 (XF24; Seahorse 
Bioscience) was used to measure extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR), which index glycolysis (by measuring the acidification in 
response to lactate release) and oxidative phosphorylation respectively.  
Table 2.10: Medias for Seahorse XF24 Assays 
Media Stock Supplements 
Basal  XF24  2.5 mM D-Glucose 
Mito Stress Test  XF24 2.5 mM D-Glucose, 2.5 mM 
sodium pyruvate, 2 mM L-
glutamine  
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2.9.1 Basal ECAR and OCR Measurements 
To measure basal ECAR and OCR GT1-7 cells were treated with vehicle control 
(dH2O) or 20 ng/ml IL-6 for three hours in 2.5 mM glucose serum-free DMEM. 
Following recovery in 2.5 mM glucose serum-containing media for approximately two 
hours, cells were trypsinised and counted using an automated cell counter. The cells 
were seeded the day before the assay at a density of 30,000 cells per well in pre-PLL-
coated 24 well Seahorse XF24 culture plates in a final volume of 400 µl GT1-7 plating 
media. The plate was incubated at 37°C overnight in a 5% CO2 incubator.  
On the day of the assay and 18-24 hours subsequent to seeding the plating media was 
removed from the wells by aspiration and replaced with 500 µl of assay medium for 
basal measurements and incubated for one hour at 37°C in a non-CO2 incubator to de-
gas the cells. This step should remove any CO2 from the cells and the culture plate that 
may interfere with the readings from the Seahorse XF24 probes. The Seahorse XF24 
system uses a cartridge that can be pre-loaded with compounds that can be injected into 
the assay wells during experiments. In the case of basal readings, no compounds were 
injected, so the cartridge was simply loaded into the Seahorse XF24 and allowed to 
undergo the calibration phase of the assay. When cartridge calibration and the one hour 
de-gassing had been completed, the cell plate was also loaded into the Seahorse XF24 
positioned such that it was underneath the recording probes of the cartridge. The 
protocol employed consisted of five repetitions of a three minute mix, two minute wait, 
three minute measure cycle.       
2.9.2 Mito Stress Test  
The commercially available Mito Stress Test (Seahorse Bioscience) was utilised for 
assessing functional mitochondrial measurements allowing detailed mitochondrial 
profiling. The test allows the measurement of key parameters of mitochondrial function 
including basal respiration, ATP production, proton leak, maximal respiration and spare 
respiratory capacity.  
For this assay GT1-7 cells were treated and plated in the same way as described for 
basal ECAR and OCR measurements and incubated overnight at 37°C in a 5% CO2 
incubator.  
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On the day of the assay and 18-24 hours subsequent to seeding the plating media was 
removed from the wells by aspiration and replaced with 500 µl of assay medium for the 
Mito Stress Test and incubated for one hour at 37°C in a non-CO2 incubator to de-gas 
the cells. During this time the cartridge was loaded with the appropriate drugs for the 
Mito Stress Test assay. The assay is conducted in a sequential fashion so the drugs were 
loaded in the appropriate ports of the cartridge to achieve this order. The additions made 
were 1 µM oligomycin to inhibit ATP synthase at complex V of the electron transport 
chain (ETC), 0.8 µM carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) 
which uncouples oxygen consumption from ATP production and finally 2 µM each of 
rotenone and antimycin A to inhibit complexes I and III respectively. The drug stocks 
loaded in the cartridge were ten times more concentrated than the working concentration 
desired during the assay, as the stock is diluted 1:10 upon injection into the assay wells. 
Once loaded the cartridge was allowed to calibrate in the Seahorse XF24. After one 
hour of de-gassing the cell plate was loaded into the Seahorse XF24 positioned such 
that it was underneath the recording probes of the cartridge. The protocol employed 
consisted of five repetitions of a three minute mix, two minute wait, three minute 
measure cycle to achieve baseline measurements of OCR prior to the addition of the 
first drug injection. Three mix, wait, measure cycles were then performed prior to the 
next drug injection and this was followed by three mix, wait, measure cycles prior to the 
final drug injection, which was followed by a final three cycles of the mix, wait and 
measurement of OCR.  
Upon completion of Seahorse XF24 assays, the assay media was removed by aspiration 
and 120 µl of 50 mM sodium hydroxide (NaOH) was added to each well to lyse the 
cells. The bases of the wells were scraped with a P200 pipette tip with the end cut to 
widen the diameter of the tip to avoid cell clogging. The lysate was transferred to an 
eppendorf tube and stored at -20°C for future protein concentration determination by the 
Bradford protein assay method previously described, to permit normalisation of ECAR 
and OCR measurements to µg protein content per well.      
2.10 Co-Immunoprecipitation of SUR1 with Kir6.2 and 
EPAC2 
Co-immunoprecipitation (Co-IP) was employed to investigate interaction between the 
KATP channel subunits SUR1 and Kir6.2 as well as with exchange protein activated by 
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cAMP 2 (EPAC2) in response to antecedent treatment with IL-6. Table 2.11 details the 
buffers used for this protocol.  
Table 2.11: Buffers for Co-Immunoprecipitation 
Buffer Components 
Lysis Buffer PBS supplemented with 1% Triton X-
100, 1:1000 protease inhibitor cocktail 
(Pierce), 0.1 mM PMSF, 1 mM Na3VO4 
(heated at 95°C for five minutes prior to 
addition) 
Wash Buffer PBS supplemented with 0.1% Triton X-
100, 1:1000 protease inhibitor cocktail 
(Pierce), 0.1 mM PMSF, 1 mM Na3VO4 
(heated at 95°C for five minutes prior to 
addition) 
2x SDS PAGE Sample Buffer Diluted 1:1 from 4x stock detailed above, 
supplemented with 5% v/v 2-
mercaptoethanol and 100 mM DTT 
 
GT1-7 cells were plated in pre-PLL-coated 100 mm culture plates in GT1-7 plating 
media. Once they had reached 70-80% confluency they were treated with vehicle dH2O 
(control) or 20 ng/ml IL-6 for three hours in 2.5 mM glucose serum-free DMEM at 
37°C in a 5% CO2 incubator. At the end of the treatment time the media was removed 
and a 37°C PBS rinse performed and cells were returned to GT1-7 plating media 
overnight and incubated at 37°C in a 5% CO2 incubator.  
The following day protein G sepharose beads (GE Healthcare) to be used for the Co-IP 
were washed prior to use. 40 µl of beads were used per IP and washed five times in 1 ml 
PBS, recovering the beads at the end of each wash by centrifugation at 17, 000 x g for 
30 seconds. The primary antibody used for the IP was raised against SUR1 nucleotide 
binding domain 2 (SUR1 NBD2). The primary antibody was immobilised on the beads 
for 3 hours at room temperature by incubating 4 µg of SUR1 NBD2 primary antibody 
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per IP with the pre-washed beads at room temperature on a rotating wheel to mix. GT1-
7 cells to be used were lysed by removing the media from the plates, performing a 4°C 
PBS rinse and adding 500 µl of lysis buffer. Plates were scraped thoroughly to harvest 
the cells and the lysates were transferred to eppendorf tubes and agitated on a rotating 
wheel at 4°C for 30 minutes. After the beads and primary antibody had been 
immobilising for three hours, the beads were recovered by centrifugation at 17,000 x g 
for 30 seconds. The supernatant was removed by aspiration and the beads were 
equilibrated in 1 ml of lysis buffer for 30 minutes on a rotating wheel at room 
temperature. After the cell lysates had agitated for 30 minutes they were centrifuged at 
17,000 x g for five minutes at 4°C. The resulting supernatants were transferred to fresh 
eppendorf tubes and the pellets were resuspended in 1 ml of 2x SDS-PAGE sample 
buffer. This material was labelled as the insoluble fraction. 30 µl of the supernatant was 
retained and diluted 1:1 in 2x SDS PAGE sample buffer in a separate eppendorf and 
labelled as the starting material, to be able to demonstrate the presence of proteins of 
interest in the lysate prior to the Co-IP procedure. The beads were given a final 1 ml 
wash in lysis buffer and were recovered by centrifugation at 17,000 x g for 30 seconds 
prior to resuspension in 100 µl lysis buffer per Co-IP reaction. 100 µl of the 
beads:antibody mixture was added to the supernatant from the cell lysates and labelled 
as the Co-IP. The Co-IP reactions were incubated at 4°C overnight on a rotating wheel.   
The following day the Co-IP reactions were centrifuged at 17,000 x g at 4°C. The 
supernatant was transferred to a fresh eppendorf tube, diluted 1:1 with 2x SDS PAGE 
sample buffer and labelled as the unbound fraction. This would allow determination of 
the amount of SUR1, Kir6.2 and EPAC2 protein not bound to the beads. The beads 
were washed five times in 1 ml of wash buffer at 4°C on a rotating wheel for ten 
minutes each time, apart from the first wash which was only one minute in duration. 
After each wash the beads were collected by centrifugation at 17,000 x g for one minute 
and the resulting supernatant was removed by aspiration and discarded. After the final 
wash the beads were resuspended in 50 µl of 2x SDS PAGE sample buffer and labelled 
as the Co-IP fraction. All the fractions from the experiment were heated at 37°C for ten 
minutes prior to storage at -20°C.           
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2.11 Protein Expression in Co-Immunoprecipitation 
Fractions Measured by Western Blot 
Initially it is important to evaluate the amount of each protein of interest in all fractions 
from the Co-IP experiment to be able to determine where the majority of each protein is 
recovered. However, the main comparison between fractions should be between the 
starting material and the Co-IP fraction to be able to determine how much of the protein 
of interest associates with the beads:antibody complexes after the reaction compared to 
before. The fractions from the Co-IP experiments were subjected to Western blot 
protein expression analysis as previously described above and probed with primary 
antibodies raised against the proteins of interest.   
2.12 ATP Assay 
The ATPLite assay (PerkinElmer) was purchased to measure GT1-7 cell ATP levels. 
GT1-7 cells were cultured in T25 flasks in plating media at a confluency of 
approximately 70%. Media was removed and a PBS rinse performed prior to incubation 
of the cells in serum-free media supplemented with vehicle dH2O control or 20 ng/ml 
IL-6 for three hours at 37°C in a 5% CO2 incubator. After this time cells were returned 
to plating media for three hours to recover prior to trypsinisation and seeding at a 
density of 10,000 cells per well in a pre-PLL-coated black 96 well plate. Cells were 
incubated overnight at 37°C in a 5% CO2 incubator. 18-24 hours after the exposure to 
control or IL-6, cells were subjected to three hours 2.5 mM glucose serum-free DMEM 
(euglycaemia) or 0.1 mM glucose serum-free DMEM (hypoglycaemia) prior to cell 
lysis and measurement of ATP according to the manufacturer’s protocol.  
2.13 cAMP Assay 
GT1-7 cells were seeded in 60 mm dishes at a density of 350, 000 cells per dish in 
plating media the day prior to study. The following day media was removed and a PBS 
rinse performed prior to application of 3 ml of serum-free media supplemented with 
vehicle dH2O control (1:250) or 20 ng/ml IL-6 for three hours and incubation at 37°C in 
a 5% CO2 incubator. After this time, media was removed and a PBS rinse performed 
prior to cell lysis in 350 µl of 0.1 M HCl. Lysates were centrifuged at 1000 x g and 
stored at -20°C. Lysates were assayed subsequently using the Direct cAMP ELISA kit 
(Enzo) using the acetylated format of the assay to enhance sensitivity. Measured cAMP 
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values were normalised to the protein concentration of the cell lysates as determined by 
Bradford assay.    
2.14 Data Analysis 
A number of parametric and non-parametric statistical analyses were performed 
depending on the data sets being analysed and whether they passed a D’Agostino-
Pearson omnibus normality test. Parametric statistical tests included unpaired student’s 
t-test and one-way analysis of variance (ANOVA) with Tukey’s or Dunnett’s multiple 
comparisons test. Non-parametric statistical tests included Mann-Whitney test, Kruskal-
Wallis test, Friedman test and one sample t-test. Data are presented as mean ± standard 
error of the mean (SEM). Statistical significance was accepted at the 95% confidence 
interval with a p value of less than 0.05. Significance was allocated to the following p 
values: * = <0.05; ** = <0.01 and *** = <0.001.    
 
Table 2.12: Commonly Used Chemicals and Reagents  
Supplier Chemical/Reagent 
Sigma-Aldrich D5671 DMEM, Interleukin-6 from 
mouse, poly-L-lysine (PLL), sodium 
fluoride (NaF), 
ethylenediaminetetraacetic acid (EDTA), 
ethylene glycol tetraacetic acid (EGTA), 
2-mercaptoethanol, benzamidine, sodium 
orthovanadate (Na3VO4), 
phenylmethylsulphonyl fluoride (PMSF), 
Bradford reagent, bovine serum albumin 
(BSA), glycerol, bromophenol blue, Tris, 
Ponceau S solution, MISSION® 
Transduction Particles, MISSION® Non-
Mammalian shRNA Control 
Transduction Particles, amphotericin B, 
tolbutamide, Polybrene, WP1066, tween   
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Seahorse Bioscience XF24 DMEM,  
Fisher D-glucose, sodium chloride (NaCl), 
methanol, isopropanol, ethanol, 
chloroform 
Harvard Apparatus GC120F-10 Borosilicate glass capillary 
tubing 
Marvel Non-fat dried milk 
Gibco D11966 DMEM, L-glutamine, penicillin-
streptomycin, 0.05% typsin-EDTA, 
Ambion DNase free H2O 
Tocris HJC 0350 
Invitrogen SeeBlue® Plus2 molecular weight 
marker, SuperScript™ II Reverse 
Transcriptase (RT), 3 µg/ml random 
primers, dNTPs, 5x First Strand Buffer, 
0.1 M DTT 
VWR Sodium dodecyl sulphate (SDS), 18 x 18 
mm glass coverslips 
Applied Biosystems 96 well plates, 2x Universal PCR Master 
Mix 
PAA Fetal Bovine Serum 
National Diagnostics 30% Acrylamide, 1x Running Buffer 
PALL Nitrocellulose membrane 
Hyclone Fetal Bovine Serum 
Falcon 35 mm culture dishes 
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Merck Millipore Triton X 100, PVDF membrane, 0.22 µm 
filters 
ThermoScientific T75 culture flasks, T25 culture flasks, 60 
mm culture dishes, 96 well plates, 
cryotubes, 12 well plates, 6 well plates, 
syringes 
Novo Nordisk NN414 
Melford Glycine 
 
Table 2.13: List of Antibody Sources and Dilutions 
Antibody Supplier Species Dilution factor 
Actin Sigma-Aldrich Rabbit 1:10,000 
Phospho AMPK 
(T172) 
Cell Signaling 
Technology 
Rabbit 1:1000 
Phospho p42/44 
MAPK 
(T202/Y204)  
Cell Signaling 
Technology 
Rabbit 1:1000 
Phospho PKB 
(S473) 
Cell Signaling 
Technology 
Rabbit 1:1000 
Phospho STAT3 
(Y705) 
Cell Signaling 
Technology 
Rabbit 1:1000 
HSP60 Cell Signaling 
Technology 
Rabbit 1:1000 
PKM2 Cell Signaling 
Technology 
Rabbit 1:1000 
Phospho STAT3 Cell Signaling Mouse 1:1000 
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(S727) Technology 
PHB1 Cell Signaling 
Technology 
Rabbit 1:1000 
EPAC1 Cell Signaling 
Technology 
Mouse 1:1000 
EPAC2 Cell Signaling 
Technology 
Mouse 1:1000 
PDH Cell Signaling 
Technology 
Rabbit 1:1000 
SUR1 NBD2 In House Sheep 1:1000 
NCX Swant Mouse 1:1000 
COX IV Cell Signaling 
Technology 
Rabbit 1:1000 
Kir6.2 In House Sheep 1:1000 
HK1 Cell Signaling 
Technology 
Rabbit 1:1000 
Phospho CREB 
(S133) 
Cell Signaling 
Technology 
Rabbit 1:1000 
IRDye 800 anti-
rabbit secondary 
Rockland Goat 1:10,000 
Alexa Fluor 680 
anti-mouse 
secondary 
Life Technologies Goat 1:10,000 
Alexa Fluor 680 
anti-sheep 
secondary 
Life Technologies Donkey 1:10,000 
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3 The Effects of IL-6 on Glucose Sensing in 
GT1-7 Cells 
3.1 Introduction 
As previously described, studies have demonstrated the importance of the CNS in the 
regulation of the CRR to hypoglycaemia (Borg et al. 1997; Borg et al. 1995; Borg et al. 
1994). Glucose alters the firing rate of neurons in the VMH, which ultimately instigate 
an appropriate CRR (Chan & Sherwin 2013). Antecedent hypoglycaemia and diabetic 
disease can lead to brain adaptations that impair CRRs (Chan & Sherwin 2013). The 
mechanisms underlying these impairments are likely complex and their study and 
interpretation is complicated as VMH glucose-sensing neurons not only contain their 
own mechanisms for detecting hypoglycaemia but also receive multiple inputs from the 
periphery and other brain regions (Chan & Sherwin 2013). The advantage of the current 
studies is the investigation of glucose sensing in an isolated population of homogenous 
GE neurons, independent from glial cell and other neuronal influences. Importantly, 
studies have found that neuronal and glial cells have distinct responses to IL-6 
stimulation (Brown et al. 2014), so it is advantageous to study these cells types in 
isolation when investigating molecular mechanisms in a specific population of cells.  
Due to the abundance of literature documenting diverse and often conflicting effects of 
IL-6 on signalling pathways and physiological and pathophysiological responses in 
peripheral tissues such as skeletal muscle, liver and adipose, the current work and 
literature cited focuses for the most part solely on IL-6 action in brain and the CNS. 
Importantly, IL-6 and IL-6R mRNA have been found in neurons of the VMH (Schöbitz 
et al. 1993). IL-6 is produced within the CNS by astrocytes and microglia (Frei et al. 
1989; Nelson et al. 2002), with documented roles as a neuroprotective and neurotrophic 
factor (Wang et al. 2015; O. Islam et al. 2009). Under normal conditions the production 
of IL-6 in the CNS is highly regulated, but chronic dysregulation of IL-6 expression 
during inflammation and infection is thought to contribute to the pathogenesis of several 
neurological disorders (Nelson et al. 2002). IL-6 has been shown to be closely aligned 
with resistance to primary herpes virus type 1 (HSV-1) infection (Chucair-Elliott et al. 
2014), accelerates nerve regeneration following trauma (Hirota et al. 1996), is 
neuroprotective following cerebral ischaemia or spinal cord injury (Loddick et al. 1998; 
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Yang et al. 2012) and promotes neuronal survival, axon outgrowth and neuronal 
differentiation in vitro (Chucair-Elliott et al. 2014; Hama et al. 1991). Neutralisation of 
IL-6 resulted in a loss of neuroblasts and neuronal cells undergoing differentiation in 
HSV-1 infected microglial and neural precursor cell (NPC) co-cultures, identifying IL-6 
as a critical cytokine in preserving the neuronal differentiation cascade of NPCs 
(Chucair-Elliott et al. 2014).  
Some studies have documented the effects of IL-6 on neuronal activity measured during 
electrophysiological analysis. In thalamic relay neurons, IL-6 was found to reduce the 
membrane resistance of these cells at the resting membrane potential, potentially by 
increasing K+ leak, and also decrease the number of action potentials in the low calcium 
threshold spike bursts, a characteristic electrophysiological signature of thalamic relay 
cells, after 25 minutes exposure to IL-6 (Samios & Inoue 2014). 
Fever induction caused by IL-6 is one of the best characterised central effects of the 
cytokine (Kluger 1991; Schöbitz et al. 1993). In the early 1960s, hypothalamic neurons 
sensitive to small, local temperature changes were found in anesthetised cats and dogs 
(Hardy et al. 1964; Nakayama et al. 1961). The neurons were further characterised as 
being warm-sensitive neurons which increased their firing rates with higher 
temperature, and cold-sensitive neurons which increased their firing rates in cooler than 
normal temperatures. In the medial preoptic area of the hypothalamus the proportions of 
warm-sensitive, cold-sensitive and thermally insensitive neurons were 30%, 10% and 
60% respectively (Shibata 1990; Silva & Boulant 1986). These neurons were also 
responsive to peripheral thermal stimulation as well as central. These data taken 
together are remarkably reminiscent of glucose-sensing neurons in the hypothalamus, 
which have similarly been demonstrated to be either GE, GI or non-glucose sensing 
(Routh 2010).  Xin and Blatteis demonstrated that the activities of hypothalamic 
neurons in slice preparations from guinea pig brains are selectively affected by human 
recombinant IL-6 (hrIL-6), with hrIL-6 depressing the majority of warm-sensitive 
neurons and exciting all cold-sensitive neurons recorded from (Xin & Blatteis 1992). 
Studies of chronic IL-6 exposure in rat Purkinje cerebellar neurons, using 
concentrations based on those seen in CSF during a variety of neurological disorders, 
induced changes in evoked action potential generation, membrane biophysical 
properties, resting Ca2+ levels and the membrane and Ca2+ signalling responses to 
glutamate receptor agonists (Nelson et al. 2002).  
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Gnv4 cells, a GnRH-expressing adult rat hypothalamic cell line, express both IL-6 and 
IL-6R mRNA (Igaz et al. 2006). In in vitro studies, the IL-6 family cytokine oncostatin 
M (OSM) was found to inhibit the NMDA-induced increase in GnRH gene expression 
in Gnv4 cells and primary rat hypothalamic neuronal cultures, suggesting that cytokines 
have the ability to modulate GnRH expression (Igaz et al. 2006). In GN11 cells, 
obtained by targeted tumourigenesis of mouse GnRH neurons, leukemia inhibitory 
factor (LIF) was found to promote the chemomigration of these immature neurons 
through independent activation of JAK/STAT3, MAPK/ERK1/2 and PI3K/PKB 
signalling pathways (Magni et al. 2007). Taken together, these data suggest that IL-6 
may also regulate GnRH expression and release in GT1-7 cells, potentially via 
regulation of membrane potential.  
The aims of the following studies were therefore to determine whether IL-6, elevated in 
response to hypoglycaemia, exerts effects on GE neurons under euglycaemic and 
hypoglycaemic conditions, by examining the biochemical and electrophysiological 
responses of GT1-7 cells upon exposure to IL-6.   
3.2 Results  
3.2.1 IL-6 Signalling in GT1-7 Cells 
Initial experiments in the current work focused on confirming whether the cytokine 
interleukin-6 (IL-6) could exert biological effects on GT1-7 cells, indicated by 
stimulation of intracellular signalling pathways known to be regulated by IL-6. IL-6 is 
known to activate the PI3K, MAPK cascade and JAK/STAT cascade of signalling 
pathways (Eulenfeld et al. 2012). The observation that cytokines can rapidly affect 
neurotransmitter release and synaptic plasticity when applied in vitro suggests that these 
effects are presumably mediated through the activation of protein phosphorylation 
processes (Arcangelo et al. 2000).  
Although Dozio et al. demonstrated expression of gp130 in GT1-7 cells and an increase 
in the phosphorylation of STAT3 in response to ciliary neurotrophic factor (CNTF) 
treatment (Dozio et al. 2005), whether IL-6 increases STAT3 phosphorylation in these 
cells has not been studied. Encouragingly, IL-6 has been shown to stimulate GnRH 
release from rat primary hypothalamic neuronal cultures, suggesting IL-6 can induce 
biological effects at least in this model (Yamaguchi et al. 1991). In the current work a 
 
 
 
72 
dose of 20 ng/ml IL-6 over a time course exposure of five, 30 and 180 minutes caused 
significant increases in STAT3 Y705 phosphorylation at all three time points compared 
to vehicle treated cells (Figure 3.1A; p=<0.05 at each time point). 
The literature concerning the effects of cytokines on ERK1/2 in neurons of the 
hypothalamus is much less profound, however the effects of IL-6 on the regulation of 
ERK in other brain regions has been studied. Restraint stress in rats increased pERK in 
IL-6 positive neurons of the hypothalamus (Jankord et al. 2010). The Benfenati lab 
observed a suppression of both MAPK and ERK1/2 phosphorylation in response to IL-6 
treatment in rat hippocampal slices (Tancredi et al. 2000). In contrast, Chang SH et al. 
found that OSM, an IL-6 family cytokine, induces expression of myeloid cell leukemia-
1 (Mcl-1) via activation of ERK1/2 (Chang et al. 2015) in cortical neurons. In rat 
cerebellar granule neurons, IL-6 exposure for eight days induced phosphorylation of 
ERK1/2 (Fang et al. 2013). In the current study, there was no significant effect of 20 
ng/ml IL-6 exposure for five-180 minutes on the phosphorylation of ERK1/2 at residues 
threonine 202 (T202) and tyrosine 204 (Y204) in GT1-7 cells (Figure 3.1B). 
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Figure 3.1 Effects of interleukin-6 (IL-6) on intracellular signalling pathways in GT1-7 
cells  
GT1-7 cells were serum starved for two hours in the presence of 2.5 mM glucose prior 
to exposure to vehicle dH2O (Control, C) for three hours or 20 ng/ml IL-6 for the 
indicated times. Cells were lysed and samples prepared for Western blot analysis of 
protein expression of pSTAT3 Y705 (A), pERK T202/Y204 (B), pPKB S473 (C) or 
pAMPK T172 (D) (n=4-6). Fold change in phosphorylation of each protein was 
determined relative to Control treated cells normalised to actin and representative blots 
are shown. Statistical significance was determined by one sample t-test where * 
indicates significantly different from control (p=<0.05).     
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Relatively little is known about the effects of cytokine exposure on the regulation of 
central AMPK in either neurons or non-neuronal cell types such as astrocytes and 
microglia. In contrast, a wealth of literature documents effects of IL-6 on the regulation 
of AMPK in multiple tissues, particularly skeletal muscle, liver and adipose. Kelly et al. 
demonstrated convincingly that incubation of skeletal muscle with IL-6 caused an 
increase in the phosphorylation of AMPK at site T172 and an increase in activity of α2-
containing AMPK (Kelly et al. 2009). The same group also demonstrated the in vivo 
importance of IL-6 in the activation of AMPK (Kelly et al. 2004). Increased AMPK 
T172 phosphorylation in response to IL-6 has also been observed in cultured mouse 
epididymal adipose tissue (Wan et al. 2012). Replacement of recombinant IL-6 protein 
in IL-6-/- mice fed a high fat diet leads to increased liver pAMPK levels compared to 
high fat diet control IL-6-/- animals, suggesting that IL-6 increases pAMPK in the liver 
as well (Vida et al. 2015). In contrast however, excess nutrient stress has been shown to 
suppress AMPK phosphorylation in the heart (Ko et al. 2009). In this study the authors 
acutely administered IL-6 to mimic the increased circulating levels of the cytokine 
observed in animals fed a high fat diet (HFD), and they observed a reduction of 
pAMPK levels in the heart compared to saline injected control mice. The discrepancy 
between the effect of IL-6 in most peripheral tissues and the heart may be due to the 
dose and length of exposure to IL-6, as well as tissue specific effects of the cytokine. In 
the current work, there was a subtle trend of 20 ng/ml IL-6 exposure for five and 180 
minutes towards increasing pAMPK T172 levels compared to vehicle treated GT1-7 
cells, however this did not reach statistical significance (Figure 3.1D; 5 minutes: 
p=0.12; 30 minutes: p=0.47; 180 minutes: p=0.35).  
In a 2010 study in GT1-7 cells, Choi et al. observed that insulin stimulation induced the 
phosphorylation of PKB (also called Akt).  Fang et al. observed increases in pPKB after 
eight days IL-6 exposure in rat cerebellar granule neurons (Fang 2013). In the current 
experiments, 20 ng/ml IL-6 exposure in GT1-7 cells for five, 30 or 180 minutes failed 
to affect the phosphorylation of PKB at serine 473 (S473) (Figure 3.1C).  
Taken together, these data show that IL-6 increases the phosphorylation of STAT3 in 
GT1-7 cells with no effect on ERK1/2 or PKB phosphorylation. IL-6 was not shown to 
have a major effect on AMPK as there was no significant effect of IL-6 to increase 
pAMPK at T172. The clearly observed increase in pSTAT3 in response to IL-6 
demonstrates activation of the JAK/STAT cascade suggesting that IL-6 is able to 
transduce a signal via the ubiquitously expressed gp130 glycoprotein and either the 
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membrane bound or soluble form of the IL-6 receptor. These data suggest that in GT1-7 
cells IL-6 does not activate the ERK1/2 and PI3K signalling cascades as has previously 
been documented in other cell types (Eulenfeld et al. 2012).      
3.2.2 Effects of IL-6 on GT1-7 Membrane Potential Under 
Euglycaemic Conditions  
Several cytokines including IL-1, TNF and IFN have been demonstrated to elicit 
pyrogenic effects in the context of fever potentially by affecting the activity of 
hypothalamic thermosensitive neurons. The fact that cytokines have been demonstrated 
to regulate thermal sensitive neurons led to the hypothesis that IL-6 may also acutely 
regulate glucose-sensing neurons of the hypothalamus. Intriguingly, thermosensitive 
neurons were also demonstrated to be sensitive to glucose fluctuations permitting 
speculation that the previously demonstrated effects of cytokines on thermosensitive 
neurons may also be applicable to glucose-sensing neurons. To address whether this 
was the case, GT1-7 cells were subjected to perforated patch current clamp recordings 
to allow monitoring of the cell membrane potential during acute perfusion of IL-6. 
Exposure of GT1-7 cells to IL-6 in this way had no effect on membrane potential, 
which remained at a constant value throughout the experiment (Figure 3.2). In 2.5 mM 
glucose the mean resting membrane potential of the cells was -44.4 +- 3.9 mV and after 
IL-6 perfusion mean membrane potential was -46.6 +- 4.8 mV. Analysis of the pooled 
data from five individual recordings demonstrated that there was no effect of IL-6 on 
either depolarisation or hyperpolarisation of the cell membrane under euglycaemic 
conditions (Figure 3.2B). To confirm that the cells had KATP channels and membrane 
potential was sensitive to alterations in KATP activity, the KATP channel opener NN414 
was delivered extracellularly at a dose of 5 µM to one of the cells, causing 
hyperpolarisation of the cell membrane to -65 mV and cessation of action potential 
firing (Figure 3.2). 
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3.2.3 IL-6 does not Regulate GT1-7 Cell Membrane Potential 
Under Acute Hypoglycaemic Conditions 
Although there was no effect of IL-6 on GT1-7 cell membrane potential under 
euglycaemic conditions I also sought to determine whether there might be an effect of 
IL-6 during acute hypoglycaemia to either potentiate or attenuate membrane potential 
hyperpolarisation in low glucose. GT1-7 cells were subjected to perforated patch clamp 
electrophysiology and current clamp recordings were made in order to assess membrane 
potential. 0.5 mM glucose physiological saline solution was perfused to induce 
membrane hyperpolarisation and after achievement of a stable membrane potential 20 
ng/ml IL-6 was perfused in 0.5 mM glucose saline. The effect of the IL-6 addition on 
membrane potential was monitored for at least ten minutes prior to washout with 2.5 
mM glucose saline. In the current experiments, a small but non-significant effect of IL-6 
perfusion on membrane potential during acute hypoglycaemic conditions was observed 
(Figure 3.3). Resting membrane potential in 2.5 mM glucose averaged -51.3 +- 0.7 mV, 
with membrane hyperpolarisation observed to -66.3 +- 3.9 mV in 0.5 mM glucose. 
Addition of 20 ng/ml IL-6 in this setting resulted in further membrane hyperpolarisation 
to -71.7 +- 6.0 mV on average (p=0.75 vs 0.5 mM glucose). 
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3.2.4 IL-6 is Secreted from Primary Mouse Astrocytes in the 
Recovery Period Following Hypoglycaemia  
Although it is clear that GT1-7 cells respond to IL-6 through classical signalling 
cascades, whether there is a CNS source of IL-6 and/or whether peripheral IL-6 
circulating in the blood stream can cross the BBB and enter the brain and the extent of 
its action when it gets there remains controversial. William A Banks demonstrated the 
appearance of radio labelled IL-6 in mouse brain tissue following peripheral injection 
confirming that IL-6 can cross the BBB at least in mice (Banks et al. 1994). However, 
in those studies only 16% of the radioactivity recovered eluted as intact IL-6. 
Importantly, other studies have demonstrated the capacity for a central source of IL-6 
through its release from brain cell types. The immortalised mouse microglial BV2 cell 
line has been demonstrated to secrete IL-6 in response to glucose deprivation (S. J. Choi 
et al. 2013). To determine whether a local source of IL-6 is present in the brain and the 
relationship of IL-6 release to hypoglycaemia, primary astrocyte cultures were prepared 
from mouse cortex and subjected to euglycaemia control (2.5 mM glucose) or 
hypoglycaemia (0.1 mM glucose) for three hours. Supernatants from the cultures were 
harvested immediately at the end of the three hour treatment or after four hours 
recovery in euglycaemic conditions in order to measure IL-6 secretion at these two time 
points. Interestingly, IL-6 release from primary astrocytes was undetectable after three 
hour treatments of either euglycaemia or hypoglycaemia. However, after a four hour 
euglycaemic recovery period post treatments, IL-6 secretion was increased from both 
euglycaemic and hypoglycaemic astrocyte cultures, with a significantly greater IL-6 
secretion observed from hypoglycaemia-exposed astrocytes compared to euglycaemia-
exposed controls (p=<0.05, n=4). These data demonstrate that IL-6 secretion from 
mouse astrocytes is significantly increased during the euglycaemic recovery period 
following a hypoglycaemic challenge. In vivo, this would lead to an increase in CNS IL-
6 levels following hypoglycaemia.  
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Figure 3.4 Interleukin-6 is released from mouse cortical astrocytes in the recovery 
period following hypoglycaemia 
Mouse cortical astrocyte cultures were subjected to euglycaemia (2.5 mM glucose) or 
hypoglycaemia (0.1 mM glucose) for three hours in serum-free DMEM which was 
harvested immediately at the end of the treatment time (0 hours). Fresh euglycaemic 2.5 
mM glucose serum-free DMEM was applied to the astrocyte cultures and this was 
harvested four hours subsequently (4 hours). The amount of IL-6 in the harvested 
supernatants was measured by ELISA (n=4). Hypoglycaemia for three hours resulted in 
significantly more IL-6 secretion in the euglycaemic recovery period following 
treatment than that observed from euglycaemia treated astrocyte cultures (compare 2.5 
mM to 0.1 mM at four hours post treatment). Statistical significance was analysed by 
Mann-Whitney test where * indicates significantly different (p=<0.05). Data generated 
in collaboration with Kathryn Wright. 
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3.2.5 Antecedent IL-6 Causes Defective Glucose Sensing of 
Subsequent Hypoglycaemia in GT1-7 Cells 
Taking together the observations that IL-6 had no major effect on GT1-7 cell membrane 
potential when applied acutely and that IL-6 is secreted from astrocytes in the 
euglycaemic recovery period following hypoglycaemia, it was hypothesised that IL-6 
might exert delayed effects on GT1-7 cells. To test this hypothesis an antecedent 
exposure for three hours to either vehicle dH2O (Control) or 20 ng/ml IL-6 was 
performed prior to a subsequent hypoglycaemic challenge in GT1-7 cells 18-24 hours 
later. This models whether elevated IL-6 levels, released following hypoglycaemia, 
effects responses of glucose-sensing neurons to subsequent hypoglycaemia. During 
perforated patch clamp electrophysiological analysis, vehicle treated control cells 
exhibited a resting membrane potential in 2.5 mM glucose of -52 +- 1 mV. These cells 
demonstrated a robust, significant hyperpolarisation by -10.2 +- 2.9 mV on average to a 
membrane potential of -65.3 +- 3.3 mV, and a silencing of neuronal firing rate in 
response to 0.5 mM glucose exposure. This was reversible upon reapplication of 2.5 
mM glucose, with cells depolarising by 12.3 +- 5.2 mV on average to a membrane 
potential of -52.5 +- 3.3 mV (Figure 3.5A and C). Antecedent 20 ng/ml IL-6 treated 
cells had a similar resting membrane potential in 2.5 mM glucose of -51.1 +- 1.7 mV as 
vehicle treated control cells. However, in contrast to controls, 20 ng/ml IL-6 treated 
cells only hyperpolarised by 3.0 +- 1.3 mV on average and maintained firing rates 
during the 0.5 mM glucose exposure (Figure 3.5B and C). In 0.5 mM glucose, 20 ng/ml 
IL-6 treated cells only hyperpolarised to -54.4 +- 2.3 mV, and they depolarised by 3.6 
+-1.8 mV on average to -50.8 +- 3.6 mV upon reapplication of 2.5 mM glucose. 
Antecedent IL-6 treatment resulted in a significant suppression of cell membrane 
hyperpolarisation in response to subsequent hypoglycaemia compared with vehicle 
treated control cells (Figure 3.5C). This data can also be represented as percentage 
reduction in the hyperpolarising response to 0.5 mM glucose in IL-6 treated cells 
compared to vehicle treated cells. This is quantified as a 70% reduction in 
hyperpolarisation by antecedent IL-6 treatment (data not shown). In summary, an 
antecedent exposure to IL-6 in GT1-7 cells causes a reduction in their ability to detect 
and respond appropriately to a 0.5 mM glucose hypoglycaemic challenge the following 
day (18 to 24 hours subsequently). 
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3.2.6 Antecedent IL-6 Does Not Affect KATP Channel 
Conductance Density in GT1-7 Cells 
The effect of antecedent IL-6 treatment to impair subsequent membrane 
hyperpolarisation in response to a hypoglycaemic challenge may be mediated by a 
reduction in the ability of the KATP channel to open. When KATP channels are opened 
either by physiological or pharmacological manipulation an increase in macroscopic 
currents can be measured in the whole-cell patch clamp configuration. This technique 
was exploited to examine whether antecedent IL-6 treatment affected the ability of KATP 
channels to conduct current 18 to 24 hours later. GT1-7 cells were exposed to dH2O 
vehicle (Control) or 20 ng/ml IL-6 (IL-6) for three hours on day one and the following 
day were subjected to electrophysiological examination in the whole-cell patch clamp 
configuration. A voltage clamp protocol (see methods) was employed to assess KATP 
channel currents under control conditions and after the cell had been dialysed with 0 
ATP. Over time (usually five to 15 minutes), the presence of 0 ATP in the patch pipette 
will cause intracellular ATP to dialyse out of the cell relieving ATP inhibition of KATP 
channels. This will lead to an increase in outward currents through KATP channels that 
can be observed using the voltage clamp protocol. By plotting the current-voltage 
relationships observed the conductance density for each cell can be extrapolated and 
normalised to cell size. The data can then be pooled together to compare conductance 
density between two different treatment groups. In the current work control and IL-6 
treated GT1-7 cells had comparable macroscopic currents measured at both baseline and 
after dialysis with 0 ATP (Figure 3.6Aii and Bii). Accordingly, there was no difference 
in the profile of whole-cell current clamp recordings made during dialysis with 0 ATP 
(Figure 3.6Ai and Bi). There was no significant difference in the conductance densities 
for control versus antecedent IL-6 treated cells (1.11 +- 0.16 vs 1.00 +- 0.17 pS/pF 
respectively), indicating that a lack of functional KATP channels in the cell membrane is 
not responsible for mediating defective glucose sensing induced by antecedent IL-6 
treatment (Figure 3.6C). This data therefore implies that antecedent IL-6 treatment does 
not affect the number of available or functional KATP channels at the cell membrane 18-
24 hours subsequently. 
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3.2.7 Generation of IL-6Rα Knockdown Cells 
To confirm that the defective glucose sensing observed following antecedent IL-6 
treatment was indeed an effect of exogenously applied IL-6, a GT1-7 cell line with 
stable knockdown of the IL-6 membrane bound receptor (IL-6Rα) was developed. 
While pharmacological intervention to impede IL-6 signalling could also have been 
employed in order to investigate this, the partial removal of the receptor through which 
IL-6 signals gave a more global inhibition of IL-6 signalling and would also be 
predicted to guard against activation of compensatory intracellular signalling pathways 
which is often observed when using pharmacological inhibition of specific signalling 
cascades. A panel of five commercially available shRNA sequences targeted against IL-
6Rα were purchased (Sigma-Aldrich) and each shRNA was delivered to separate 
populations of GT1-7 cells in culture via the lentiviral delivery system (see methods for 
details). Additionally a scrambled shRNA sequence known not to target any 
mammalian genes was delivered to a population of GT1-7 cells as a control (shControl). 
Virally infected cells were selected for by resistance to puromycin, conferred by the 
inclusion of a puromycin-resistant cassette in the shRNA constructs. Stable cell lines of 
each genotype (shControl and shIL-6Rα1-5) were grown up and RNA from these 
cultures was isolated and used to synthesise cDNA which was then subjected to 
TaqMan® RT-PCR analysis to quantify shIL-6Rα gene expression (normalised to the 
house-keeping gene cyclophillin A). In Figure 3.7A the reduction in IL-6Rα gene 
expression in shIL-6Rα1-5 infected GT1-7 cells is shown compared to expression in 
shControl GT1-7 cells. shIL-6Rα4 cells were confirmed as demonstrating the most 
robust and reproducible knockdown of expression of the IL-6Rα gene, achieving ~75% 
reduction in expression compared to shControl treated cells (Figure 3.7C). The virally 
infected cell lines were frozen down and stored in liquid nitrogen. Upon re-suspension 
of shControl and shIL-6Rα4 cells (henceforth referred to as shIL-6Rα cells) in culture 
the expression of IL-6Rα was reconfirmed by TaqMan® RT-PCR. It should be noted 
that a slight decrease in the knockdown of IL-6Rα was observed in shIL-6Rα compared 
to shControl GT1-7 cells following the freeze thaw cycle compared to before it. The 
percentage expression of IL-6Rα in shIL-6Rα GT1-7 cells was quantified as 43% that of 
shControl cells, therefore meaning a 57% knockdown of IL-6Rα was achieved (data not 
shown).  
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Figure 3.7 Generation of stable IL-6Rα knockdown GT1-7 cells using shRNA 
A panel of five different shRNA sequences targeting the IL-6Rα (shIL-6Rα 1-5) or a 
scrambled control sequence (shControl) were delivered to GT1-7 cells via the lentiviral 
method. Stable cell lines of each transfection were cultured and after selection for 
virally infected cells RNA was isolated and cDNA synthesised to quantify gene 
expression of IL-6Rα by TaqMan® RT-PCR. (A) Bar chart demonstrating fold decrease 
in IL-6Rα mRNA expression in shIL-6Rα1-5 treated compared to shControl treated 
GT1-7 cells (n=2). (B) Direct comparison of IL-6Rα mRNA expression in shControl 
and shIL-6Rα4 GT1-7 cells, the shIL-6Rα sequence giving the most robust knockdown 
of IL-6Rα mRNA measured by TaqMan® RT-PCR (n=2). (C) For illustrative purposes 
the decrease in IL-6Rα mRNA expression in shIL-6Rα4 cells is shown as a percentage 
of IL-6Rα expression in shControl GT1-7 cells (n=2). Statistical significance was 
analysed by Kruksal-Wallis test ANOVA in panel (A) where * indicates significantly 
different from shControl (p=<0.05) and by one-sample t-test in panels (B) and (C) 
where * indicates significantly different from shControl (p=<0.05).    
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3.2.8 shControl and shIL-6Rα GT1-7 Cells Have Comparable 
KATP Channel Conductance 
To confirm that shControl or shIL-6Rα infection didn’t affect KATP channel expression 
or function, the two cell types were subjected to whole-cell patch clamp 
electrophysiology analysis. This technique was exploited to analyse whether the shRNA 
infections affected the ability of KATP channels to conduct current. A voltage-clamp 
protocol (see methods) was employed to assess KATP channel currents under control 
conditions and after the cell had been dialysed with 0 ATP. shControl and shIL-6Rα 
GT1-7 cells had comparable macroscopic currents measured at both baseline and after 
dialysis with 0 ATP (Figure 3.8Aii and Bii). Accordingly, there was no difference in the 
profile of whole-cell current clamp recordings made during dialysis with 0 ATP (Figure 
3.8Ai and Bi). There was no significant difference in conductance density between 
shControl and shIL-6Rα cells (1.01 +- 0.21 and 1.35 +- 0.15 pS/pF respectively), 
confirming that shRNA mediated infection of GT1-7 cells does not affect the ability of 
KATP channels to conduct current (Figure 3.6C). Furthermore, the virally infected GT1-
7 cells had comparable conductance densities with those observed in WT GT1-7 cells 
(compare Figure 3.6C with Figure 3.8C). 
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3.2.9 Antecedent IL-6 Induces Defective Glucose Sensing of 
Subsequent Hypoglycaemia in shControl GT1-7 Cells 
To confirm that the shControl GT1-7 cells behaved physiologically the same as WT 
GT1-7 cells, as would be predicted, shControl cells were subjected to the antecedent IL-
6 experiment previously performed in WT GT1-7 cells. shControl GT1-7 cells were 
exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three hours prior to 
undergoing a 0.5 mM glucose hypoglycaemic challenge 18-24 hours subsequently 
during perforated patch clamp electrophysiological analysis. Similarly to WT GT1-7 
cells, vehicle treated shControl GT1-7 cells exhibited a resting membrane potential of -
51.7 +- 1.9 mV in 2.5 mM glucose and these cells hyperpolarised and firing rates ceased 
in response to the low glucose challenge (Figure 3.9A and C). Antecedent IL-6 
treatment in shControl cells prevented the hyperpolarising response and resulted in 
maintained firing rates during the low glucose stimulus, replicating the glucose sensing 
defect observed with antecedent IL-6 exposure in WT GT1-7 cells (Figure 3.9B and C). 
It should be noted that in vehicle treated shControl GT1-7 cells, the hyperpolarising 
response to 0.5 mM glucose was reduced compared to that observed in vehicle treated 
WT GT1-7 cells (Appendix I). In response to 0.5 mM glucose, vehicle treated shControl 
cells only hyperpolarised by -2.3 +- 2.2 mV to -54.0 +- 2.2 mV on average. However, 
this was due to over 50% (4 of 7) of the cells studied failing to detect the 0.5 mM 
glucose challenge (see Appendix I for details). Although this was an unexpected 
observation, importantly, the hyperpolarising response to 0.5 mM glucose in shControl 
cells exposed to antecedent IL-6 treatment was prevented in all cells studied, such that 
from a resting membrane potential in 2.5 mM glucose of -47.5 +- 3.1 mV, cells in fact 
depolarised by 2.7 +- 0.7 mV on average to a membrane potential of -44.8 +- 2.8 mV in 
response to 0.5 mM glucose (Figure 3.9C and Appendix I). Furthermore, separation of 
the vehicle treated hypoglycaemia-responsive cells from the non-responsive cells 
demonstrated that they hyperpolarised by -8.0 +- 2.1 mV on average in response to 0.5 
mM glucose, whereas the non-responders in fact depolarised by 2.0 +- 0.7 mV on 
average (Appendix I). The hyperpolarising response to 0.5 mM glucose in responsive 
shControl cells is therefore comparable with that observed in WT cells in previous 
experiments (-8.0 +- 2.1 vs -10.2 +- 2.9 mV respectively). Therefore, the responses of 
shControl cells to antecedent vehicle and IL-6 treatments were phenotypically 
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comparable to WT GT1-7 cells, with antecedent IL-6 treatment inducing defective 
hypoglycaemia detection in shControl GT1-7 cells. 
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3.2.10 Antecedent IL-6 Fails to Induce Defective Glucose 
Sensing in shIL-6Rα GT1-7 Cells 
To prove that the defect in glucose sensing observed in Figure 5 was indeed mediated 
by IL-6, shIL-6Rα cells were treated antecedently with either vehicle (dH2O) or 20 
ng/ml IL-6 on day one prior to being subjected to a 0.5 mM glucose hypoglycaemic 
challenge the following day during perforated patch clamp electrophysiology. In vehicle 
treated shIL-6Rα cells a normal physiological response to the hypoglycaemic challenge 
was observed the following day during current clamp recordings with cells significantly 
hyperpolarising by 14 mV on average and inhibition of firing rates in response to the 
hypoglycaemic stimulus (Figure 3.10A and C). Importantly, antecedent IL-6 treated 
shIL-6Rα GT1-7 cells also exhibited a normal physiological response to the 
hypoglycaemic challenge the following day, also significantly hyperpolarising by 14 
mV on average and ceasing firing rates in response to the hypoglycaemic stimulus 
(Figure 3.10B and C). Statistical analysis confirmed there was no significant difference 
in the hyperpolarising response to 0.5 mM glucose in IL-6 treated cells compared to 
vehicle treated cells (Figure 3.10C) and therefore, partial knockdown of the membrane 
bound IL-6α by shRNA resulted in a complete prevention of the antecedent IL-6 
induced glucose sensing defect observed in WT GT1-7 cells. 
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3.2.11 Antecedent IL-6-Induced Suppression of Glucose 
Sensing is Prevented in shIL-6Rα GT1-7 Cells 
Figure 3.11 depicts the compiled data from the antecedent IL-6 glucose sensing 
experiments. For illustrative purposes, vehicle treated WT and shIL-6Rα GT1-7 cells 
were combined for analysis as the Control column as their hyperpolarising responses 
were comparable. In the Kruskal-Wallis analysis performed in this figure the effect of 
antecedent IL-6 treatment to suppress hyperpolarisation in response to 0.5 mM glucose 
in WT GT1-7 cells did not reach statistical significance, however the same treatment in 
shControl cells did. Importantly, antecedent IL-6 treated shIL-6Rα cells had comparable 
hyperpolarising responses to 0.5 mM glucose as WT GT1-7 cells, confirming that IL-6 
via IL-6Rα-mediated signalling induced defective hypoglycaemia detection in GT1-7 
cells.   
3.2.12 Effects of IL-6 on STAT3 Phosphorylation in 
shControl and shIL-6Rα GT1-7 Cells 
To confirm that the shRNA-mediated knockdown of IL-6Rα expression had functional 
consequences, shControl and shIL-6Rα GT1-7 cells were subjected to 20 ng/ml IL-6 
timecourse experiments, similar to those performed in WT GT1-7 cells in Figure 3.1.  
20 ng/ml IL-6 exposure in shControl cells elicited a robust increase in STAT3 Y705 
phosphorylation, particularly at 30 minutes and three hours exposure to IL-6, however 
the increase in STAT3 Y705 phosphorylation in response to IL-6 in shIL-6Rα cells was 
much less pronounced (Figure 3.12A and B). In Figure 3.12C the fold increase in 
STAT3 Y705 phosphorylation in response to three hours 20 ng/ml IL-6 exposure from 
vehicle dH2O exposure is compared in shControl and shIL-6Rα cells, and the increase 
observed in shIL-6Rα cells is only 42% of that observed in shControl cells. This data 
demonstrates that partial reduction of IL-6Rα results in an attenuation of IL-6 mediated 
intracellular signalling in GT1-7 cells.  
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Figure 3.11 Antecedent 20 ng/ml IL-6 treatment causes an attenuation in the 
hyperpolarising response to subsequent 0.5 mM glucose exposure in WT GT1-7 cells 
but not in GT1-7 cells with partial knockdown of IL-6Rα by shRNA 
WT GT1-7 and shIL-6Rα GT1-7 cells were treated with vehicle (dH2O) or 20 ng/ml IL-
6 for three hours on day one and exposed to a 0.5 mM glucose hypoglycaemic challenge 
the following day (18-24 hours later). Hyperpolarising responses to the low glucose 
stimulus were monitored during current clamp electrophysiological recordings in the 
perforated patch clamp configuration. The bar chart depicts the average hyperpolarising 
response (mV) to the hypoglycaemic stimulus in vehicle (Control) and IL-6 treated WT, 
shControl and shIL-6Rα GT1-7 cells. For illustrative purposes the responses to vehicle 
treatment have been pooled together for WT and shIL-6Rα cell genotypes as they did 
not differ between cell types (n=15). Antecedent IL-6 treatment is an average of n=8, 
n=6 and n=6 cells in WT, shControl and shIL-6Rα cells respectively. Statistical 
significance was analysed by Kruskal-Wallis test where *** indicates significantly 
different to Control (p=<0.001).  
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Figure 3.12 IL-6 induced STAT3 phosphorylation is reduced in shIL-6Rα GT1-7 cells 
compared to shControl GT1-7 cells 
shControl (A) and shIL-6Rα (B) GT1-7 cells were serum starved for two hours in the 
presence of 2.5 mM glucose prior to exposure to 20 ng/ml IL-6 for the indicated times 
or vehicle dH2O (Control) for 180 minutes. Cells were lysed and samples prepared for 
Western Blot analysis of pSTAT3 Y705 protein expression. Fold change in 
phosphorylation of STAT3 was determined compared to Control cells normalised to 
actin expression and representative blots are shown (n=3). (C) Comparison between 
fold increase in pSTAT3 Y705 in response to 20 ng/ml IL-6 treatment for 180 minutes 
in shControl and shIL-6Rα cells (n=3). Statistical significance was analysed by one 
sample t-test in (A) and (B) and Mann-Whitney test in (C).  
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3.2.13 Regulation of SOCS3 Gene Expression by IL-6 in 
GT1-7 Cells 
SOCS3 mRNA and protein is rapidly induced in response to IL-6 stimulation (Endo et 
al. 1997; Starr et al. 1997; Naka et al. 1997; Sasaki et al. 1999; Kershaw et al. 2013).  In 
GT1-7 cells, after 30 minutes exposure to IL-6, no upregulation of SOCS3 mRNA 
expression was observed four or 24 hours later (Figure 3.13A). In order to confirm IL-6 
did not induce an upregulation of SOCS3 mRNA expression earlier than four hours 
after exposure, GT1-7 cells were exposed to 20 ng/ml IL-6 for one, two or three hours 
and SOCS3 mRNA was measured at these three time points by RT-PCR. Unexpectedly, 
no increases in SOCS3 mRNA were observed at any of the time points and in fact, a 
significant suppression of SOCS3 mRNA was observed in cells exposed to IL-6 for two 
hours compared to vehicle treated control cells (Figure 3.13B; 2 hours IL-6: p=<0.01). 
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Figure 3.13 Effects of IL-6 on SOCS3 mRNA expression in GT1-7 cells 
(A) GT1-7 cells were exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 for 30 
minutes then lysed four or 24 hours subsequently. RNA was extracted and used to 
synthesise cDNA which was subjected to Taqman qRT-PCR analysis to determine 
SOCS3 gene expression (n=1). (B) GT1-7 cells were exposed to vehicle dH2O (Control) 
for three hours or 20 ng/ml IL-6 for one, two or three hours and lysed. RNA was 
extracted and used to synthesise cDNA which was subjected to Taqman qRT-PCR 
analysis to determine SOCS3 gene expression. Fold change in gene expression was 
determined relative to Control treated cells normalised to the housekeeping gene 
cyclophillin A (n=2). Data was analysed by one sample t-test in (B) where ** indicates 
significantly different from Control (p=<0.01). 
  
 
 
 
99 
3.3 Discussion 
IL-6 was found to activate the JAK/STAT3 signalling pathway in GT1-7 cells 
demonstrated by robust increases in the phosphorylation of STAT3 Y705 in response to 
IL-6 stimulation, persisting for at least three hours. Somewhat unexpectedly, IL-6 was 
not observed to activate other pathways classically activated in response to IL-6 
stimulation, namely the MAPK/ERK pathway or PI3K/PKB pathway, which were 
indexed in the current work by phosphorylation of ERK1/2 and PKB respectively. 
Interestingly, studies have shown that IL-6 typically activates ERK1/2 in subconfluent 
cells, but that this response is lost in post-confluent cultures, suggesting that cell density 
may be a factor determining ERK1/2 responses to IL-6 stimulation (Raptis et al. 2011). 
Molecular studies of the IL-6Rα complex have identified that residue Y759 of gp130 is 
critical in controlling the balance between STAT and MAPK activation in IL-6, as it 
recruits SHP2 to activate MAPK signalling and is also the recruitment site of SOCS3 
mediated inhibition of STAT signalling (Eulenfeld et al. 2012). Potentially in GT1-7 
cells, the STAT3 signalling axis is preferentially activated over the MAPK cascade. 
Interestingly, in GT1-7 cells no apparent regulation of SOCS3 mRNA in response to IL-
6 stimulation was observed. Literature suggests that SOCS3 mRNA and protein is 
rapidly upregulated in response to IL-6 stimulation of its receptor complex. In the 
current work the earliest time point that SOCS3 mRNA levels was measured was after 
one hour of IL-6 exposure. It would be of interest to investigate SOCS3 mRNA levels 
after a shorter exposure to IL-6 and also to investigate SOCS3 protein levels in these 
cells. IL-6 stimulation also failed to activate the PI3K cascade in GT1-7 cells, 
demonstrated by a lack of an effect of IL-6 exposure on PKB phosphorylation. The 
PI3K signalling cascade is also activated through the Y759 SHP2 binding site 
(Eulenfeld et al. 2012). Taking this data together raises the possibility that in GT1-7 
cells the Y759 residue of gp130 fails to recruit SHP2 to activate MAPK and PI3K 
signalling pathways. Similarly, IL-6-induced phosphorylation of STAT3 Y705 might 
persist beyond three hours due to a lack of induction of SOCS3 and a failure of SOCS3 
to be recruited to Y759 of gp130 to inhibit IL-6 induced STAT signalling. The 
interaction of SHP2 with Y759 of gp130 could be investigated by co-
immunoprecipitation experiments in the future to determine whether these two proteins 
can interact in GT1-7 cells.  
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AMPK has been shown to be important in regulating the CRR to hypoglycaemia 
(McCrimmon et al. 2008) and its importance in glucose sensing capacity of 
hypothalamic neurons has been documented (Beall, Hamilton, et al. 2012). The effect of 
IL-6 exposure on pAMPK T172 was investigated in GT1-7 cells and phosphorylation of 
this residue was not found to be significantly regulated by IL-6. Phosphorylation of 
AMPK at this residue increases activity of the enzyme, suggesting that IL-6 doesn’t 
regulate AMPK activity in GT1-7 cells. AMPK activity assays or phosphorylation 
status of its downstream target ACC would have given a better indication of whether 
IL-6 regulates this enzyme in GT1-7 cells. Given the importance of AMPK in 
hypoglycaemia detection, it would be of interest to investigate the activity of AMPK 
18-24 hours after IL-6 exposure, as this is the time point at which defective glucose 
sensing following antecedent IL-6 exposure was observed. An attempt at this 
experiment was performed (see Appendix II). The lack of any acute effects of IL-6 on 
GT1-7 cell membrane potential correlates with the lack of effect of IL-6 on AMPK 
phosphorylation. 
Acute exposure of GT1-7 cells to IL-6 during perforated patch current clamp recordings 
during euglycaemia was performed to see if IL-6 regulated the resting membrane 
potential of GT1-7 cells. No significant effects of IL-6 exposure on GT1-7 cell 
membrane potential were observed. A similar study involving exposure of thalamic 
neurons to 1 nM IL-6 found no change in resting membrane potential with IL-6 
exposure compared to control treated cells (Samios & Inoue 2014), supporting the 
current finding of no acute regulation of membrane potential by IL-6 in GT1-7 cells.   
The effect of IL-6 on membrane potential delivered during acute hypoglycaemia was 
also investigated, to determine whether IL-6 played a role in the regulation of glucose-
sensing neuron activity during low glucose. GT1-7 neurons hyperpolarise in response to 
a low glucose challenge and action potential firing rates are ablated. The average data 
from three separate neurons suggested a trend of IL-6 to potentiate the hyperpolarising 
response to low glucose exposure in GT1-7 cells. Although this did not reach statistical 
significance, it does not completely exclude a subtle effect of IL-6 on glucose-sensing 
neurons. It would be of interest to study this further, as it suggests that IL-6 action may 
be coordinated to further enhance the response of glucose sensing neurons to 
hypoglycaemia upon detection of the low glucose stress. A more detailed study of the 
acute effect of IL-6 during a range of low glucose exposures (e.g. 0.5, 0.25, 0.1 mM) 
would have been required to confirm this.   
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IL-6 secretion from primary mouse cortical astrocytes in response to hypoglycaemia 
was confirmed in the current work. Plasma increases in IL-6 in response to 
hypoglycaemia have been confirmed in multiple studies but whether there is a CNS 
source of IL-6 during hypoglycaemia is less documented. Glial cells types in the brain 
have been shown to synthesise and release IL-6 (Gruol 2015; Dong & Benveniste 
2001), and models of hypoglycaemia and oxygen and glucose deprivation 
simultaneously result in increased IL-6 secretion (S. J. Choi et al. 2013). In the current 
work, a three hour hypoglycaemic challenge in primary mouse cortical astrocytes had 
no immediate effect on the secretion of IL-6, with levels unchanged from euglycaemia 
treated cultures. However, in the euglycaemic recovery period following 
hypoglycaemia, IL-6 release was significantly increased from hypoglycaemia-exposed 
astrocyte cultures compared to euglycaemia-exposed cultures, indicating that 
hypoglycaemia increased IL-6 secretion from astrocytes. This data suggests that there is 
a local source of IL-6 in the CNS following hypoglycaemia. The delayed release of IL-6 
following hypoglycaemia suggests that during hypoglycaemia the role of IL-6 in the 
regulation of glucose sensing machinery may be minimal, and rather that IL-6 is more 
likely involved in mediating the adaptive, recovery phase of hypoglycaemia to limit 
brain injury. This is in keeping with more recent evidence documenting a protective role 
of IL-6 in the response to endotoxaemia infection (Mauer et al. 2014; Mauer et al. 
2015). In line with protective roles of IL-6, studies have shown IL-6 to be one of the 
molecular mechanisms by which hypoxic preconditioning induces tolerance to brain 
ischaemia (Westberg et al. 2007). A limitation here is the use of cortical astrocyte 
preparations rather than hypothalamic, the latter of which would serve as a better model 
for the physiological environment in which VMH glucose-sensing neurons would be 
situated, especially since cultured astrocytes have been demonstrated to exhibit brain 
region-specific responses (Takeda et al. 2014). Furthermore, the concentrations of IL-6 
release measured from astrocytes raise a discrepancy with those concentrations used to 
stimulate GT1-7 cells in the current work (pg/ml range released vs ng/ml range 
stimulated). The 20 ng/ml IL-6 dose used was selected based on previous work 
investigating the effects of cytokines on neuronal cultures in vitro (Xin & Blatteis 1992; 
Qiu et al. 1995; Yamada & Hatanaka 1994; Hama et al. 1989), and importantly, CNS 
concentrations of IL-6 are elevated in numerous neurological diseases and injury (Gruol 
2015). It is also impossible to infer what concentration of IL-6 glucose-sensing neurons 
would be exposed to in response to hypoglycaemia in vivo, however, if the glucose-
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sensing neuron is surrounded by IL-6-secreting astrocytes and glial cells, the local 
concentration of IL-6 that the neuron sees would be considerable.  
The most interesting finding of this work was that antecedent IL-6 exposure induced a 
defective detection of and physiological response to hypoglycaemia 18-24 hours 
subsequently in GT1-7 cells. IL-6 treated cells failed to hyperpolarise in response to 
hypoglycaemia and maintained action potential firing rates during low glucose exposure 
in stark contrast to vehicle treated cells which hyperpolarised and silenced appropriately 
in response to 0.5 mM glucose, as has been described for GE neurons of the 
hypothalamus (Beall, Hamilton, et al. 2012; Routh 2010). The defect in glucose sensing 
observed with antecedent IL-6 exposure was proven not to be due to an absence of 
functional KATP channels, as whole cell voltage clamp analysis 18-24 hours 
subsequently demonstrated comparable KATP channel conductance between vehicle and 
IL-6 treated cells. In keeping with this, non-glucose sensing GT1-7 cells following 
antecedent IL-6 exposure were capable of hyperpolarising in response to 
pharmacological opening of KATP channels with NN414 (Appendix III). The subsequent 
aims of the work were to elucidate the mechanisms by which antecedent IL-6 exposure 
induced defective hypoglycaemia detection and glucose sensing in GT1-7 cells.  
Initial focus of mechanistic investigation was on the involvement of the JAK/STAT3 
pathway since it was robustly induced in response to IL-6, as evidenced by increased 
phosphorylation of STAT3 Y705. Since phosphorylation of STAT3 Y705 leads to 
dimerisation and nuclear translocation, and given the latent onset (18-24 hours 
subsequently) of defective glucose sensing, it was hypothesised that STAT3-mediated 
gene expression was involved in mediating the effects of IL-6 to induce defective 
glucose sensing. As a proof of principle, expression of the IL-6Rα was partially reduced 
using shRNA interference to confirm that the IL-6Rα signalling complex was mediating 
the effects of IL-6 in GT1-7 cells. The IL-6Rα is the most upstream target involved in 
transducing IL-6 signalling and permitted a global impedance of IL-6 mediated 
signalling. Partial knockdown of the IL-6Rα prevented the defective glucose sensing 
phenotype induced by antecedent IL-6 exposure in GT1-7 cells, confirming that IL-6 
signalling via IL-6Rα was necessary for this effect. This intervention could not 
determine whether IL-6 signals predominantly via the classical or trans-signalling mode 
of IL-6 signalling in GT1-7 cells, as given the knowledge that IL-6Rα can be shedded 
from the cell membrane to permit trans-signalling, knockdown of IL-6Rα could 
suppress both modes of signalling. shIL-6Rα 
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Y705 induction in response to IL-6 stimulation compared to shControl cells, and indeed 
WT GT1-7 cells, suggesting that this activation of STAT3 phosphorylation may be of 
importance for mediating the development of defective glucose sensing induced by 
antecedent IL-6 exposure. However, the apparent lack of regulation of SOCS3 mRNA 
expression by IL-6 stimulation in GT1-7 cells raises doubts over whether the induction 
of STAT3-mediated gene transcription is involved in mediating the effects of 
antecedent IL-6 on glucose sensing, as SOCS3 mRNA and protein is potently induced 
by IL-6 in other cell types (White & Nicola 2013). It may be that induction of SOCS3 
transcription occurs very rapidly in GT1-7 cells, and an upregulation of the mRNA 
transcript was missed with the earliest time point studied at one hour of exposure to IL-
6. In an attempt to prevent STAT3-induced gene transcription, the JAK2 inhibitor 
WP1066 was used to specifically prevent JAK2-mediated phosphorylation of STAT3 in 
response to IL-6, thereby abolishing its dimerisation, nuclear translocation and 
subsequent regulation of gene expression. Although WP1066 was effective at 
preventing acute IL-6-induced increases in phosphorylation of STAT3 at residue Y705 
(Appendix IV), it was not compatible for use with the current experimental model as it 
exhibited cytotoxic effects on GT1-7 cells making it impossible to perform 
electrophysiological analysis on cells 18-24 hours after exposure to WP1066 and IL-6 
(data not shown). In order to confirm if IL-6 requires transcription to mediate its 
negative effects on glucose sensing, antecedent IL-6 exposure could have been 
performed in the presence of a transcriptional inhibitor, for example 
dichlorobenzimidazole 1-β-D-ribofuranoside, to avoid the cytotoxic effects exhibited by 
JAK2 inhibition. A small molecule inhibitor of STAT3 is commercially available 
(Stattic, Sigma-Aldrich) and it would be of great interest to test whether treatment with 
this agent is capable of preventing the IL-6-induced glucose sensing defect in GT1-7 
cells. Importantly, Stattic has been demonstrated to inhibit STAT3 Y705 
phosphorylation and mRNA expression of STAT3 targets (Abkhezr & Dryer 2014). A 
particularly insightful experiment would be to investigate IL-6 regulated STAT3 DNA 
binding in GT1-7 cells. This could be determined by chromatin immunoprecipitation 
and would identify which genes were regulated by STAT3 in response to IL-6 
stimulation and may therefore identify potential mediators of IL-6-induced defective 
glucose sensing.  
Unfortunately, it wasn’t confirmed in the current work how soon after three hour 
exposure to IL-6 negative effects on glucose sensing are first observed. The model used 
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involved studying the cells 18-24 hours subsequently as it was then comparable with 
other on-going studies in the laboratory investigating the effects of antecedent 
hypoglycaemia on GT1-7 cell glucose sensing capacity. The time scale in which IL-6 
regulates glucose sensing in GT1-7 cells may indicate whether transcriptional regulation 
is required for its effects. Similarly, it wasn’t confirmed how long the suppression of 
glucose sensing by antecedent IL-6 exposure persists for.  
Although the data comparing the effects of antecedent IL-6 on glucose sensing in WT 
and shIL-6Rα GT1-7 cells was robust, the studies in shControl cells were less 
reproducible. During the current work, a decrease in glucose sensing capacity of GT1-7 
cells, regardless of genotype, has been observed over time (Appendix V). 
Unfortunately, the shControl cell studies were performed later than those of WT and 
shIL-6Rα cells. Due to this, the hyperpolarising responses to low glucose in vehicle 
treated shControl cells were reduced in magnitude compared to those seen in WT and 
shIL-6Rα cells (Figures 3.5, 3.9, 3.10 and Appendix V). This made comparisons 
between the genotypes difficult, due to vehicle treated shControl cells having 
suppressed responses to low glucose, such that vehicle treated shControl cells had a 
hyperpolarising response to hypoglycaemia comparable in magnitude to that initially 
observed in IL-6 treated WT GT1-7 cells with defective glucose sensing. This meant 
that comparisons between shControl and the other GT1-7 cell lines were not valid. The 
important comparison between WT GT1-7 and shIL-6Rα GT1-7 cells is valid however, 
and clearly demonstrates that partial reduction of the IL-6Rα prevents IL-6-induced 
defective glucose sensing, as one would predict. Furthermore, the data demonstrating 
that antecedent IL-6 induces defective glucose sensing in shControl GT1-7 cells is clear, 
as no IL-6 treated shControl cells hyperpolarised in low glucose where as some vehicle 
treated cells did (3/7), albeit fewer and with lower magnitude than that observed in WT 
and shIL-6Rα cells (Appendix I and Figures 3.5, 3.9, 3.10).  
GT1-7 cells and other glucose-sensing neurons have been shown to exhibit a robust 
increase in AMPK T172 phosphorylation in response to hypoglycaemia (Beall, 
Hamilton, et al. 2012; Lamy et al. 2014). When populations of GT1-7 cells were 
exposed to hypoglycaemia in the current work, there was an absence of an increase in 
AMPK T172 phosphorylation (Appendix II). Electrophysiological single cell analysis 
of GT1-7 cells shows that a proportion of the cells hyperpolarise in response to low 
glucose challenge, however, many GT1-7 cells do not (Appendix VI). However, GT1-7 
cells do hyperpolarise in response to metabolic inhibition by 2-DG or oligomycin 
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(Appendix VI), suggesting that ATP depletion is capable of hyperpolarising these cells, 
but glucose deprivation alone is not. The studies investigating AMPK phosphorylation 
in a population of GT1-7 cells exposed to hypoglycaemia suggests that the majority of 
GT1-7 cells do not respond to low glucose with an upregulation of AMPK T172 
phosphorylation. This is in line with electrophysiological analysis identifying a lack of 
hyperpolarisation in response to hypoglycaemia in many GT1-7 cells. The reason for 
this finding is not known, however, given that whole cell metabolic inhibition can 
hyperpolarise the cells (Appendix VI) the fact that glucose deprivation alone isn’t 
sufficient to induce membrane hyperpolarisaiton, points to the availability of alternate 
fuel substrates to provide ATP when glucose is reduced. It has been reported that lactate 
is able to modulate metabolic and neuronal activity, and that elevated levels are critical 
for maintaining glucose metabolism under hypoglycaemia, preserving neuronal function 
(Herzog et al. 2013). Ketone infusion has been demonstrated to reduce hormonal 
responses to hypoglycaemia, consistent with the hypothesis that human neurons can 
utilise ketones as a fuel source (Amiel et al. 1991). There are no other fuels present in 
the media during electrophysiological experiments, therefore GT1-7 cells may have 
internal fuel stores that can maintain activity during glucose deprivation. In support of 
this, preliminary studies have identified fat droplets in GT1-7 cells (data not shown). 
This would provide an alternate energy source for GT1-7 cells to utilise during glucose 
deprivation, and although IL-6 stimulates lipolysis in adipose tissue (Hoene & Weigert 
2007), fatty acids are only used poorly as fuel in the brain (Schönfeld & Reiser 2013). 
Clearly, the population of GT1-7 cells used in the current work appear to have 
heterogeneous responses to hypoglycaemia, making studies difficult. In the future it 
would be of interest to attempt to sort the cells based on their AMPK T172 
phosphorylation response to hypoglycaemia to try to isolate a more pure population of 
hypoglycaemia-responsive GE cells, as the current studies suggest that the GT1-7 cell 
population are heterogeneous, at least in their response to glucose deprivation.    
Taken together, these data demonstrate that antecedent exposure of GT1-7 cells to IL-6 
attenuates their glucose sensing capacity the following day, resulting in a failure of 
these cells to hyperpolarise in response to a hypoglycaemic challenge. The effect of IL-
6 was confirmed to be mediated via its receptor complex, with the transcription factor 
STAT3 potentially playing a role, as Y705 phosphorylation and therefore activation of 
STAT3 was reduced in cells lacking the IL-6Rα, which were resistant to IL-6-induced 
defective glucose sensing. The lack of induction of SOCS3 mRNA in response to IL-6 
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stimulation and STAT3 activation in these cells questioned whether IL-6 negatively 
regulated glucose sensing via transcriptionally mediated changes, even though the time 
scale of the induction of defective glucose sensing suggested that this might be the case. 
The absence of an increase of SOCS3 mRNA in response to IL-6 stimulation 
contradicts other studies, and should be repeated to confirm this observation. The 
expression of SOCS3 protein should also be determined in response to IL-6 stimulation, 
as this would give a more functional readout of the negative regulation of STAT3 
signalling via SOCS3. It raised the possibility that IL-6 activation of STAT3 results in 
stimulation of an alternate pathway by which IL-6 signals, independent from the well-
described classical IL-6-JAK-STAT-SOCS3 axis. Interestingly, cAMP response 
element-binding protein (CREB) has been identified as a downstream mediator of the 
effects of the IL-6 family cytokine OSM in rat cortical neurons, although its induction 
was stimulated by ERK1/2 rather than JAKs (Chang et al. 2015). This is consistent with 
data in neural stem cells, where IL-6 is proposed to activate neurogenesis via the 
MAPK/CREB cascade whereas it activates gliogenesis via the JAK/STAT signalling 
pathway (O. Islam et al. 2009). Another study suggested that phosphorylation of 
STAT3 and CREB by peripheral inflammation in primary afferent neurons may be 
mediated via the OSM receptor (OSMR) (Tamura et al. 2005), indicating that IL-6 
family cytokines can activate CREB phosphorylation in neurons.  
The investigation of the JAK/STAT, MAPK and PI3K intracellular signalling cascades 
classically activated by IL-6 did not suggest a major involvement of any of these 
pathways in the mediation of the action of IL-6 to suppress glucose sensing and 
membrane hyperpolarisation to hypoglycaemia 18-24 hours after exposure. The 
following studies therefore investigated other potential mechanisms that may mediate 
the effects of IL-6, with attention focussed next on IL-6 regulation of whole cell 
metabolism.  
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4 The Role of Cell Metabolism in the 
Regulation of Glucose Sensing by IL-6 
4.1 Introduction 
The next focus of the current work was to determine the mechanisms by which 
antecedent IL-6 exposure induced defective glucose sensing. The failure of GT1-7 cells 
to hyperpolarise appropriately to a low glucose stimulus following antecedent IL-6 
exposure is associated with a maintenance of a depolarised cell membrane and action 
potential firing rates during the hypoglycaemic challenge. This suggests that KATP 
channels maintain a closed state during the low glucose exposure, and this was 
supported by the finding that pharmacological opening of KATP channels with 5 µM 
NN414 induced membrane hyperpolarisation and silencing of firing rates in cells that 
had been antecedently exposed to IL-6, confirming that KATP channels were still 
functional (Appendix III). It was hypothesised that an increase in ATP-mediated 
inhibition of KATP channels might be responsible for the effect of antecedent IL-6 
exposure to induce defective glucose sensing in GT1-7 cells. 
The brain relies on glucose metabolism to maintain its function, and has a high demand 
for ATP, with neurons demonstrating the highest demand for energy compared to other 
brain cell types. The mitochondria are the major site of brain cellular ATP generation, 
with over 90% of ATP generation occurring via oxidative phosphorylation of substrates 
in the mitochondria (Schönfeld & Reiser 2013). In neurons, glucose undergoes 
glycolysis, yielding a small amount of ATP and the generation of pyruvate, which 
becomes the main hydrogen source for mitochondrial oxidative phosphorylation 
(Schönfeld & Reiser 2013). 
Roles for IL-6 in the regulation of whole body metabolism and energy homeostasis have 
been described. Immune cell accumulation in adipose tissue during obesity has been 
well documented, and is associated with a pro-inflammatory phenotype of the 
infiltrating cells and release of cytokines, including IL-6 (Pal et al. 2014). IL-6 has been 
demonstrated to reduce insulin signalling in liver and adipose (Lagathu et al. 2003; 
Rotter et al. 2003; Siegmund et al. 2004), but its administration has also been shown to 
enhance glucose tolerance and insulin sensitivity in skeletal muscle and liver (Holmes et 
 
 
 
108 
al. 2007). Muscle derived IL-6 has been demonstrated to regulate metabolic factors in 
mouse inguinal white adipose tissue (iWAT), affecting iWAT mass through regulation 
of glucose uptake capacity as well as lipogenic and lipolytic factors (Knudsen et al. 
2015).  
IL-6 deficient mice develop mature onset obesity (V. Wallenius et al. 2002) suggesting 
that IL-6 is involved in the regulation of body weight. Wallenius et al. showed that CNS 
administration of IL-6 increased energy expenditure and reduced body fat mass in rats, 
implicating a role of central IL-6 to regulate whole body metabolism (K. Wallenius et 
al. 2002) Jansson et al. 2003). Li et al. showed that chronic elevation of IL-6 in the CNS 
reduces body weight gain and visceral adiposity by a mechanism involving sympathetic 
induction of UCP1 in brown adipose tissue (BAT) in rats (Li et al. 2002). IL-6 has been 
demonstrated to exert effects in the ARC resulting in regulation of body fat, with 
speculation that IL-6 can inhibit obesity partly by inhibiting orexigenic NPY expression 
(Schéle et al. 2013), providing a potential molecular mechanism by which the 
development of obesity in IL-6-/- mice may be mediated. Furthermore, astroglial IL-6 
production has been implicated as the mechanism by which amylin interacts with leptin 
signalling in the VMH to increase its effect on weight loss (Le Foll et al. 2015).  
While IL-6 regulation of peripheral metabolism and effects of CNS IL-6 to regulate 
energy expenditure and body weight have been described, studies documenting the roles 
of IL-6 in neuronal and glial cell metabolism are lacking. When Brown et al. challenged 
developing mouse neurons with IL-6 they responded by increasing their consumption of 
resources from the media, suggesting that IL-6 exposure increased neuronal metabolism 
in this model (Brown et al. 2014).    
 
Very recently, Chang and colleagues demonstrated that the IL-6 family cytokine OSM 
increases mitochondrial respiration indexed by increased OCR in cortical neurons 
measured using the XF24 (Chang et al. 2015). Likewise, others have demonstrated that 
IL-17 can modulate mitochondrial function in sensory neurons from rats. IL-17 was 
shown to enhance mitochondrial bioenergetic function via ERK and PI3K signalling 
pathways, with increased protein level and activity of ETC components (Habash et al. 
2015). These studies suggest that cytokines can regulate mitochondrial function in 
neurons, although whether IL-6 also can has not been investigated.  
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The current experiments were therefore designed to investigate whether IL-6 regulates 
GT1-7 cell metabolism. The XF24 was employed to study GT1-7 cell metabolism. By 
indexing oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), 
the XF24 permits measurement of the two major pathways of ATP generation, 
mitochondrial oxidative phosphorylation and glycolysis respectively. OCR measures the 
cell’s utilisation of oxygen that is mainly consumed by the mitochondria during 
oxidative phosphorylation of substrates to generate ATP. ECAR measures the 
acidification rate of the extracellular media, driven by lactate accumulation from 
glycolysis, giving an indirect measure of glycolytic rates. The question of whether IL-6 
exposure altered metabolism in GT1-7 cells was addressed using the XF24 to measure 
OCR and ECAR. Further indications of regulation of metabolism and ATP production 
by IL-6 included biochemical investigation of expression of metabolically relevant 
proteins and genes and direct measurement of cellular ATP production by ELISA.  
4.2 Results 
4.2.1 Effects of Antecedent IL-6 on Oxygen Consumption and 
Extracellular Acidification Rates 24 Hours Subsequently 
In the following studies I examined the hypothesis that the reduction in the 
hyperpolarising response to 0.5 mM glucose in GT1-7 cells antecedently exposed to IL-
6 may be due to increased ATP-mediated inhibition of KATP channels, preventing 
channel opening, potassium efflux and therefore membrane hyperpolarisation. To study 
this I used the XF24 to examine GT1-7 whole cell bioenergetics after vehicle or IL-6 
treatment. Since the defective glucose sensing observation had been made 18-24 hours 
subsequent to IL-6 treatment, measurements of cellular metabolism were made at the 
same time point post treatment. The XF24 gives two read outs of cellular metabolism, 
namely OCR and ECAR. OCR measures the oxygen consumption of the cells and 
therefore provides an index of mitochondrial respiration and oxidative phosphorylation. 
ECAR provides an indirect measure of cellular glycolysis by measuring the 
acidification of the extracellular media by lactate that accumulates from glycolysis 
(Appendix VII). In the current work, GT1-7 cells were exposed to vehicle dH2O 
(Control) or 20 ng/ml IL-6 (IL-6) for three hours before being returned to plating media 
for two hours prior to cell counting and seeding at a density of 30,000 cells per well in 
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Seahorse XF24 culture plates. 18-24 hours subsequently cells were transferred to assay 
medium containing 2.5 mM glucose, consistent with substrate availability during 
electrophysiological analyses, and OCR and ECAR were measured every eight minutes 
for a total of 40 minutes. The final measurements taken at 40 minutes gave the most 
stable results so these were averaged and plotted to determine OCR and ECAR in the 
two treatment groups. Antecedent IL-6 treatment trended towards increasing OCR 
(p=0.21) 18-24 hours subsequently compared to vehicle treated cells with no effect 
observed on ECAR (p=0.72) (Figure 4.1A and B). The slight increase in OCR is 
suggestive of an increase in oxygen consumption directed towards mitochondrial 
respiration (Figure 4.1B). Although the effect of IL-6 exposure on OCR did not reach 
statistical significance it was deemed a large enough increase to be worthwhile studying 
in further detail using the commercially available Mito Stress Test Kit.  
4.2.2 Effect of Antecedent IL-6 on the Profile of OCR During 
Mito Stress Tests 
The XF Mito Stress Test Kit provides a complete mitochondrial profile and reveals 
critical information not evident in basal metabolism measurements. The kit allows the 
measurement of key parameters of mitochondrial function including basal respiration, 
ATP production, proton leak and spare respiratory capacity. The assay consists of serial 
injections of the compounds oligomycin, FCCP and a mix of rotenone and antimycin A 
to measure ATP production, spare respiratory capacity and non-mitochondrial 
respiration respectively. Proton leak can then be determined using these parameters. 
GT1-7 cells were treated with vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three 
hours before being returned to plating media for two hours prior to cell counting and 
seeding at a density of 30,000 cells per well in Seahorse XF24 culture plates. 18-24 
hours later the cells underwent the Mito Stress Test and OCR was measured throughout. 
The assay protocol involved measuring OCR every eight minutes. Initially, five OCR 
measurements were made to achieve a stable basal OCR. To allow for inter-plate 
comparison of the Mito Stress Test data each OCR measurement is reported as a 
percentage of the 40 minute basal OCR measurement, giving a percentage change from 
baseline for each data point (Figure 4.2).   
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Figure 4.1 Antecedent IL-6 treatment trends towards increasing basal oxygen 
consumption rate (OCR) 24 hours subsequently with no effect on extracellular 
acidification rate (ECAR) 
WT GT1-7 cells were exposed to dH2O vehicle (Control) or 20 ng/ml IL-6 (IL-6) for 
three hours prior to seeding for Seahorse analysis the following day. 24 hours after 
treatment cells were transferred to assay medium containing 2.5 mM glucose and OCR 
and ECAR were measured over a 40 minute period using the Seahorse Bioscience 
Extracellular Flux Analyser 24. (A) Basal ECAR at the 40 minute time point of the 
assay (n=25 for both treatments). (B) Basal OCR at the 40 minute time point of the 
assay (n=31 for Control and n=32 for IL-6). Statistical significance was analysed by 
unpaired student’s t-test with p=0.21 in (A) and p=0.72 in (B).  
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Figure 4.2 Profile of oxygen consumption rate (OCR) during a Mito Stress Test in GT1-
7 cells 
WT GT1-7 cells were treated with vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for 
three hours prior to seeding for subsequent Mito Stress Tests using the Seahorse 
Bioscience XF24 the following day (18-24 hours after treatment). OCR was measured 
every eight minutes for a total of 112 minutes with sequential drug additions of the ATP 
synthase inhibitor Oligomycin (1 µM), the electron transfer chain (ETC) accelerator 
FCCP (0.8 µM) and ETC complex I and III inhibitors Rotenone (2 µM) and Antimycin 
A (2 µM) respectively. To allow for inter-plate comparison, OCRs were normalised to a 
100% baseline at the final basal measurement made at the 40 minute time point and all 
other OCR measurments were calculated as percentage change from this baseline. Data 
represents n=35 individual wells from seven plates.  
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Upon inhibition of the ATP synthase with 1 µM oligomycin a reduction in OCR is 
observed in both control and IL-6 treated cells, allowing determination of the 
percentage of cellular oxygen consumption directed towards mitochondrial ATP 
production. FCCP is an uncoupling agent that disrupts ATP synthesis by transporting 
hydrogen ions across the mitochondrial membrane instead of the proton channel of ATP 
synthase. Collapse of the mitochondrial membrane potential leads to rapid consumption 
of energy and oxygen in the absence of ATP generation causing an increase in OCR. 
This allows determination of spare respiratory capacity, defined as the quantitative 
difference between maximal uncontrolled OCR and the initial basal OCR. The spare 
respiratory capacity demonstrates the ability of cells to respond to stress under 
conditions of increased energy demand and is influenced by the bioenergetic capacity of 
mitochondria. The third and final injection is a mix of rotenone and antimycin A, 
complex I and III inhibitors respectively, that shut down mitochondrial respiration 
enabling calculation of non-mitochondrial respiration driven by processes outside the 
mitochondria. The profile of OCR in response to the compound injections during a Mito 
Stress Test is depicted in Figure 4.2.  
4.2.3 Effects of Antecedent IL-6 on Respiration Parameters 
Measured During Mito Stress Tests  
Figure 4.3 demonstrates the quantification of the parameters measured during Mito 
Stress Tests in WT GT1-7 cells treated antecedently with vehicle dH2O (Control) or 20 
ng/ml IL-6 (IL-6). Upon inhibition of ATP synthase with oligomycin there is a 
reduction in OCR, with the decrease observed approximating the proton current flowing 
through the ATP synthase and therefore ATP production. IL-6 treated GT1-7 cells 
direct slightly more oxygen towards ATP production than vehicle treated GT1-7 cells, 
although this does not reach statistical significance (Figure 4.3A). Upon addition of the 
mitochondrial uncoupling agent FCCP, OCR is increased maximally, allowing 
determination of the spare respiratory capacity of the cells.  
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Figure 4.3 Effects of IL-6 on cellular respiration parameters measured during Mito 
Stress Tests in GT1-7 cells. 
WT GT1-7 cells were treated with vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for 
three hours prior to being seeded for Mito Stress Tests using the Seahorse Bioscience 
XF24 the following day (18-24 hours after treatment). (A) Percentage of cellular 
oxygen consumption (OCR) directed towards mitochondrial ATP production measured 
upon inhibition of ATP synthase by 1 µM oligomycin (n=29-34). (B) Percentage 
increase in OCR indexing spare respiratory capacity upon acceleration of the electron 
transport chain (ETC) by 0.8 µM FCCP (n=35). (C) Percentage of OCR directed 
towards non-mitochondrial respiration calculated upon inhibition of ETC complexes I 
and III by 2 µM rotenone and 2 µM antimycin A respectively (n=23-31). (D) Percentage 
of OCR required to maintain the mitochondrial protein leak (n=22-27). Statistical 
significance was analysed by unpaired student’s t-test.  
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After IL-6 treatment there was a slight increase in spare respiratory capacity in GT1-7 
cells compared to vehicle control cells, suggesting that IL-6 exposure enhances 
mitochondrial bioenergetics under conditions of increased energy demand in GT1-7 
cells, although again this did not reach statistical significance (Figure 4.3B). The 
complex I and III inhibitors rotenone and antimycin A respectively reduce OCR by 
completely blocking the ETC, allowing determination of the percentage of cellular OCR 
directed towards non-mitochondrial respiration. In IL-6 treated GT1-7 cells, a smaller 
percentage of cellular oxygen consumption is directed towards non-mitochondrial 
respiration compared to control cells, therefore indicating that an increase in 
mitochondrial OCR may occur in GT1-7 cells following IL-6 treatment (Figure 4.3C). 
The proton current generated by basal respiration involves proton re-entry to the 
mitochondria via two parallel pathways, namely via ATP synthase and via the proton 
leak. The residual OCR after inhibition of ATP synthase with oligomycin is attributable 
to the mitochondrial proton leak. By subtracting the non-mitochondrial respiration OCR 
from the oligomycin-inhibited OCR gives a more accurate estimation of the OCR 
directed towards maintaining the proton leak. There was no difference observed in the 
OCR directed towards maintaining the mitochondrial proton leak between control and 
IL-6 treated GT1-7 cells, suggesting that IL-6 treatment does not alter mitochondrial 
uncoupling or the proton current (Figure 4.3D). Taken together these data suggest that 
antecedent IL-6 treatment does not have any significant effects on mitochondrial 
respiration in GT1-7 cells, but trends towards increasing the bioenergetic capacity of 
mitochondria. 
4.2.4 Effect of Antecedent IL-6 on GT1-7 Cell ATP Levels 
Under Euglycaemic and Hypoglycaemic Conditions 24 
Hours Subsequently  
The Seahorse studies did not identify a clear effect of IL-6 on whole cell bioenergetics. 
To further investigate whether the subtle effects of antecedent IL-6 exposure might 
impact on ATP production an assay was performed to directly measure whole cell ATP 
levels using a commercially available ATP assay (ATPLite, PerkinElmer). GT1-7 cells 
were exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three hours prior to 
seeding in a 96 well plate at a density of 10,000 cells per well. 24 hours later the cells 
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were subjected to three hours of 2.5 mM glucose euglycaemia (2.5 mM) or 0.1 mM 
glucose hypoglycaemia (0.1 mM) prior to cell lysis and ATP measurement according to 
the manufacturer’s protocol. As predicted, in vehicle treated control cells, 
hypoglycaemia exposure reduced the total level of cellular ATP compared to 
euglycaemia (0.302 +- 0.036 vs 0.402 +- 0.009 µM ATP/104 cells respectively; 
p=0.0022) (Figure 4.4A). This would be expected due to a decrease in glucose uptake 
and subsequent glycolysis and mitochondrial oxidative phosphorylation. Intriguingly, 
antecedent IL-6 treatment led to a small, yet significant decrease in ATP levels under 
euglycaemic conditions compared to vehicle treated control cells (0.323 +- 0.03 vs 
0.402 +- 0.009 µM ATP/104 cells respectively; p=0.016) (Figure 4.4A). This meant that 
ATP levels at euglycaemia in antecedent IL-6 treated cells were comparable with ATP 
levels under hypoglycaemia in vehicle treated cells (p=0.57). In response to 
hypoglycaemia in antecedent IL-6 treated cells a small, non-significant decrease in ATP 
levels was observed compared to euglycaemic levels (0.2508 +- 0.026 vs 0.323 +- 0.03 
µM ATP/104 cells respectively, p=0.093). Hypoglycaemia reduced ATP levels to a 
similar percentage of euglycaemic levels in both control treated and IL-6 treated cells 
(75.0 and 77.6 % respectively), confirming a comparable percentage decrease in ATP 
levels upon hypoglycaemia exposure (Figure 4.4B).  
4.2.5 Antecedent IL-6 Treatment Does Not Effect Expression 
of Mitochondrial Proteins 24 hours Subsequently 
In the next series of studies I asked whether antecedent IL-6 treatment affected 
mitochondrial number. In order to give an indication of whether antecedent IL-6 
treatment of GT1-7 cells induces an increase in mitochondrial number, GT1-7 cells 
were exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three hours and 
lysed 24 hours subsequently and subjected to Western blot analysis of mitochondrial 
protein expression. Cytochrome c oxidase or complex IV (COX IV) is the last enzyme 
in the mitochondrial ETC, prohibitin 1 (PHB1) is a mitochondrial protein required for 
optimal ETC activity (Han et al. 2014) and heat shock protein 60 (HSP60) is a 
mitochondrially expressed stress protein (Grundtman et al. 2011). No significant 
increase in protein expression of either COX IV, PHB1 nor HSP60 was observed in 
antecedent IL-6 treated cells compared to Control treated cells, suggesting that 
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antecedent IL-6 treatment does not increase or decrease the number of functional 
mitochondria in GT1-7 cells (Figure 4.5A-C).  
  
 
 
 
118 
 
Figure 4.4 Effect of antecedent IL-6 treatment on ATP levels under euglycaemic and 
hypoglycaemic conditions in GT1-7 cells 
GT1-7 cells were exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three 
hours prior to seeding in a 96 well plate at a density of 10,000 cells per well in 
euglycaemic plating media (2.5 mM glucose). (A) 24 hours later cells were exposed to 
2.5 mM glucose euglycaemia (2.5 mM) or 0.1 mM glucose hypoglycaemia (0.1 mM) 
for three hours prior to cell lysis and ATP measurement (n=6 per group). (B) The 
percentage of 2.5 mM glucose ATP levels was determined under hypoglycaemic 
conditions in control vs IL-6 cells, demonstrating a similar percentage reduction in 
response to hypoglycaemia in both treatment groups. Data was analysed by Mann-
Whitney test in (A) where * or ** indicate significantly different (p=<0.05 or p=<0.01 
respectively).  Data generated in collaboration with Kathryn Wright. 
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Figure 4.5 Antecedent IL-6 treatment does not effect expression of mitochondrial 
proteins 24 hours subsequently 
GT1-7 cells were exposed to vehicle dH2O (Control, C) or 20 ng/ml IL-6 (IL-6) for 
three hours and were lysed 24 hours later and processed for Western blot analysis of 
mitochondrial protein expression of (A) complex IV (COX IV), (B) prohibitin 1 (PHB1) 
or (C) heat shock protein 60 (HSP60). Fold change in protein expression relative to 
Control cells was determined and representative blots are shown (n=9). Representative 
GAPDH blots for the samples are also shown. Statistical significance was analysed by 
one sample t-test. 
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4.2.6 Antecedent IL-6 Exposure Does Not Regulate the 
Expression of Glycolytic Proteins 24 Hours 
Subsequently in GT1-7 Cells 
The lack of any alterations in ECAR following antecedent IL-6 treatment in GT1-7 cells 
(Figure 4.1A) suggested that IL-6 does not affect glycolysis when administered in this 
manner. In an effort to confirm this observation, GT1-7 cells were exposed to vehicle 
dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three hours and lysed 24 hours subsequently 
and subjected to Western blot analysis of expression of several glycolytic proteins. 
Hexokinase 1 (HK1), pyruvate dehydrogenase (PDH) and pyruvate kinase muscle 2 
(PKM2) are key enzymes of the glycolytic pathway (Li et al. 2014). No significant 
differences in expression of any of the four proteins investigated was observed 
following antecedent IL-6 treatment compared to vehicle control treated GT1-7 cells, 
suggesting that IL-6 administration in this manner does not regulate glycolysis in these 
cells (Figure 4.6A-C).  
4.2.7 Effects of Antecedent IL-6 Exposure on Mitochondrial 
Gene Expression 
To strengthen the observation that antecedent IL-6 had no effect on the expression of 
mitochondrial proteins, whether IL-6 regulated expression of key genes involved in 
mitochondrial regulation was also investigated. GT1-7 cells were exposed to vehicle 
dH2O (Control) or 20 ng/ml IL-6 for 30 minutes and lysed four or 24 hours 
subsequently and gene expression was measured. Peroxisome proliferator-activated 
receptor γ co-activator 1α (PGC1α) is a positive regulator of mitochondrial biogenesis 
and respiration (Austin & St-Pierre 2012) and uncoupling protein 2 (UCP2) is a 
mitochondrial anion carrier protein which uncouples oxidative phosphorylation from 
ATP production by dissipating the proton gradient generated across the mitochondrial 
inner membrane (Toda & Diano 2014). No significant alterations in PGC1α or UCP2 
expression were observed either four or 24 hours after IL-6 exposure compared to 
vehicle treated control cells (Figure 4.7C and D).  
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Figure 4.6 Antecedent IL-6 treatment does not effect expression of glycolytic proteins 
24 hours subsequently 
GT1-7 cells were exposed to vehicle dH2O (Control, C) or 20 ng/ml IL-6 (IL-6) for 
three hours on day one and 24 hours later were lysed and processed for Western blot 
analysis of glycolytic protein expression of (A) hexokinase 1 (HK1), (B) pyruvate 
dehydrogenase (PDH) or (C) pyruvate kinase muscle 2 (PKM2). Fold change in protein 
expression relative to Control cells was determined and representative blots are shown 
(n=9). Representative GAPDH blots for the samples are also shown. Statistical 
significance was analysed by one sample t-test. 
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Figure 4.7 Effect of IL-6 on gene expression of mitochondrial genes PGC1α and UCP2 
(A) and (B) GT1-7 cells were treated with vehicle dH2O (Control) for three hours or 20 
ng/ml IL-6 for one, two or three hours and lysed. RNA was extracted and used to 
synthesise cDNA which was subjected to Taqman qRT-PCR analysis to analyse gene 
expression of (A) PGC1α (n=2) or (B) UCP2 (n=2). Fold change in expression was 
determined relative to the expression of each gene in Control cells. (C) and (D) GT1-7 
cells were treated with vehicle dH2O (Control) or 20 ng/ml IL-6 for 30 minutes and 
lysed four or 24 hours subsequently. RNA was extracted and used to synthesise cDNA 
which was subjected to Taqman qRT-PCR analysis to analyse gene expression of (C) 
PGC1α (n=1) or (D) UCP2 (n=1). Fold change in expression was determined relative to 
the expression of each gene in Control cells. Data was analysed by one sample t-test in 
(A) and (B) where ** indicates p=<0.01.  
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To confirm that any effects of IL-6 on the regulation of PGC1α or UCP2 weren’t 
missed due to the length of exposure to IL-6 or the time points at which gene expression 
was analysed, separate experiments were performed in which GT1-7 cells were exposed 
to vehicle dH2O for three hours (Control) or 20 ng/ml IL-6 for one, two or three hours 
and lysed and gene expression was measured. No significant effect of IL-6 at the three 
time points studied on PGC1α mRNA expression was observed (Figure 4.7A), however, 
robust increases in UCP2 mRNA were observed after one hour and three hours 
exposure to IL-6 (Figure 4.7B). Interestingly, UCP2 mRNA expression after two hours 
IL-6 exposure was comparable with expression levels observed in Control treated cells, 
potentially indicating a biphasic induction of UCP2 mRNA expression in response to 
IL-6 stimulation in GT1-7 cells (Figure 4.7B)  
4.2.8 Effects of IL-6 on Phosphorylation of STAT3 S727 in 
GT1-7 Cells 
STAT3 is phosphorylated at residue Y705 in response to IL-6 stimulation of its receptor 
complex leading to nuclear translocation of STAT3 dimers and regulation of target gene 
expression (Wolf et al. 2014). STAT3 can also be phosphorylated at residue S727, 
which specifically targets STAT3 to the mitochondria where it plays a role in 
mitochondrial respiration (Meier & Larner 2014). To further investigate whether IL-6 
regulates mitochondrial function in GT1-7 cells, the phosphorylation status of STAT3 
S727 was investigated in response to IL-6 exposure. GT1-7 cells were exposed to 
vehicle dH2O for three hours (Control) or 20 ng/ml IL-6 for 30 minutes or three hours 
and lysed and samples were prepared for Western blot analysis of phosphorylation of 
STAT3 at residues Y705 and S727. A separate population of GT1-7 cells were 
antecedently exposed to 20 ng/ml IL-6 for three hours and lysed 24 hours subsequently 
to determine whether antecedent IL-6 treatment affects the phosphorylation status of 
either of the stated STAT3 residues 24 hours subsequently. Exposure of GT1-7 cells to 
20 ng/ml IL-6 for 30 minutes or three hours robustly stimulated the phosphorylation of 
STAT3 at residue Y705 (Figure 4.8A). These IL-6-induced increases in pSTAT3 Y705 
were comparable with those observed in the initial IL-6 time course experiments 
performed in the previous chapter (Figure 3.1A). Antecedent exposure to IL-6 did not 
affect pSTAT3 Y705 levels 24 hours subsequently as levels were comparable with 
vehicle treated control cells (Figure 4.8A).   
 
 
 
124 
 
Figure 4.8 Effects of IL-6 on phosphorylation of STAT3 S727 in GT1-7 cells  
GT1-7 cells were exposed to vehicle dH2O (Control, C) for three hours or 20 ng/ml IL-6 
for 30 minutes (0.5), three hours (3) or for three hours on day one and allowed to 
recover for 24 hours (Antecedent 3, A) then lysed and samples prepared for Western 
blot analysis of protein expression of pSTAT3 Y705 (A) and pSTAT3 S727 (B). Fold 
change in phosphorylation of each residue was determined relative to Control treated 
cells normalised to actin with representative blots shown for each residue (n=1)  
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In contrast the same treatments had no effects on the phosphorylation status of STAT3 
S727 (Figure 4.8B). Exposure to 20 ng/ml IL-6 for 30 minutes, three hours or 
antecedently for three hours did not affect the pSTAT3 S727 levels relative to vehicle 
treated control cells (Figure 4.8B). Taken together these data demonstrate that IL-6 
exposure robustly increases the phosphorylation of STAT3 Y705 with no effect on 
STAT3 S727 phosphorylation. The lack of an increase in the phosphorylation of STAT3 
S727 in response to IL-6 exposure suggests that IL-6 does not induce mitochondrial 
targeting of STAT3 molecules in GT1-7 cells.  
4.2.9 The JAK2 Inhibitor WP1066 Prevents IL-6-Induced 
Phosphorylation of STAT3 Y705 but has no Effect on 
STAT3 S727 in GT1-7 Cells 
To validate the observations regarding IL-6 regulation of STAT3 phosphorylation at 
residues Y705 and S727 in GT1-7 cells, the JAK2 inhibitor WP1066 was utilised to 
prevent the IL-6 induced phosphorylation of STAT3 Y705. Pre-exposure of GT1-7 cells 
to 0.5, 1 or 5 µM WP1066 for 60 minutes dose-dependently prevented subsequent 20 
ng/ml IL-6-induced phosphorylation of STAT3 Y705 (Figure 4.9A). 0.5 or 1 µM 
WP1066 pre-exposure for 60 minutes in GT1-7 cells had no effect on subsequent 
STAT3 S727 phosphorylation following 20 ng/ml IL-6 exposure for 30 minutes (Figure 
4.9B). There was a trend for 5 µM WP1066 pre-exposure for 60 minutes to enhance 
subsequent 20 ng/ml IL-6 exposure for 30 minutes to increase pSTAT3 S727 levels in 
GT1-7 cells, although this experiment was only performed once and would need to be 
repeated to consolidate this finding (Figure 4.9B). Together these data demonstrate that 
IL-6-induced increases in STAT3 Y705 phosphorylation occur in a JAK2-dependent 
manner, as pre-exposure with the JAK2 inhibitor WP1066 dose-dependently decreased 
IL-6-induced pSTAT3 Y705 levels. The lack of an effect of IL-6 on the regulation of 
pSTAT3 S727 was confirmed, and the level of pSTAT3 S727 does not appear to be 
regulated by JAK2, as WP1066 failed to effect STAT3 S727 phosphorylation status.  
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Figure 4.9 The JAK2 inhibitor WP1066 prevents IL-6 induced phosphorylation of Y705 
of STAT3 but has no effect on phosphorylation of S727 of STAT3 in GT1-7 cells  
GT1-7 cells were exposed to vehicles DMSO and dH2O (Control, C) for 90 minutes, 
DMSO vehicle and 20 ng/ml IL-6 for 60 minutes and 30 minutes respectively (IL-6) or 
0.5, 1 or 5 µM WP1066 for 60 minutes and 20 ng/ml IL-6 for 30 minutes (0.5, 1 and 5 
respectively) then lysed and samples prepared for Western blot analysis of protein 
expression of pSTAT3 Y705 (A) and pSTAT3 S727 (B). Fold change in 
phosphorylation of each residue was determined relative to Control treated cells 
normalised to actin with representative blots shown for each residue (n=1).  
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4.3 Discussion 
The present results investigated the effects of IL-6 exposure on indices of GT1-7 cell 
metabolism. Overall, the data indicate that IL-6 does not have any significant effects to 
regulate metabolism in these cells. Subtle effects of IL-6 to increase mitochondrial 
oxygen consumption were observed, although no effects on the expression of 
mitochondrial genes and proteins were observed, and perhaps most conclusively, direct 
measurement of ATP showed no differences between vehicle treated and IL-6 treated 
GT1-7 cells. 
There is some evidence that cytokines can act to increase neuronal oxidative 
phosphorylation (Habash et al. 2015). Direct effects of IL-6 on oxidative 
phosphorylation in neurons have not been described, although have been addressed in 
an adipocyte cell line (Hahn et al. 2014). When GT1-7 cells were exposed to IL-6 for 
three hours and studied 18-24 hours subsequently, in keeping with the model developed 
in the previous chapter, there was a subtle increase in mitochondrial OCR, suggestive of 
increased ATP production. In the adipocyte study mentioned, IL-6 only had an effect to 
increase basal respiration when administered for 96 hours (Hahn et al. 2014). An earlier 
study of the same adipocyte cell line found that IL-6 treatment reduced mitochondrial 
function with a reduction in ATP production (Ji et al. 2011). It may be that a much more 
chronic exposure to IL-6 is required to induce alterations in mitochondrial metabolism 
in GT1-7 cells. IL-6 preconditioning of neural stem cells has been shown to induce 
superoxide dismutase 2 (SOD2) expression, leading to beneficial effects on 
mitochondrial function by the reduction of oxidative stress (Sakata et al. 2012). In 
contrast however, IL-6 has been shown to induce expression of free radicals in the brain 
(Behrens et al. 2008) one of which, NO, is a potent inhibitor of COX IV (Brown 1995; 
Giuffrè et al. 1996) and therefore induces mitochondrial dysfunction. Administration of 
antioxidants in a rat model of sepsis improved mitochondrial respiration and decreased 
IL-6 levels, suggesting an association between IL-6 and mitochondrial dysfunction 
(Lowes et al. 2013). The literature regarding the role of IL-6 in the regulation of 
neuronal metabolism is therefore mixed and warrants further investigation.  
 
Studies have shown that IL-6 can enhance glycolysis in mouse embryonic fibroblasts 
and human cell lines, with IL-6 induced activation of STAT3 enhancing the expression 
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of the glycolytic enzymes HK2 and 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase-3 (PFKFB3) (Ando et al. 2010). The IL-6 family cytokine LIF was 
found to down-regulate expression of HK2 and increase the expression of fructose 1, 6 
bisphosphatase 1 in AtT-20 corticotrope cells, while in GH3 somatolactotrope cells LIF 
induced expression of 6-phosphofructokinase C, suggesting opposite effects of LIF on 
glycolysis in the two cell types (Abbud et al. 2004). IL-6 subtly increased glycolysis in 
hepatocytes, indexed by an increase in lactate release over control treated cells (Vaartjes 
et al. 1990). However, neurons have a relatively low glycolytic capacity caused by a 
lack of activity of the glycolysis-promoting enzyme PFKFB (Bolaños et al. 2010; 
Pellerin & Magistretti 2012). In the present studies no significant effect of IL-6 on 
ECAR, a measure of lactate acidification of the extracellular media, was observed. 
Further insight into the role of IL-6 in the regulation of glycolysis could have been 
gained by performing assays to measure glucose uptake and HK activity.  
There are reports demonstrating that ATP can induce astrocytes to produce and release 
IL-6 (Noguchi et al. 2013) but whether IL-6 stimulation of CNS cell types regulates 
ATP levels has not been studied. In the study investigating OSM effects in cortical 
neurons, Chang et al. demonstrated stimulation of ATP production by OSM indexed by 
increased OCR measured using the XF24, but a direct measurement of ATP in this 
study was not made (Chang et al. 2015). In a recent study by Yang et al. IL-6 enhanced 
mitochondrial membrane potential in CD4 cells but this was uncoupled from oxidative 
phosphorylation and therefore ATP synthesis (Yang et al. 2015). In the current 
experiments, a significant reduction in ATP levels at euglycaemia was observed in IL-6 
treated cells compared to vehicle treated control cells, such that ATP levels at 
euglycaemia following IL-6 treatment were comparable with levels observed under 
hypoglycaemia following vehicle treatment. Based on the defective glucose sensing 
phenotype of GT1-7 cells following antecedent IL-6 exposure, it was hypothesised that 
an increase in, or maintenance of, ATP levels may be responsible for maintaining the 
closed state of KATP channels during subsequent hypoglycaemia. After exposure to 
hypoglycaemia following antecedent IL-6 treatment, a decrease in ATP levels was 
observed compared to euglycaemia, importantly of similar magnitude to that observed 
in vehicle treated cells, suggesting that ATP levels do fall in response to hypoglycaemia 
even after IL-6 treatment. It is unlikely therefore that increased ATP production or 
maintenance of ATP levels is mediating the effects of IL-6 to induce defective glucose 
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sensing. It is important to note however that ATP levels were measured following 
exposure to 0.1 mM glucose for three hours, a much more profound hypoglycaemic 
challenge than the 0.5 mM glucose exposure for 15 minutes employed during 
electrophysiological analysis. This discrepancy is due to differences in sensitivity of the 
techniques. GT1-7 cells have been demonstrated to respond to low glucose challenge in 
a dose-dependent manner (Beall, Hamilton, et al. 2012), and based on this 0.5 mM 
glucose was selected as the glucose concentration that induced a robust membrane 
hyperpolarisation in the majority of cells. Electrophysiology permits a highly sensitive, 
rapid measure of single cell membrane responses to hypoglycaemia. In contrast, the 
ATP assay involves making a measurement from a population of cells that likely exhibit 
a heterogeneous response to hypoglycaemia, and therefore, a more robust 
hypoglycaemic exposure was employed to ensure a decrease in ATP levels was 
observed in response to hypoglycaemia in vehicle treated cells. To indicate whether 
ATP levels are maintained at hypoglycaemia during electrophysiological recordings 
following antecedent IL-6 exposure, ATP levels should be measured after 15 minutes 
exposure to 0.5 mM glucose, making the two studies directly comparable. The more 
profound hypoglycaemic challenge induced for the ATP assay may have over ridden 
any IL-6-induced adaptations conferring GT1-7 cells an ability to preserve cellular ATP 
levels during subsequent hypoglycaemia.  
Expression of mitochondrial protein expression was investigated in GT1-7 cells 24 
hours after IL-6 exposure to indicate whether IL-6 increased the number of 
mitochondria. No effects of IL-6 exposure were observed on the expression levels of 
COX IV, PHB1 or HSP60. This is in accordance with the study by Hahn et al. where 
they found no change in COX IV protein expression in 3T3-L1 adipocytes in response 
to IL-6 exposure for 24, 48 or 96 hours (Hahn et al. 2014). Four weeks of IL-6 
overexpression in a mouse model of cancer cachexia reduced muscle COX IV protein 
expression by 57%, but no effect of IL-6 overexpression for 10 weeks on COX IV 
expression was observed in WT mice (White et al. 2011). In the current study, PHB1 
simply served as a mitochondrial protein whose expression could be quantified to give 
an indication of mitochondrial number, however, it has been shown to be upregulated 
by eight hours IL-6 exposure in an intestinal epithelial cell line, with STAT3 binding to 
the promoter region of the PHB1 gene observed (Theiss et al. 2007). Another study 
showed that IL-6 protected cardiomyocytes from hydrogen peroxide induced injury by 
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upregulation of PHB1 via STAT3 phosphorylation (Jia et al. 2012). Consistent with the 
expression levels of PHB1 being unchanged by IL-6 exposure, expression of another 
mitochondrial protein, HSP60, was also unchanged by IL-6 stimulation in GT1-7 cells, 
supporting the suggestion that IL-6 does not affect mitochondrial number.  
The lack of an effect of IL-6 on ECAR measurements suggested that IL-6 did not 
regulate glycolytic rate in GT1-7 cells. The protein expression of three key glycolytic 
enzymes was investigated to confirm the Seahorse findings. No induction of HK1, PDH 
or PKM2 was observed 24 hours after IL-6 exposure in GT1-7 cells, indicating that this 
treatment had no effect on glycolysis. HK1 is expressed in all mammalian tissues, with 
high expression observed in the brain (Wilson 2003). HK expression was found to be 
increased in brain following recurrent hypoglycaemia (Osundiji et al. 2011). Its 
expression has been demonstrated in GT1-7 cells (Beall, Hamilton, et al. 2012) and in 
the current work its expression was not regulated by antecedent IL-6 exposure. IL-6 
regulates the phosphorylation of PDH in mouse skeletal muscle but not total protein 
expression of PDH, consistent with the observations in the current work (Biensø et al. 
2014). Examining the phosphorylation status of PDH would have given an indication of 
its activity, and therefore substrate delivery to the mitochondria, which could be 
addressed in future studies. Antecedent IL-6 exposure did not regulate expression of 
PKM2 measured 24 hours later, and IL-6 regulation of PKM2 has not been described 
elsewhere.  
PGC1α and UCP2 are two key genes involved in mitochondrial regulation. PGC1α is 
the major regulator of mitochondrial biogenesis (Austin & St-Pierre 2012). Its 
expression was investigated in response to IL-6 stimulation to further investigate 
whether IL-6 regulated mitochondrial number in GT1-7 cells. In a recent study, IL-6 
gene delivery has been shown to upregulate mRNA and protein expression of PGC1α 
and mRNA expression of UCP2 in BAT (Ma et al. 2015). In the current work 
antecedent IL-6 exposure did not regulate the expression of PGC1α 24 hours 
subsequently, indicating that IL-6 does not affect mitochondrial biogenesis when 
administered in this manner, and therefore that increased mitochondrial number is 
unlikely to mediate the effects of IL-6 to induce defective glucose sensing in GT1-7 
cells. This finding was further verified by exposure to IL-6 for one, two or three hours 
failing to significantly affect expression of PGC1α mRNA in GT1-7 cells. It is 
important to note however that in the antecedent IL-6 exposure model used to 
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investigate mRNA expression, IL-6 exposure was only for a duration of 30 minutes 
rather than the previously used three hour model, and therefore is not directly 
comparable with the electrophysiological and Seahorse studies. In porcine adipocytes, 
IL-6 was found to upregulate PGC1α mRNA expression but only at 50 ng/ml or 100 
ng/ml for 48 hours, suggesting that a more chronic exposure to IL-6 may regulate 
PGC1α (Yang et al. 2008).  
UCP2 is a major regulator of mitochondrial ATP production, as it uncouples oxidative 
phosphorylation from ATP production by dissipating the proton gradient generated 
across the mitochondrial inner membrane (Toda & Diano 2014). UCP2 has been shown 
to be important in the CNS in the regulation of food intake, energy expenditure, glucose 
homeostasis and reward behaviours (Toda & Diano 2014). In the antecedent IL-6 
exposure model, no effect of IL-6 exposure on mRNA expression of UCP2 24 hours 
subsequently was observed. Interestingly however, robust increases in UCP2 mRNA 
expression were observed when GT1-7 cells were exposed to IL-6 for one or three 
hours, suggesting that acutely IL-6 may increase mitochondrial uncoupling and 
therefore reduce ATP production. Intriguingly, IL-6 exposure for two hours did not 
increase UCP2 mRNA levels compared to vehicle treatment, indicative of a biphasic 
regulation of UCP2 mRNA expression by IL-6 in GT1-7 cells. The acute effects of IL-6 
on UCP2 mRNA expression are pronounced, however they do not correlate with the 
functional XF24 data where antecedent IL-6 exposure did not affect mitochondrial 
proton leak OCR compared to vehicle treated cells, although these measurements were 
not made at the same time point. It would be of interest to perform the XF24 analysis 
after either a one or three hour exposure to IL-6, to see if the effects of IL-6 exposure 
for these times on UCP2 mRNA levels have functional consequences on mitochondrial 
bioenergetics. A rat in vivo study showed that chronic IL-6 administration for 14 days 
increased UCP2 protein expression in skeletal muscle, supporting a role for IL-6 in the 
regulation of UCP2 (Holmes et al. 2008). 50 ng/ml and 100 ng/ml IL-6 for 48 hours 
increased UCP2 mRNA in porcine adipocytes (Yang et al. 2008). An increase in UCP2 
mRNA may only be of physiological relevance if the message is transcribed into 
functional protein that can exert biological effects. UCP2 protein expression in response 
to IL-6 stimulation could be determined by Western blot analysis to investigate if the 
IL-6 effects of mRNA are consistent with an increase in protein expression.  
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S727 phosphorylation of STAT3 assigns the protein mitochondrial regulatory functions 
independent of its transcriptional activity (Reich 2009). To further investigate whether 
IL-6 exerts metabolic regulation, particularly via mitochondrial metabolism, the 
phosphorylation of S727 of STAT3 was investigated. Experiments demonstrated that 
IL-6 does not regulate the phosphorylation of STAT3 S727 in GT1-7 cells, with an 
induction of STAT3 Y705 providing a positive control for IL-6 stimulation of GT1-7 
cells. Furthermore, inhibition of JAK2 with WP1066 prevented Y705 phosphorylation 
of STAT3 induced by IL-6 but had no effect on S727 phosphorylation, which remained 
at a basal level in response to IL-6 alone, or in response to IL-6 after pretreatment with 
WP1066. This is in keeping with data demonstrating that ERK, JNK and PKCδ are 
involved in the phosphorylation of S727 of STAT3 rather than JAKs (Eulenfeld et al. 
2012). The lack of an increase in STAT3 S727 phosphorylation in response to IL-6 
stimulation of GT1-7 cells suggests that there is no induction of mitochondrial targeting 
of STAT3, further complementing the above data indicating that IL-6 does not exert 
significant regulatory effects on GT1-7 cell metabolism.  
Comparisons can be made between the current work and the recent study by Chang et 
al. investigating OSM exposure in rat cortical neurons (Chang et al. 2015). In their 
study, they described an OSM pathway to increase mitochondrial ATP production via a 
JAK1/2-STAT1/3 and CREB mediated induction of Mcl-1. In the current work, IL-6 
has been demonstrated to increase STAT3 phosphorylation via JAK2, and also increase 
CREB phosphorylation (data in following chapter). The increases in mitochondrial 
OCR in response to IL-6 were only moderate in this work, however based on the OSM 
pathway described, it would be of interest to investigate Mcl-1 expression as another 
indicator of enhanced mitochondrial respiratory capacity. In the Chang et al. paper, the 
OSM effects on mitochondrial function were shown to confer neuroprotection against 3-
NP-induced toxicity. In GT1-7 cells the IL-6 effects described may confer protection 
against hypoglycaemic stress, with the adverse complication of inducing defective 
glucose sensing. 
The data presented in this chapter do not implicate a role for IL-6 in the regulation of 
GT1-7 whole cell bioenergetics or metabolism. Functional XF24 assays failed to 
identify a significant effect of IL-6 on either OCR or ECAR 24 hours subsequently. 
This finding was supported by studies showing no change in expression of 
mitochondrial or glycolytic protein expression, suggesting that IL-6 did not increase 
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mitochondrial number in GT1-7 cells. IL-6 acutely increased expression of UCP2 at the 
mRNA level, but the effect did not persist 24 hours subsequently, the time point at 
which cells were studied electrophysiologically. A lack of alteration in OCR directed 
towards maintaining the mitochondrial leak in XF24 studies complemented this 
observation. Investigation of the phosphorylation status of the S727 site of STAT3 ruled 
out a mitochondrial targeting of this signal transducing molecule in response to IL-6 
stimulation in GT1-7 cells, further invalidating a role for IL-6 in the regulation of 
metabolism in GT1-7 cells. Furthermore, direct measurement of cellular ATP levels 24 
hours after IL-6 exposure demonstrated a decrease in ATP in response to 
hypoglycaemia. This suggested that enhanced ATP production or maintenance of ATP 
levels during acute hypoglycaemia exposure was unlikely to mediate the closed state of 
KATP channels and conserved membrane depolarisation observed in the prior 
electrophysiological studies during hypoglycaemia following antecedent IL-6 treatment. 
Taken together these data suggest that antecedent IL-6 exposure does not result in 
defective hypoglycaemia detection 24 hours later by altering whole cell bioenergetics or 
metabolism. The findings do not rule out an acute regulation of metabolism by IL-6, as 
functional measurements of bioenergetics and ATP levels were only made 24 hours 
after exposure to IL-6. Similarly, a more chronic exposure to the cytokine (e.g. over 24 
hours) may also modulate cellular metabolism, as has been observed elsewhere (Hahn et 
al. 2014). Therefore, studies were performed to address other potential mechanisms by 
which antecedent IL-6 exposure may mediate its effects on glucose sensing, with focus 
turning more directly on the KATP channel. 
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5 The Role of EPAC2 in the Regulation of 
Glucose Sensing by IL-6 
5.1 Introduction 
A role for IL-6 in the regulation of GT1-7 cell metabolism and ATP production was not 
confirmed, suggesting that IL-6-induced suppression of GT1-7 glucose sensing ability 
was mediated by an alternative mechanism. Attention was focused on more direct 
mechanisms of KATP channel regulation.   
Aside from intracellular nucleotide modulation of the KATP channel, other regulators of 
channel function, such as post translational modifications, have been described (Dzeja 
& Terzic 1998; Yang et al. 2014). Hormonal regulation of KATP has also been 
uncovered, with leptin regulating channel trafficking (Holz et al. 2013) and β-estradiol 
decreasing KATP channel activity in beta-cells (Soriano et al. 2011). Discovered in 1998 
(de Rooij et al. 1998; Kawasaki et al. 1998) exchange proteins activated by cAMP 
(EPACs), of which there exists two isoforms, EPAC1 and EPAC2, are guanine-
nucleotide-exchange factors for the Ras-like small GTPases Rap1 and Rap2 (Breckler et 
al. 2011). They function as intracellular sensors that, along with the classic protein 
kinases As (PKAs), transduce the effects of the second messenger cyclic AMP (cAMP). 
Both PKAs and EPACs have roles in energy homeostasis (Almahariq et al. 2014). 
Importantly, an EPAC2-selective activator has been shown to potentiate first and 
second phase insulin secretion from mouse, rat and human pancreatic beta-cells (Kelly 
et al. 2009; Chepurny et al. 2009). The importance of EPAC2 in GLP-1-induced insulin 
secretion was demonstrated with the finding that in EPAC2-/- mice the effects of the 
GLP-1 analogue E4 to enhance insulin secretion were significantly reduced (Song et al. 
2013). Interestingly, EPAC2 may potentially participate in the CRR to hypoglycaemia 
by promoting the production of glucagon, as EPAC2 has been demonstrated to regulate 
pro-glucagon gene expression in intestinal cells, pancreatic alpha-cells and 
hypothalamic neurons (Lotfi et al. 2006; D. Islam et al. 2009; Dalvi et al. 2012). EPAC 
has been shown to regulate KATP channel ATP-sensitivity in human pancreatic beta-
cells and rat INS-1 cells (G. Kang et al. 2008). This is an important finding as it means 
that EPAC can modulate the function of KATP channels independently of a change in 
absolute ATP levels. The same group subsequently demonstrated that EPAC was 
capable of facilitating sulphonylurea-mediated inhibition of KATP channels in human 
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pancreatic beta-cells and rat INS-1 cells (Leech et al. 2010). Of particular interest was 
the recent demonstration that EPAC interacts directly with the SUR1 subunit of KATP 
channels in mouse synaptosomes (Zhao et al. 2013). Taking together the observations 
that EPAC potentiates insulin secretion and regulates pancreatic beta-cell KATP activity, 
and interacts directly with SUR1 in mouse synaptosomes, it was hypothesised that an 
increase in EPAC expression or activity may mediate the effects of antecedent IL-6 
exposure to induce defective hypoglycaemia detection in GT1-7 cells.  
To test this hypothesis, firstly the expression of the two isoforms of EPAC proteins was 
determined in GT1-7 cells and subsequently it was investigated whether IL-6 could 
regulate the cAMP signalling pathway in these cells. Immunoprecipitation experiments 
were performed to identify if EPAC interacted with the KATP channel in GT1-7 cells 
and electrophysiology was employed to assess the effects of EPAC on KATP channel 
activity.  
5.2 Results 
5.2.1 IL-6 Increases CREB Phosphorylation in GT1-7 Cells  
In the aforementioned work of Kelly and co-workers, a robust increase in the 
phosphorylation of CREB was observed in skeletal muscle incubated with IL-6. This 
was associated with an increase in cAMP, and they proceeded to demonstrate that the 
action of IL-6 to increase α2 AMPK activity was dependent on increases in the 
intracellular levels of cAMP, as an adenyl cyclase inhibitor prevented these effects of 
IL-6 (Kelly et al. 2009). In the current work in GT1-7 cells, exposure to 20 ng/ml IL-6 
for five-180 minutes increased the phosphorylation of CREB at serine 133 (S133) and 
this effect almost reached statistical significance upon exposure to IL-6 for 30 minutes 
(Figure 5.1). Interestingly, the observed increase in pCREB does not appear to lead to 
increased AMPK activity as has been shown in skeletal muscle (Kelly et al. 2009) as 
there was no significant effect of IL-6 to increase pAMPK at T172 in GT1-7 cells 
(Chapter 3, Figure 3.1D).  
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Figure 5.1 IL-6 increases pCREB S133 phosphorylation in GT1-7 cells 
GT1-7 cells were serum starved for two hours in the presence of 2.5 mM glucose prior 
to exposure to vehicle dH2O (Control, C) for three hours or 20 ng/ml IL-6 for the 
indicated times. Cells were lysed and samples prepared for Western blot analysis of 
protein expression of pCREB S133 (n=4). Fold change in phosphorylation was 
determined relative to Control treated cells normalised to actin and a representative blot 
is shown. Statistical significance was determined relative to control by one sample t-test 
with p values approaching significance displayed above the appropriate bars on the 
graph. 
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5.2.2 IL-6 Exposure Leads to a Subtle Increase in cAMP in 
GT1-7 Cells 
Given the increase in pCREB levels observed with IL-6 treatment, it would be expected 
that upstream of CREB, an increase in levels of cellular cAMP would be observed. To 
investigate this, GT1-7 cells were exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 
(IL-6) for three hours prior to lysis and cAMP measurement using a commercially 
available assay (Direct cAMP ELISA, Enzo). IL-6 trended towards increasing cellular 
cAMP levels compared to vehicle treated control cells, although this did not reach 
statistical significance (p=0.41) (Figure 5.2). The trend towards an increase in cAMP in 
IL-6 treated cells is supported by the observation that IL-6 also leads to increases in 
pCREB levels, and taking these data together suggest that IL-6 increases the cAMP-
pCREB signalling axis in GT1-7 cells.  
5.2.3 EPAC2, But Not EPAC1, is Expressed in GT1-7 Cells 
But its Expression is Not Regulated by IL-6     
The major intracellular functions of cAMP are transduced by PKA and EPACs. 
Interestingly, the roles of both PKA, and more recently EPACs, in energy homeostasis 
have been studied (Almahariq et al. 2014). Crucially, EPAC2 has been shown to play a 
critical role in the potentiation of insulin secretion from mouse, rat and human 
pancreatic beta-cells (Chepurny et al. 2009; Almahariq et al. 2014; Chepurny et al. 
2010). This led to the hypothesis that EPAC2 may mediate functions of IL-6-induced 
increases in cAMP, potentially involving a regulation of KATP channels and therefore 
membrane excitability in GT1-7 cells. 
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Figure 5.2 IL-6 exposure leads to a subtle increase in cAMP in GT1-7 cells 
GT1-7 cells were exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three 
hours prior to cell lysis and cAMP measurement using a commercially available assay, 
performed according to the manufacturer’s protocol (Direct cAMP ELISA, Enzo) (n=5). 
Data was analysed by Mann-Whitney test (p=0.41).  Data generated in collaboration 
with Kathryn Wright. 
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Initially, the protein expression of the two EPAC isoforms, EPAC1 and EPAC2, and 
whether their expression was regulated by IL-6 was determined in GT1-7 cells. GT1-7 
cells were exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three hours 
and were lysed 24 hours subsequently, in keeping with the antecedent IL-6 exposure 
model in which the negative effects of IL-6 on GT1-7 glucose sensing were observed. 
Samples were prepared and subjected to Western blot analysis of protein expression of 
EPAC1 and EPAC2. In GT1-7 cells, EPAC1 protein expression was undetected, 
however EPAC2 was expressed (Figure 5.3A and B). To confirm that the antibody used 
to detect EPAC1 was indeed capable of doing so, a mouse brain sample was run 
alongside GT1-7 samples and EPAC1 expression was detectable in mouse brain tissue 
(Figure 5.3A). There was no difference observed in EPAC2 expression between vehicle 
treated and IL-6 treated cells, demonstrating that antecedent IL-6 exposure does not 
regulate the expression level of EPAC2 protein 24 hours subsequently in GT1-7 cells 
(Figure 5.3B).  
5.2.4 A Proportion of EPAC2 is Associated with KATP 
Channels in GT1-7 Cells  
Given the existing data demonstrating that EPAC regulates KATP channel activity in 
human beta-cells and rat INS-1 cells (G. Kang et al. 2006; G. Kang et al. 2008; Leech et 
al. 2010), and that EPAC is able to bind directly to SUR1 in mouse synaptosomes (Zhao 
et al. 2013), the question was posed whether EPAC2 associates with the KATP channel 
in GT1-7 cells. To answer this question GT1-7 cells were treated with vehicle dH2O 
(Control) or 20 ng/ml IL-6 (IL-6) for three hours and lysed 24 hours subsequently and 
subjected to a immunoprecipitation (IP) experiment whereby the SUR1 subunit of the 
KATP channel was immunoprecipitated out of the cell lysates using a SUR1 NBD2 
specific monoclonal antibody. The aims of the experiment were to determine firstly 
whether EPAC2 co-immunoprecipitates with SUR1 from GT1-7 cells, thereby 
confirming an interaction between EPAC2 and the KATP channel, and secondly whether 
the degree of interaction between the two was regulated by IL-6. The results 
demonstrated that EPAC2 co-immunoprecipitated with the KATP channel in GT1-7 cells 
(Figure 5.4A, IP fractions). However, quantification of this interaction by densitometry 
demonstrated that there was no significant difference in the amount of EPAC2 
associated with the channel in IL-6 treated cells compared to vehicle treated control 
cells (p=0.33, Figure 5.4B).  
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Figure 5.3 EPAC2 but not EPAC1 protein is expressed in GT1-7 cells but its expression 
is not regulated by IL-6 
GT1-7 cells were exposed to vehicle dH2O (Control, C) or 20 ng/ml IL-6 (IL-6) for 
three hours and were lysed 24 hours subsequently and samples were prepared for 
Western blot analysis of EPAC1 (A) and EPAC2 (B) protein expression (n=2). A mouse 
brain sample expressing EPAC1 was used as a positive control for EPAC1 expression. 
Data in (B) was analysed by one sample t-test (p=0.84). 
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Figure 5.4 A proportion of EPAC2 is associated with KATP channels in GT1-7 cells but 
the amount of association is not regulated by IL-6 
GT1-7 cells were exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three 
hours on day 1 and lysed 24 hours subsequently and an immunoprecipitation (IP) 
experiment was performed from the lysates using a mouse SUR1 NBD2 specific 
monoclonal antibody (detailed in Methods). Fractions were obtained throughout the 
protocol and subsequently subjected to Western blot analysis to determine expression of 
SUR1, Kir6.2, EPAC2 and sodium-calcium exchanger (NCX) in each fraction (n=2). 
NCX served as a negative control, a protein known not to interact with SUR1 or Kir6.2 
of the KATP channel. The insoluble fraction was obtained by resuspending the pellet 
from the centrifuged cell lysates in sample buffer before starting the IP (Insoluble). A 
portion of the supernatant from this centrifugation step was used as the Starting 
Material fraction (SM). After overnight incubation IP reactions were centrifuged and a 
proportion of the supernatant was obtained as the unbound fraction (Unbound). Finally, 
the IP fraction (IP) consisted of the complex of antibody and capture beads and any 
associated proteins. Representative Western blots for each protein of interest are shown 
in (A) with quantification of the fold change in abundance of each protein in the IL-6 
treated IP fractions relative to vehicle treated control cells in (B) (n=2). Data was 
analysed for each protein in (B) by one sample t-test relative to control.   
 
 
 
144 
In the current experiments, fractions were taken at several intervals throughout the IP. 
Initially, a representative fraction of the supernatant from the cell lysates following 
centrifugation was taken prior to starting the IP to demonstrate presence of proteins in 
the sample at the beginning of the procedure from which the IP would be performed 
(Starting Material). The pellet from this centrifugation step served as the fraction 
allowing determination of any protein that was not soluble in the cell lysate (Insoluble). 
Following the overnight reaction, IPs were centrifuged to pellet the complex of capture 
beads, antibody and associated proteins (IP), while the supernatant contained any 
protein that did not form this complex (Unbound). After Western blot analysis of 
protein expression in the above fractions the amount of EPAC2 protein co-
immunoprecipitated from GT1-7 cell lysates could be determined and compared 
between control and IL-6 treated reactions. The sodium calcium exchanger (NCX) 
served as a negative control in the current work as it is a cell membrane localised 
protein that does not interact with the KATP channel, and its utility as a negative control 
was confirmed by an absence of any NCX expression in the IP fractions, with all NCX 
remaining in the Unbound fraction (Figure 5.4A).  
The results from the IP experiment confirm that SUR1 is associated with Kir6.2 in 
GT1-7 cells, forming functional KATP channels, and that a proportion of EPAC2 is 
associated with the KATP channel in GT1-7 cells. Furthermore, antecedent IL-6 
treatment did not affect the association of EPAC2 with the channel 24 hours 
subsequently in these cells.  
5.2.5 EPAC2 Inhibition Prevents Antecedent IL-6-Induced 
Defective Glucose Sensing in GT1-7 Cells  
EPAC2 expression and association with KATP was confirmed in GT1-7 cells, and 
although antecedent IL-6 treatment did not regulate the expression level or association 
of EPAC2 with KATP channels, the possibility remained that IL-6 potentially regulates 
EPAC2 activity. The key question to address therefore was whether the effect of 
antecedent IL-6 to induce defective detection of subsequent hypoglycaemia in GT1-7 
cells was mediated by EPAC2. Studies have demonstrated that enhanced EPAC activity 
increases the ATP-mediated inhibition of KATP channels (G. Kang et al. 2008). In the 
current work, the potent, selective EPAC2 inhibitor HJC 0350 was used to selectively 
inhibit EPAC2 activity in GT1-7 cells during antecedent vehicle dH2O (Control) or 20 
ng/ml IL-6 treatment (IL-6) for three hours. Treated cells were assayed 
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electrophysiologically 18-24 hours subsequently and were subjected to a 0.5 mM 
glucose hypoglycaemic challenge during perforated patch current clamp recording. 
Control cells were exposed only to the vehicles in which HJC 0350 and IL-6 were 
delivered for three hours, which were DMSO at a dilution of 1:1000 and dH2O at 1:250 
respectively. When subjected to a hypoglycaemic challenge 18-24 hours subsequently, 
vehicle treated cells hyperpolarised from an average resting membrane potential in 2.5 
mM glucose of -56.1 +- 2.2 mV, by -3.4 +- 2.2 mV on average to -59.6 +- 1.6 mV, and 
ceased action potential firing rates upon detection of the hypoglycaemic stimulus 
(Figure 5.5A and C). Importantly, GT1-7 cells treated antecedently with 0.5 µM HJC 
0350 and 20 ng/ml IL-6 for three hours exhibited a similar resting membrane potential 
in 2.5 mM glucose of -53.3 +-2.1 mV, and also hyperpolarised by -3.0 +- 2.5 mV on 
average to -56.3 +- 3.8 mV, and ceased action potential firing rates, thereby 
demonstrating physiological responses to hypoglycaemia comparable to those observed 
in vehicle treated cells (Figure 5.5B and C). This is in stark contrast to the defective 
glucose sensing response of GT1-7 cells exposed to antecedent IL-6 treatment alone as 
described in Chapter 3 (Chapter 3, Figure 3.5B and C). These data suggest that EPAC2 
is a potential mediator of the defective glucose sensing induced by antecedent IL-6 
treatment, as co-application of the EPAC2 inhibitor HJC 0350 during antecedent IL-6 
exposure prevents the development of defective glucose sensing of subsequent 
hypoglycaemia in GT1-7 cells.  
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It was noted that the mean hyperpolarising responses to hypoglycaemia were reduced in 
magnitude in GT1-7 cells studied in Figure 5.5 compared to those studied in Chapter 3 
Figure 3.5 (compare Figure 5.5C with Figure 3.5C). This was shown to be due to a 
number of the vehicle treated cells studied in Figure 14 failing to hyperpolarise 
appropriately to the low glucose stimulus (Appendix VIII). Of seven vehicle treated 
cells studied, only two hyperpolarised appropriately in response to 0.5 mM glucose, 
resulting in a 28.6% hypoglycaemia-responsive population of cells. Separation of the 
hypoglycaemia-responsive and non-responsive cells demonstrated that the responsive 
cells hyperpolarised by -11.5 +- 2.5 mV on average in response to 0.5 mM glucose, 
exhibiting hyperpolarising responses to low glucose comparable to those in WT GT1-7 
from previous studies (Chapter 3, Figure 3.5C). The cells antecedently treated with 0.5 
µM HJC 0350 and 20 ng/ml IL-6 (HJC + IL-6) had variable hyperpolarising responses 
to subsequent 0.5 mM glucose challenge, exhibiting a mean hyperpolarising response of 
-3.0 +- 2.5 mV, suggesting that HJC 0350 only partially prevents the glucose sensing 
defect induced by antecedent IL-6 treatment. Analysis of individual cell responses to 
0.5 mM glucose indicated that HJC 0350 co-treatment with IL-6 exhibited variable 
degrees of prevention of the defective glucose sensing phenotype induced by IL-6 
(Appendix VIII).  
5.3 Discussion 
The lack of effect of IL-6 on whole cell metabolism in GT1-7 cells led to investigations 
focusing more on an effect of IL-6 to regulate KATP directly or via one of its interacting 
proteins. Studies have identified EPAC as a regulator of KATP function in pancreatic 
beta-cells and an interaction between EPAC and SUR1 of KATP has been described in 
mouse synaptosomes (G. Kang et al. 2006; G. Kang et al. 2008; Leech et al. 2010; Zhao 
et al. 2013). The data in the current results confirmed that IL-6 stimulation of GT1-7 
cells leads to increases in cAMP and phosphorylation of its downstream target CREB. 
Furthermore, EPAC2 is expressed in GT1-7 cells and associates with KATP channels. 
Administration of an EPAC2 selective inhibitor during antecedent exposure to IL-6 
partially prevented the glucose sensing defects observed with IL-6 treatment alone.  
EPAC2 transduces the effects of cAMP and is an important regulator of insulin 
secretion in beta-cells via its regulation of KATP (G. Kang et al. 2006; G. Kang et al. 
2008; Leech et al. 2010). IL-6 stimulation in the current work increased both cAMP 
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levels and CREB phosphorylation, albeit nonsignificantly. The cAMP measurement was 
performed after exposure to vehicle or IL-6 for three hours. However, IL-6-induced 
increases in CREB phosphorylation occurred more rapidly, with larger increases in 
phosphorylation observed after five and 30 minutes exposure to IL-6 than after three 
hours. It would be worthwhile measuring cAMP levels in response to a shorter exposure 
of IL-6, in case a more robust increase occurs prior to the three hour time point studied. 
In support of this notion, exposure to 50 ng/ml IL-6 for 15 minutes increased cAMP 
content in C2C12 myocytes (Kelly et al. 2009). In rat hepatocytes, exposure to 10 ng/ml 
IL-6 for 30 minutes increased the phosphorylation of CREB (Chou et al. 2013). In 
Chang and colleagues’ study investigating OSM functions in cortical neurons, a robust 
increase in pCREB was observed upon exposure to 100 ng/ml of the IL-6 family 
cytokine for two to eight hours (Chang et al. 2015). IL-18, an IL-1 family cytokine, 
administered at a dose of 50 ng/ml for three to 12 hours increases pCREB in rat cortical 
neurons (Jiang et al. 2014) and a study in superficial dorsal horn neurons demonstrated 
IL-6-induced increases in CREB phosphorylation upon exposure to 10 ng/ml of the 
cytokine for 30 minutes (Kawasaki et al. 2008). The hyper IL-6 fusion protein, 
consisting of IL-6 fused to its specific receptor, induced increases in pCREB in neural 
stem cells when given at a dose of 100 ng/ml for ten minutes (O. Islam et al. 2009). IL-6 
has been shown to rapidly increase both cAMP levels and CREB phosphorylation in 
C2C12 cells, and also led to increases in pCREB and cAMP content in rat skeletal 
muscle when quantified one hour after i.p administration of 2.5 µg IL-6 to rats in vivo 
(Kelly et al. 2009). The current data and the cited literature provides strong evidence 
that IL-6 can activate the cAMP/pCREB signalling axis in GT1-7 cells.  
Whether IL-6 regulates EPAC has not been studied. EPAC regulation of KATP channel 
activity has been well described (G. Kang et al. 2006; G. Kang et al. 2008; Leech et al. 
2010), implicating it as a potential mediator of the effects of IL-6 on glucose sensing 
observed in the current work. The results here demonstrated EPAC2, but not EPAC1, 
expression in GT1-7 cells, consistent with the predominant expression of EPAC2 in the 
brain (Kawasaki et al. 1998). Association of EPAC2 with the KATP channel in GT1-7 
cells was demonstrated by co-immunoprecipitation, consistent with previous findings 
(Zhao et al. 2013). In the current work, densitometry quantification on Western blot 
analyses of protein expression in the IP fractions was performed and suggested that IL-6 
did not regulate the association of EPAC2 with the KATP channel either positively or 
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negatively. However, it should be noted that this is not a very sensitive way of 
quantifying protein-protein interactions and the analysis was only performed on two 
independent IP experiments. A more sensitive measure of protein-protein interaction 
could be exploited to better understand whether IL-6 regulates the interaction of EPAC2 
with the KATP channel in GT1-7 cells, such as fluorescence resonance energy transfer 
(FRET). Also, by selectively expressing only the SUR1 or Kir6.2 proteins with EPAC2 
in a cell-based system it could be determined whether EPAC2 interacts specifically with 
the SUR1 or Kir6.2 subunit of KATP channels. Furthermore, EPAC is found at many 
cellular locations such as the plasma membrane, nuclear membrane, cytosol and 
mitochondria (Breckler et al. 2011). Depending on their cellular localisation and 
molecular partners, EPACs can activate different downstream effectors (Breckler et al. 
2011). In line with this, the spatial regulation of EPACs is important for their function. 
Imaging studies could be employed to investigate the spatial localisation of EPAC2 in 
GT1-7 cells and may be able to determine whether IL-6 regulates the localisation of 
EPAC2. It would be of particular interest if IL-6 exposure induced a membrane 
targeting of EPAC2, as this would potentially make an interaction between EPAC2 and 
KATP channels more likely.  
Importantly, inhibition of EPAC2 during IL-6 pre-exposure prevented the development 
of defective hypoglycaemia detection observed in antecedent IL-6 treated cells. The 
dose of HJC 0350 used was based on its published half maximal inhibitory 
concentration (IC50) of 0.3 µM for competing with 8-NBD-cAMP for binding of 
EPAC2; which is about 133-fold more potent than cAMP for binding EPAC2 (Chen et 
al. 2013). In order to determine whether IL-6 requires EPAC2 function to mediate its 
negative regulation of glucose sensing, HJC 0350 was administered at the same time as 
IL-6 for three hours. The results from this study demonstrated a prevention of the 
defective glucose sensing phenotype induced by IL-6 in prior experiments. This data 
suggests that IL-6 mediates an alteration in EPAC2 function that persists for at least 18-
24 hours resulting in altered KATP channel function in response to subsequent 
hypoglycaemia. Since EPAC2 has been demonstrated to regulate KATP channel activity 
in beta-cells acutely (G. Kang et al. 2006; G. Kang et al. 2008; Leech et al. 2010), it 
would be of interest to investigate the effects of EPAC2 inhibition and activation on 
GT1-7 cell membrane potential under euglycaemic conditions. Further investigation of 
the temporal effects of IL-6 on glucose sensing capacity in GT1-7 cells would be 
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interesting as well, in particular to determine a) how soon after IL-6 exposure defective 
glucose sensing is observed and b) how long defective glucose sensing induced by IL-6 
persists for. Similarly, determining whether EPAC2 inhibition-mediated prevention of 
IL-6-induced defective glucose sensing is reversible or temporary would warrant further 
investigation.   
The finding that EPAC2 inhibition during IL-6 pre-exposure prevented the development 
of defective hypoglycaemia detection, in conjunction with other work, suggests that IL-
6 may induce defective hypoglycaemia detection and hyperpolarising responses to low 
glucose in GT1-7 cells via EPAC2-mediated enhancement of ATP-mediated inhibition 
of KATP channels. No increase in EPAC2 protein, or association of EPAC2 with KATP 
channels, was observed upon IL-6 treatment, however this doesn’t rule out that IL-6 
may enhance EPAC2 activity. An assay is available to measure Rap1 activity, which is 
the downstream target of EPAC, giving an indication of EPAC activity, and it would be 
of great interest to determine whether IL-6 increases EPAC activity in GT1-7 cells. Due 
to the absence of an increase in ATP production or EPAC2 expression following 
antecedent IL-6 treatment, together with the observation that EPAC2 inhibition prevents 
IL-6 induced defective glucose sensing, it is tempting to speculate that IL-6 may 
increase EPAC2 activity, leading to enhanced sensitivity of KATP channels to ATP-
mediated inhibition, resulting in the defective glucose sensing phenotype. This may 
occur via a direct interaction of EPAC2 with NBD2 of SUR1 (Shibasaki et al. 2004a; 
Shibasaki et al. 2004b). EPAC2 binding to SUR1 might influence allosteric interactions 
of NBD1 with its partner NBD2, with such interactions dictating the MgADP-
dependent stimulation of KATP channel activity (Gribble, Tucker et al. 1997). At the 
same time, SUR1 recruitment of EPAC2 to the cell membrane permits interaction of 
EPAC2 with the Rap GTPases (G. Kang et al. 2006). In this way, EPAC is involved in a 
signalling complex comprising EPAC1, Rap2B and PLC-ε in human embryonic kidney 
(HEK) cells (Schmidt et al. 2001). PLC-ε catalyses the hydrolysis of membrane-bound 
PIP2, and because PIP2 stimulates the activity of KATP channels in part by reducing the 
channel’s sensitivity to ATP (Baukrowitz et al. 1998; Shyng & Nichols 1998; Nichols 
2006), a cAMP signalling mechanism that uses EPAC, RAP and PLC-ε to reduce levels 
of PIP2 in the plasma membrane would be expected to increase the sensitivity of KATP 
channels to ATP (G. Kang et al. 2008). Investigating the affinity of KATP for ATP-
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mediated inhibition following antecedent IL-6 treatment, which could be assessed 
electrophysiologically, would be of great interest for future research. 
Another avenue for future research is encouraged by work demonstrating that cAMP 
elevation can inhibit activation of the JAK-STAT pathway in response to an IL-6/sIL-
6Rα trans-signalling complex by promoting the accumulation of SOCS3 in vascular 
endothelial cells. Intriguingly, this was demonstrated to occur via a PKA-independent 
mechanism and was mimicked by activation of EPAC (Sands et al. 2006). The authors 
suggested that this data represented a new function for EPAC that is consistent with the 
predominantly anti-inflammatory effects of cAMP induction observed for endothelial 
cells (Sands et al. 2006; Blease et al. 1998). In hypothalamic slices, the cAMP elevating 
agent forskolin has also been shown to increase SOCS3 at the protein and mRNA level 
via an EPAC-dependent pathway (Fukuda et al. 2011). SOCS3 is an inhibitor of leptin 
signalling and the authors went on to demonstrate that activation of cAMP-Epac 
signalling directly densensitised POMC neurons to leptin (Fukuda et al. 2011). 
Furthermore, chronic exposure of mice to high fat diet resulted in obesity and leptin 
resistance, with increased Rap1 activity observed in the hypothalamus, suggesting that 
the hypothalamic EPAC-Rap1 pathway is activated in response to high fat exposure 
(Fukuda et al. 2011). Future work further elucidating the cross talk between cAMP and 
IL-6 signalling would be of interest to see how these signalling pathways interact, as the 
data cited suggests that EPAC2 may be a negative regulator of IL-6 mediated 
JAK/STAT signalling, initiating a negative feedback loop upon elevation of cAMP 
levels.  
IL-6 stimulation of GT1-7 cells results in an increase in the cAMP/pCREB pathway, 
which may be associated with an increase in EPAC2 activity. In turn, this enhanced 
EPAC2 activity may regulate the sensitivity of the KATP channel to ATP-mediated 
inhibition, resulting in the maintenance of cell membrane depolarisation and action 
potential firing rates and associated defects in hyperpolarising responses to subsequent 
low glucose challenge. Future work should address the regulation of EPAC2 activity by 
exposure to IL-6 to increase understanding of this proposed mechanism in GT1-7 cells.
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6 General Discussion 
This work identified IL-6 as a novel regulator of hypothalamic glucose-sensing neurons, 
with the major observation that antecedent IL-6 exposure in GT1-7 neurons resulted in a 
suppression of hypoglycaemia detection and membrane hyperpolarisation in response to 
0.5 mM glucose challenge 18-24 hours subsequently, affording cells the capacity to 
maintain neuronal activity during subsequent glucose deprivation. Based on the 
mechanisms studied in an attempt to elucidate how IL-6 elicits these effects, EPAC2 
was identified as a potential mediator of defective glucose sensing, with the inference 
that the effect of IL-6 is potentially achieved by increasing the affinity of KATP channels 
for ATP-mediated channel inhibition. Based on these findings it will be of future 
importance to address the contribution and role of EPAC2 in hypothalamic glucose 
sensing further, as both IL-6 and EPAC2 may be potential therapeutic targets whose 
inhibition may combat defective hypoglycaemia detection and therefore help restore 
CRRs in patients with defective CRR due to recurrent hypoglycaemia.  
The acute effects of IL-6 on GT1-7 cell membrane potential were studied but no 
regulation of resting membrane potential was observed by IL-6 under euglycaemic 
conditions. Acute hypoglycaemia hyperpolarises GT1-7 cells resulting in silencing of 
action potential activity, and in this setting IL-6 did not significantly affect membrane 
potential, suggesting that IL-6 does not regulate glucose-sensing neurons acutely. 
Interestingly, IL-6 secretion from primary mouse cortical astrocytes was observed to 
occur in the recovery period following hypoglycaemia rather than during 
hypoglycaemia itself, with significantly more IL-6 release observed from 
hypoglycaemic cultures compared to euglycaemic cultures following a four hour 
euglycaemic recovery period. Investigation of whether IL-6 exerted delayed effects on 
GT1-7 cells led to the observation that antecedent exposure to IL-6 attenuated 
hyperpolarising responses to subsequent hypoglycaemia, resulting in maintenance of 
neuronal activity. This finding implicated a role for IL-6 in the induction of 
physiological cellular adaptations resulting in a defective glucose sensing phenotype of 
GT1-7 cells. Importantly, partial reduction of the IL-6Rα prevented the effects of 
antecedent IL-6 treatment to induce defective glucose sensing, confirming that IL-6 
activation of its receptor complex is required for the initiation of any downstream 
effects regulating glucose sensing.  
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Mechanistic investigation of the effects of IL-6 on glucose sensing focussed initially on 
the involvement of the JAK/STAT3 signalling pathway which was robustly induced in 
GT1-7 cells upon exposure to IL-6, evidenced by increases in the phosphorylation of 
STAT3. In GT1-7 cells lacking the IL-6Rα, a reduction in the phosphorylation of 
STAT3 was observed in cells that were protected from IL-6-induced defective glucose 
sensing, implicating a role for activation of STAT3 in the transduction of the IL-6 
effects on glucose sensing. Given the latent onset (18-24 hours subsequently) of the 
defective glucose sensing phenotype, and that STAT3 phosphorylation leads to 
dimerisation and translocation to the nucleus, the hypothesis that STAT3-mediated gene 
transcription was required to induce the effects of IL-6 on glucose sensing was tested. 
STAT3 inhibition with the JAK2 inhibitor WP1066 prior to antecedent IL-6 exposure 
was effective at blocking IL-6-induced phosphorylation of STAT3, and therefore its 
transcriptional activity, however, by the time cells were due to be studied 
electrophysiologically 18-24 hours subsequently, inhibition of STAT3 had exerted 
cytotoxic effects on GT1-7 cells resulting in cell death. A limitation of the current work 
was that an alternative way of inhibiting STAT3-mediated gene transcription was not 
attempted, as alternatives for targeting this, such as small molecule inhibitors, are 
available and should be studied in the future. 
A role for an IL-6-induced increase in cellular ATP production via increased cellular 
metabolism was not confirmed, and therefore did not support the hypothesis that an 
increase in ATP production leading to enhanced inhibition of KATP channels was 
responsible for mediating the IL-6-induced glucose sensing defect. However, a role for 
the cAMP/EPAC2 pathway was implicated, with cAMP assays confirming increases in 
cAMP in response to IL-6 and phosphorylation of CREB by IL-6 exposure indicating 
activation of cAMP signalling cascades. Inhibition of EPAC2 during antecedent IL-6 
exposure partially prevented the induction of defective glucose sensing, implicating a 
role for EPAC2 in mediating the effects of IL-6. This is hypothesised to occur via an 
EPAC2-mediated increase in the sensitivity of KATP channels to inhibition by ATP, and 
future studies should focus on elucidating if this is the case.         
A limitation of this work was the lack of confirmation of the role of STAT3 in 
mediating the effects of IL-6 on glucose sensing. Initial studies suggested an 
involvement of STAT3 in this observation, but were not followed up effectively. There 
are also limitations induced by inconsistencies between the electrophysiological and 
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biochemical studies. The hypoglycaemic challenge in electrophysiological experiments 
was 0.5 mM glucose for a 15 minute duration. In contrast, many of the functional assays 
performed, such as ATP measurement, were following a hypoglycaemic challenge of 
0.1 mM glucose for three hours. Electrophysiology allows a highly sensitive 
measurement of single cell neuronal activity. In contrast, assays performing 
measurements from cell populations exhibiting heterogeneous responses are less robust, 
and therefore a more profound hypoglycaemic challenge was performed for these 
assays. In doing this however, subtle effects of IL-6 on measured parameters may have 
been missed. It will be important to re-assess the functional measurements of ATP and 
cAMP content in GT1-7 cells after exposure to a 15 minute 0.5 mM glucose 
hypoglycaemic challenge in order to be more consistent with the electrophysiological 
studies.     
Further limitations of the current work are associated with the model used to perform 
these studies. The GT1-7 cell line provided an attractive model to study the effects of 
IL-6 on glucose sensing. As a homogenous population of GE neurons, which 
recapitulates the glucose sensing machinery expressed in GE neurons of the VMH 
(Beall, Hamilton, et al. 2012; Ogunnowo-Bada et al. 2014), it permitted the study of 
mechanisms regulating glucose sensing in isolation from glial cell influences and other 
central and peripheral innervation. Unfortunately, during the current work, 
heterogeneous responses to low glucose exposure were observed in these cells, 
complicating experiments and interpretation of the data obtained. It will be of 
significant importance in the future to confirm whether antecedent IL-6 exposure results 
in similar suppression of glucose sensing in other models. An ideal experimental model 
to validate this would be to utilise a reporter mouse that has fluorescent tagging of GE 
neurons of the VMH. This could potentially be achieved by selectively tagging a 
component of the glucose sensing machinery in, for example, SF-1-expressing neurons 
of the VMH, as these have been identified to be glucose-sensing cells (Y.-H. Choi et al. 
2013; Silver & Erecińska 1998; Tong et al. 2007). Hypothalamic slices could then be 
obtained from these animals and fluorescent cells could be examined 
electrophysiologically to determine whether antecedent IL-6 exposure regulates glucose 
sensing in similar ways to those observed in the current work.  
The inference of the IL-6-induced suppression of glucose sensing would be an 
associated suppression of CRR to hypoglycaemia (Chan & Sherwin 2013). Whether this 
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is the case could be studied in vivo by measuring CRR hormone release in response to 
acute hypoglycaemia following antecedent VMH IL-6 microinjection. If antecedent IL-
6 treatment suppressed CRR hormonal secretion in response to hypoglycaemia this 
would suggest that IL-6 could induce impaired CRR to hypoglycaemia. Together with 
data demonstrating IL-6 regulation of glucose-sensing neurons in hypothalamic slices, 
this would help elucidate whether IL-6 induced defective glucose sensing in a more 
physiological model of the VMH and whether this had functional consequences in terms 
of whole body CRR to hypoglycaemia in vivo. If the experiments above are successful, 
a further level of investigation could involve attempting to specifically knockout the IL-
6Rα, or impede IL-6 action pharmacologically, in glucose-sensing neurons of the VMH 
and see if this could prevent any effects of antecedent IL-6 treatment on either glucose 
sensing or CRR hormone secretion to acute hypoglycaemia.  
The current work highlights the potential physiological role of factors released in the 
recovery period following hypoglycaemia. Hypoglycaemic clamp studies in humans 
have shown increases in plasma IL-6 levels after one-two hours of hypoglycaemia 
exposure (Ceriello et al. 2013a). However, temporal IL-6 release in brain in response to 
hypoglycaemia has not been the focus of many studies. IL-6 mRNA accumulation in rat 
cortical mixed glial cells occurred as early as 15 minutes after exposure to glucose 
deprivation, but secretion was not measured in this study (Wang et al. 2001).  The 
current work demonstrates that IL-6 is released from astrocytes only in the euglycaemic 
recovery period following hypoglycaemia. The importance of controlled regulation of 
the recovery period following hypoglycaemia has been demonstrated, at least in terms 
of glucose concentration, in a study demonstrating that hyperglycaemia exposure during 
recovery from hypoglycaemia worsens endothelial function and increases oxidative 
stress and inflammation in both healthy individuals and patients with T1D (Ceriello et 
al. 2013b). This data also suggests that the secretion of inflammatory mediators such as 
IL-6 in the recovery period following hypoglycaemia may be influenced by glucose 
concentration. The essential role of IL-6 produced locally by resident brain cells for 
post-stoke angiogenesis has been demonstrated (Gertz et al. 2012). IL-6 promoted early 
transcriptional changes in angiogenesis-related gene networks after brain ischaemia, 
which led to increased angiogenesis after experimental stroke (Gertz et al. 2012). 
Therefore, IL-6 affords long-term, functional protection, assigning an important role of 
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neuroinflammation for post-stroke recovery (Gertz et al. 2012). It may be speculated 
that IL-6 exerts similar neuroprotective effects during recovery from hypoglycaemia. 
The current work suggests that the inflammatory response associated with 
hypoglycaemia may be of functional, physiological relevance in the CNS and also 
strengthens the hypothesis that pro-inflammatory states associated with diseases such as 
obesity, T2D and cancer, and increases in IL-6 in particular, are more than just a 
biomarker for disease state (Mauer et al. 2015; Ataie-Kachoie et al. 2014; Kristiansen & 
Mandrup-Poulsen 2005). Particularly in the CNS, IL-6 released following 
hypoglycaemia appears to play a key role in the regulation of hypothalamic glucose-
sensing neurons. The data presented here suggest that IL-6 exposure can impair 
neuronal responses to subsequent hypoglycaemia and implicate a role for EPAC2 in this 
observation. Therefore, IL-6 and EPAC2 are identified as two novel factors regulating 
glucose-sensing neurons, and warrant further study to determine their importance in the 
regulation of hypothalamic glucose sensing. If their roles can be confirmed and 
validated in more physiological models, then they provide two potential targets for 
therapeutic intervention to restore defective CRRs associated with recurrent 
hypoglycaemia in patients with T1D. Given the pleiotropic roles of IL-6 (Mauer et al. 
2015; Pal et al. 2014), specifically targeting and inhibiting only its action to suppress 
hypothalamic glucose sensing would be challenging, and a risk given the many 
physiologically beneficial roles of IL-6 reported (Scheller et al. 2011; Gertz et al. 2012). 
Antibodies neutralising IL-6 signalling have been used to great effect to treat chronic 
inflammatory disorders such as rheumatoid arthritis (Kang et al. 2014), so effective 
pharmacology is available, but whether it would be a useful intervention in this setting 
is questionable. EPAC2 on the other hand provides an exciting novel target that may be 
exploited therapeutically. In the current work a potent, selective inhibitor of EPAC2 
was demonstrated to prevent the IL-6-induced suppression of hypothalamic glucose 
sensing responses to hypoglycaemia.  Given the physiological importance of EPAC in 
the brain and CNS (Laurent et al. 2012) and other tissues including heart (Métrich et al. 
2010), as well as its documented roles in the immune system (Shirshev 2011), axonal 
growth (Peace & Shewan 2011) and tissue fibrosis (Insel et al. 2012), targeting of 
EPAC2 activity specifically in GE VMH neurons would be difficult. Nevertheless, it 
would be of interest to pursue the relevance of modulation of EPAC2 activity in the 
context of defective CRRs to hypoglycaemia further.  
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Several potential mediators of brain adaptations to recurrent hypoglycaemia that result 
in defective CRRs to subsequent hypoglycaemia have been identified (Chan & Sherwin 
2013), and the current work identifies IL-6 and EPAC2 as two novel, potential 
mediators of suppressed glucose sensing, at least in GT1-7 cells. Confirmation of these 
findings is required in other models and certainly in an in vivo setting, but they may be 
exciting, therapeutically exploitable targets for future research to focus on. The recovery 
period following hypoglycaemia should also be the attention of future research as the 
current results implicate functional, regulatory roles for secreted factors released during 
this period. 
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7 Concluding Statements 
The current work identifies the importance of the recovery period following 
hypoglycaemia and the potential significance of functional effects exerted by factors 
secreted during this time. It is demonstrated that IL-6 can exert a suppressive effect on 
subsequent hypoglycaemia detection in GT1-7 cells, an effect that may also be true in 
GE neurons of the hypothalamus. IL-6 exposure activates the cAMP signalling axis 
leading to phosphorylation and therefore activation of CREB as well as activating the 
JAK/STAT3 signalling cascade in GT1-7 cells. Finally, EPAC2 appears to mediate the 
effect of IL-6 to induce defective detection of subsequent hypoglycaemia and associated 
hyperpolarising responses to low glucose.  
Future work should address whether IL-6 increases the activity of EPAC2 in GT1-7 
cells and whether the sensitivity of the KATP channel to inhibition by ATP is altered 
following antecedent IL-6 exposure. Finally, it would be of interest to determine how 
activation of CREB and STAT3 link in with EPAC2 activity and the regulation of KATP 
channel activity.              
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8 Appendices 
8.1 Appendix I 
 
 
Figure 8.1 A percentage of vehicle dH2O (Control) treated shControl cells are 
unresponsive to hypoglycaemia  
shControl GT1-7 cells were exposed to either vehicle dH2O (control) or 20 ng/ml IL-6 
(IL-6) for three hours on day one and their electrical response to a 0.5 mM glucose 
hypoglycaemic challenge was assessed the following day during perforated patch 
current clamp recordings. (A) 4 of the 7 control cells studied failed to hyperpolarise in 
response to 0.5 mM glucose. (B) The percentage of control treated hypoglycaemia-
responsive cells was quantified as 43%, while no hypoglycaemia-responsive cells were 
observed following antecedent IL-6 exposure.  (C) Separation of vehicle treated cells 
that responded (responders) or failed to respond (non-responders) to 0.5 mM glucose 
demonstrated that responders hyperpolarised by -8.0 +- 2.1 mV on average compared to 
non-responders that demonstrated a depolarisation of 2.0 +- 0.7 mV on average in 
response to 0.5 mM glucose challenge (n=3 and n=4 respectively).  All six of the 
antecedent IL-6 treated shControl cells studied failed to respond to hypoglycaemia, and 
depolarised by 2.7 +- 0.7 mV on average in response to 0.5 mM glucose 
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8.2 Appendix II 
 
 
Figure 8.2 Hypoglycaemia fails to induce phosphorylation of AMPK in GT1-7 cells 
GT1-7 cells were exposed to vehicle dH2O (Control) or 20 ng/ml IL-6 (IL-6) for three 
hours and 24 hours subsequently were exposed to 2.5 mM glucose (Eugly) or 0.1 mM 
glucose (Hypo) for 15 minutes.  Cells were lysed and samples prepared for Western blot 
analysis of expression of pAMPK T172 (n=3).  Data was analysed by one-way ANOVA 
with Dunnett’s multiple comparisons test.    
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8.3 Appendix III 
 
 
Figure 8.3 Antecedent 20 ng/ml IL-6 treated GT1-7 cells hyperpolarise in response to 
response to NN414 
Pharmacological opening of KATP channels with 5 µM NN414 resulted in membrane 
hyperpolarisation of GT1-7 cells with defective hyperpolarising responses to 
hypoglycaemia following antecedent IL-6 treatment (n=10; n=2 for NN414 treatment).    
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8.4 Appendix IV 
 
 
 
Figure 8.4 Pre-incubation with WP1066 dose-dependently prevents IL-6-induced 
phosphorylation of STAT3 Y705 
GT1-7 cells were pre-treated with vehicle DMSO at 1:1000 for 60 minutes prior to 
exposure to vehicle dH2O at 1:250 for 30 minutes (Ctrl), or pre-treated with vehicle 
DMSO at 1:1000 for 60 minutes prior to exposure to 20 ng/ml IL-6 for 30 minutes (IL-
6) or pre-treated with 0.1 – 30 µM WP1066 for 60 minutes prior to exposure to 20 
ng/ml IL-6 for 30 minutes.  Cells were lysed and samples prepared for Western blot 
analysis of expression of pSTAT3 Y705.       
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8.5 Appendix V 
 
 
 
Figure 8.5 A suppression of the hyperpolarising response to 0.5 mM glucose was observed 
over time in vehicle treated WT GT1-7 cells 
WT GT1-7 cells were exposed to vehicle control (dH2O) for three hours on day one and their 
electrical response to a 0.5 mM glucose challenge was assessed the following day (18-24 
hours subsequently) during perforated patch current clamp electrophysiological recordings.  
Data represents the hyperpolarising response to 0.5 mM glucose exposure in studies 
performed in 2013 (n=9) and 2015 (n=7).  Data was analysed by Mann-Whitney test 
(P=0.11).   
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8.7 Appendix VII 
 
Figure 8.7 Cellular bioenergetic pathways measured using the Seahorse Bioscience 
Extracellular Flux Analyser 
Oxygen consumption rate (OCR) provides an index of mitochondrial respiration and 
oxidative phosphorylation, whereas the extracellular acidification rate (ECAR) provides 
a measure of glycolysis.  Schematic obtained and adapted from 
www.seahorsebio.com/learning/image-library.php  
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Figure 8.8 A percentage of vehicle treated WT GT1-7 cells were unresponsive to 
hypoglycaemia in the HJC 0350 studies 
WT GT1-7 cells were exposed to either DMSO at 1:1000 + dH2O at 1:250 (Vehicle) or 
0.5 µM HJC 0350 + 20 ng/ml IL-6 (HJC + IL-6) for three hours on day one and their 
electrical response to a 0.5 mM glucose hypoglycaemic challenge was assessed the 
following day during perforated patch current clamp recordings.  (A) Five of the seven 
vehicle treated cells failed to hyperpolarise in response to 0.5 mM glucose.  (B) The 
percentage of vehicle treated hypoglycaemia-responsive cells was quantified as 28.6% 
while 50% of HJC + IL-6 treated cells were hypoglycaemia-responsive in terms of 
exhibiting a hyperpolarising response to 0.5 mM glucose.  (C) Separation of vehicle 
treated cells that responded (responders) or failed to respond (non-responders) to 0.5 
mM glucose demonstrated that responders hyperpolarised by -11.5 +- 2.5 mV on 
average compared to non-responders that demonstrated a -0.2 +- 0.6 mV 
hyperpolarisation on average in response to 0.5 mM glucose (n=2 and n=5 
respectively).  HJC + IL-6 treated cells hyperpolarised by -3.0 +- 2.5 mV on average in 
response to 0.5 mM glucose (n=6).  
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